dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Väljaminev kiriAvalik

Otsus

Sotsiaalministeerium · 14. aprill 2020
Viit
1.1-12/678
Registreeritud
14. aprill 2020
Dokumendi liik
Väljaminev kiri
Adressaat
Tartu Ülikool
Saabumis/saatmisviis
Outlook
Funktsioon
1.1 Juhtimine, arendus ja planeerimine
Sari
1.1-12 Ministeeriumi moodustatud komisjonide ja töögruppide tegevuse korraldamine (Arhiiviväärtuslik)
Toimik
1.1-12
Vastutaja
Ingrid Ots-Vaik (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Tervisesüsteemi arendamise osakond)

Failid

  • 📎EBINiotsusIrs.asice5744 KB

Sisu (failidest)

EESTI BIOEETIKA JA INIMUURINGUTE NÕUKOGU OTSUS 14. aprill 2020 nr 1.1-12/678 Nõukogu koosseisus: Esimees: Liina Vahter Tallinna Ülikool Aseesimees: Aime Keis Tartu Ülikooli inimuuringute eetika komitee Teadussekretär: Aive Pevkur Tallinna Tehnikaülikool Liikmed: Kristi Rüütel Tervise Arengu Instituudi inimuuringute eetikakomitee Irja Lutsar Tartu Ülikool Kärt Salumaa-Lepik Tallinna Tehnikaülikool Meego Remmel Eesti Kirikute Nõukogu Agne Velthut-Meikas Tallinna Tehnikaülikool Merike Sisask Tallinna Ülikool Ingeri Luik-Tamme TGS Baltic Advokaadibüroo Pärt Peterson Tartu Ülikool Kristjan Kask Tallinna Ülikool Arutas 7. aprillil 2020.a Tartu Ülikooli genoomika instituut projekti “ Varasemalt kirjeldamata CYP450 geenivariatsioonide mõju ravimite metabolismile” („Study of the effects of previously uncharacterized rare variants in genees encoding CYP450 enzymes "). Uuringu viivad läbi Tartu Ülikool ja Karolinska Instituut. Uuringu taotluse menetlusest taandas ennast Maarja Kirss, Andmekaitse Inspektsioonist. Uuringu taotluse menetluses ei osalenud Priit Ennet, MTÜ Eesti Teadusajakirjanike Selts. Läbiviidava uuringu üldine eesmärk on hinnata hiljuti Eesti populatsioonis avastatud tsütokroomi ensüümide 2D6 ja 2C19 geenivariantide mõju ravimite metabolismile. Selleks kutsutakse uuringukriteeriumitele vastavad geenidoonorid farmakokineetilisse uuringusse. Uuringus osalema nõustunud geenidoonoritele manustatakse kahte ravimit ning hinnatakse iga indiviidi ravimite metaboliseerimise kiirust sõltuvalt tema genotüübist, laborianalüüsi tulemusest ja teistest teadaolevatest faktoritest. Uuringus töödeldakse järgmise andmekategooriaid ja –koosseis on toodud Eesti bioeetika ja inimuuringute nõukogule esitatud taotluse punktis 8. Valimi moodustab kuni 215 000 geenidoonorit. Depseudonüümitakse kuni 900 geenidoonori andmed. Andmeandjateks on geenivaramu. Otsus: anda luba uuringu läbiviimiseks. Otsuse lahutamatu lisad on Tartu Ülikooli Genoomika Instituudi“ Varasemalt kirjeldamata CYP450 geenivariatsioonide mõju ravimite metabolismile” („Study of the effects of previously uncharacterized rare variants in genees encoding CYP450 enzymes ").uuringutaotlus koos lisadega. /allkirjastatud digitaalselt/ Liina Vahter Eesti bioeetika ja inimuuringute nõukogu esimees Application to Estonian Committee on Bioethics and Human Research for project approval 1. RESEARCH DATA Name of the study: Study of the effects of previously uncharacterized rare variants in genes encoding CYP450 enzymes Varasemalt kirjeldamata CYP450 geenivariatsioonide mõju ravimite metabolismile Sponsor of the study: Institute of Genomics, University of Tartu Number of the study plan: 1-2019 Version: 2 Date: 25.02.2020 List of Collaborating Countries: Estonia, Tartu, Tallinn Sweden, Stockholm The main aim of the study is to assess the effect of recently identified genetic variants in the cytochrome 2D6 and 2C19 genes on the metabolizing activity of these enzymes in the Estonian population. The effects of the genetic variants will be evaluated by re-contacting relevant participants from the Estonian Biobank, and after review of their health status, invite them to participate in a pharmacokinetic study. The eligible individuals comprise the study group and will take an oral low dose of omeprazole and metoprolol. Venous blood will be drawn at fixed time points to determine the metabolizing capacity of the enzymes based on the genetic profile, laboratory analyses’ results and other known factors. Uuringu põhiline eesmärk on hinnata hiljuti Eesti populatsioonis avastatud tsütokroomi ensüümide 2D6 ja 2C19 geenivariantide mõju ravimite metabolismile. Selleks kutsutakse uuringukriteeriumitele vastavad geenidoonorid farmakokineetilisse uuringusse. Uuringus osalema nõustunud geenidoonoritele manustatakse kahte ravimit ning hinnatakse iga indiviidi ravimite metaboliseerimise kiirust sõltuvalt tema genotüübist, laborianalüüsi tulemusest ja teistest teadaolevatest faktoritest. 2. INVESTIGATORS AND PARTICIPATING INSTITUTIONS 2.1. Principal investigator Dr. Alar Irs Tartu University Hospital, Heart Clinic 511 8592 [email protected] /signed electronically/ 1 2.2. Sub-investigators Dr. Lili Milani Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu 737 4039 [email protected] /signed electronically/ Dr. Alar Irs Tartu University Hospital Heart Clinic 511 8592 [email protected] /signed electronically/ Dr. Kersti Oselin North Estonia Regional Hospital Oncology and Haematology Clinic 617 1792 [email protected] /signed electronically/ Dr. Jana Lass Tartu University Hospital Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu731 8333 [email protected] /signed electronically/ Kristi Krebs, MSc Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu737 4039 [email protected] /signed electronically/ Tuuli Jürgenson, BSc (statistics) Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu [email protected] /signed electronically/ 2 Dr. Anton Pohanka Karolinska University Hospital Department of Clinical Pharmacology [email protected] /signature in Annex/ Dr. Volker M Lauschke Dept of Physiology and Pharmacology Karolinska Institutet [email protected] /signature in Annex/ Prof. Erik Eliasson, MD Department of Laboratory Medicine Clinical Pharmacology Karolinska Institutet [email protected] /signature in Annex/ 2.3. Director of the institution or head of the structural unit of the principal investigator Katrin Kaarna Head of the Clinical Research Centre, University of Tartu Ravila 19, 50411 Tartu [email protected] 737 4119 /signed electronically/ 2.4. Consent from director or authorised person of the institution(s)/partner organisation(s) Institute of Genomics University of Tartu Riia 23b, 51010 Tartu Mait Metspalu Director 737 5052 [email protected] /signed electronically/ COMMENT: the additional application will be submitted to the Estonian Committee on Bioethics and Human Research for adding medical personnel from study centers (nurses) to the list of investigators. This application for ethical approval has been reviewed and approved by persons authorized by the Chief Data Protection Officer of the University of Tartu, Helene Alavere, Head of Data Collection Department and Project Manager of the Estonian Biobank, Institute of Genomics and Evelin Tali, Analyst of the Estonian Biobank, Institute of Genomics. 3 3. STUDY FINANCING Source: 1. PRG184 (PRG184) "Role of Rare and Common Genetic Variants in Adverse Drug Reactions (1.01.2018−31.12.2022)", Lili Azin Milani, University of Tartu, Institute of Genomics. 2. PP1GI Science base funding, University of Tartu, Institute of Genomics (yearly allocation for 2020 ca 1M €). Study costs: Payment for the study nurse 150 EUR/per day. Probe drugs: 150 EUR/total cost Compensation for the study participants: compensation for participation will not be paid. The study drug administration is scheduled for the weekend. During the study, it is planned to cover the participant's transportation costs on the basis of expense receipt(s). As the research centers are located in both Tallinn and Tartu, transport costs in Estonia are unlikely to exceed 50€/visit. As the participant has to come to the study center twice during the study, altogether the travel compensation is up to 100€. If the subject is unable to come to the study center in the morning on the day when the drug will be administered or travel home in the evening after the day of the study, accommodation costs will also be reimbursed. As participants are healthy subjects we do not foresee necessity for involving an accompanying person. Insurance for the study participants: all of the study participants will be covered by insurance during the study period. An insurance policy offer is attached to the application. 4. SHORT OVERVIEW OF SIMILAR STUDIES Cytochrome P450 (CYP) enzymes play an important role in drug metabolism by being responsible for oxidative metabolism of approximately 50 % of drugs and xenobiotics. Variation in the CYP genes can produce enzyme products with abolished, reduced, altered or increased enzyme activity. In addition to metabolizing enzymes of which the CYP genes are the by far most well studied, drug transporter proteins are important sources of pharmacokinetic variability in drug response (Kozyra et al, 2016). Considerable inter- and intra-individual variability in the expression and function of CYP enzymes exists, which is determined by multiple factors. A large degree of variability exists within any particular genotype group, which confirms that in addition to known genetic variants, novel rare genetic factors as well as non-genetic host factors (age, gender, disease states), and environmental influences (such as smoking, diet, concomitant drugs) are also important (Wilkinson et al, 2005). Consequently, each individual has its own CYP450 metabolic profile and the phenotype (i.e. the real activity) of an individual enzyme is important for predicting possible therapeutic failures or toxic reactions to medicines. 4 Several common genetic variants have been described which lead to altered enzyme activity and thus variation in treatment outcome (Reisberg et al, 2019). However, the effect of some novel rare genetic variants is not known on drug metabolism. The aim of our study is to examine in a clinical trial the effect of novel predicted loss-of-function (LoF), missense genetic variants and large deletions that were detected in the Estonian population by analysing the whole genome sequence data of 2500 participants of the Estonian Biobank (Tasa and Krebs et al, 2018). The effect of the variants was first assessed with bioinformatic tools, incl. Variant Effect Predictor (VEP, https://www.ensembl.org/info/docs/tools/vep/index.html) and filtered for loss- of-function and missense variants. For this study, we have also included missense variants that were selected using a recently published framework for pharmacogenetic variants (Zhou et al, 2018). In order to determine the effect of the previously uncharacterized genetic variants, we will use in vivo phenotyping by using previously tested and validated phenotyping probe drugs. This will allow us to determine the enzyme activities and describe the net effect of all influencing factors on CYP activity. It has been shown that using phenotyping probe drugs is an accurate and minimally invasive method for the in vivo assessment of CYP enzyme activities in a single experiment. Probe drugs can be used in various combinations (Donzelli et al, 2014; Christensen et al, 2003; Keller et al. 2017), allowing for the in vivo assessment of multiple pathways of drug metabolism in a single experiment, taking into account genetic, non-genetic and environmental influencing factors. Probe drugs should predominantly be metabolized by an individual CYP enzyme, can be safely administered to humans and have no other significant cause of variability, in addition to the one for which they will be used as a probe. There are several phenotyping cocktails used in clinical studies, each of these having their benefits and flaws. The basel phenotyping cocktail (containing caffeine, efavirenz, losartan, omeprazole, metoprolol, and midazolam as probe drugs for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, respectively) has been well tolerated and has had good correlations of metabolic ratios with AUC (Area Under The Curve - one of the most important evaluation metrics for checking any classification model’s performance) ratios of the corresponding probe drugs and their metabolites (Derungs et al. 2016). References 1. Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. (2016). doi:10.1038/gim.2016.33. 2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–21. 3. Reisberg et al. "Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions." Genetics in Medicine 21.6 (2019): 1345. 4. Tasa, et al. "Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records." European Journal of Human Genetics 27.3 (2019): 442. 5 5. Donzelli, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet., 2014, 53(3), 271-282. 6. Christensen, et al. "The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes." Clinical Pharmacology & Therapeutics 73.6 (2003): 517-528. 7. Keller, et al. "In vivo phenotyping methods: cytochrome P450 probes with emphasis on the cocktail approach." Current pharmaceutical design 23.14 (2017): 2035-2049. 8. Derungs, et al. "Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the basel cocktail: a randomized crossover study." Clinical pharmacokinetics 55.1 (2016). 9. Zhou, et al. “Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.” Front Pharmacol 4;9:1437. (2018). 5. DETAILED OVERVIEW OF THE STUDY The aim of the study is to assess if the newly described mutations and deletions in cytochrome 2D6 and 2C19 change the metabolizing activity of these enzymes. A prospective study will be performed at Tartu University Clinic’s Hematology and Oncology Clinic and North Estonia Medical Centre Foundation’s Oncology and Haematology Clinic. The subjects will be selected and re-contacted based on the availability of whole genome sequencing or genotype data, the health status of the subjects and their suitability for such a study, according to standard ethical procedures regarding clinical studies involving drugs. Based on initial review of the existing whole genome sequencing data (n=2500) and genotype data (n=50,000) of the Estonian Biobank (EstBB) participants, we have detected the following number of individuals with previously uncharacterized genetic variants in the CYP450 genes: Table 1. Current1 number of individuals with rare genetic variants in the CYP450 genes Allele 1 Allele 2 N Nmax Coordinate CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1 CYP2C19_del CYP2C19_del 1 1 CYP2C19_del CYP2C19_Increased 162 10 CYP2C19_del CYP2C19_LoF 54 10 CYP2C19_del CYP2C19_Normal 324 10 CYP2C19_Novel_missense 1 1 chr10:96535248 CYP2C19_Novel_missense 1 1 chr10:96580257 CYP2C19_Novel_missense 4 4 chr10:96540331 1 The final number of individuals carrying different identified deletions or mutations may increase before the study, as we analyze additional genotype data of 100,000 new biobank participants. We will still limit the number of individuals with identical mutations/deletions that will be invited to participate in the study to max 10. 6 CYP2C19_Novel_missense 1 1 chr10:96541688 CYP2C19_Novel_missense 1 1 chr10:96580323 CYP2C19_Novel_missense 1 1 chr10:96602648 CYP2C19_Novel_missense 1 1 chr10:96535156 CYP2C19_Novel_missense 1 1 chr10:96602634 CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820 CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820 CYP2D6_Novel_LoF 6 10 22:42522982 CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847 CYP2D6_Novel_LoF 1 1 chr22:42522916 CYP2D6_Novel_missense 1 1 chr22:42523889 CYP2D6_Novel_missense 1 1 chr22:42523916 CYP2D6_Novel_missense 2 2 chr22:42523928 CYP2D6_missense? * 109 10 chr22:42522613 CYP2D6_missense? * 86 10 chr22:42523943 CYP2D6_missense? * 45 10 chr22:42526694 CYP2D6_missense? * 33 10 chr22:42524814 CYP2D6_missense? * 30 10 chr22:42526763 CYP2D6_missense? * 23 10 chr22:42525811 CYP2D6_missense? * 23 10 chr22:42525821 CYP2D6_missense? 10 10 chr22:42524947 CYP2D6_missense? 6 10 chr22:42523558 CYP2D6_missense? 4 4 chr22:42523613 CYP2D6_missense? 3 3 chr22:42523567 CYP2D6_missense? 3 3 chr22:42524310 CYP2D6_missense? 2 2 chr22:42523897 CYP2D6_missense? 2 2 chr22:42525115 CYP2D6_missense? 1 1 chr22:42522601 CYP2D6_missense? 1 1 chr22:42523844 CYP2D6_missense? 1 1 chr22:42526712 Total 984 197 *) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3. Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid change, missense? = amino acid change with unknown function Coordinate = chromosome and position according to human genome build hg37. The deletion of CYP2C19 spans exons 1-5 and the deletion of CYP2D6 the entire gene. Table 1 is shared to illustrate the complexity of the different mutations and deletions selected for the study and the final number of individuals in each category may still change after analysis of new genotype data from EstBB, but the principle will remain the same. We will not invite hundreds of individuals with the same genetic profile, each novel allele will be characterized by a subset of the healthiest individuals that best match the inclusion criteria of the study. 7 6. STUDY TIMELINES Study start date: 03.2020 Study completion date: 02.2025 7. DESCRIPTION OF THE STUDY PARTICIPANTS AND THE METHOD OF RECRUITMENT Study participants will be selected from the EstBB participants whose whole genome has been sequenced (n=2500) or genotyped (n=150,000) and found to carry deletions or mutations in CYP2C19 and/or CYP2D6. The participants have joined EstBB voluntarily and signed an informed consent. They have been informed that the research done at the EstBB is continuous and not confined to presently available technology and that their pseudonymised data may be used for further research (https://www.riigiteataja.ee/aktilisa/1170/4201/9016/SOM_11042019_m39lisa.pdf). Currently, 984 EstBB participants have been selected selected for the study based on their genotype (please see Table 1- list of rare CYP enzyme variants). After the review of recently generated genotype data for additional biobank participants, we estimate that this number may increase to 1000 that can be invited to participate in the study. Finally, we aim to enrol up to 200 ± 50 participants for the clinical study. The genotypes of the participants represent different genetic variants described in Table 1. Based on the genetic profiles of the EstBB patients listed in the Table 1 above, the composition of the basel cocktail has been reduced to 2 components (omeprazole and metoprolol) to cover the most important and common drug metabolizing CYP enzymes (CYP2D6 and CYP2C19). We will consider separate pharmacokinetic studies of novel missense mutations (n=2) and deletion (n=1) in CYP2C9 and missense mutations (n=2) in CYP3A4 with separate substrates and matched controls, if we are able to identify more mutation carriers based on genotype data of the EstBB participants. It is planned to describe the statistical pharmacokinetic (PK) parameters on a case-by-case basis (individuals with different mutations vs wildtype) and the sample size estimate is therefore not applicable. Inclusion criteria: 1. All biobank participants (> 18 years, no upper limit of age) who have (according to performed genotyping analysis) previously not described/studied mutations or deletions in the metabolizing enzymes (CYP2D6 and CYP2C19) 2. Able to understand the nature of the study and content and meaning of consent. Exclusion criteria: 1. Clinically relevant abnormality of renal or liver function or anemia identified at the laboratory screening 2. Pregnancy or lactation 3. History or clinical evidence of alcoholism or drug abuse within the last year period prior to screening 8 4. Excessive alcohol consumption within 2 days before the first drug administration 5. Previous treatment with any medicines interfering with the measurement of phenotyping probe drugs 6. Any of the probe drugs contraindicated or had a history of allergy to any study medication 7. Patient's weight 50% more or less than their ideal body weight (for assessment the on- line calculator will be used e.g.https://www.calculator.net/ideal-weight- calculator.html) Informed consent will be taken from the study participants before the study-related procedures. Informed consent form allows to: - Take blood samples for the PK analysis - Administer probe drugs - Assess relevant electronic medical records to obtain drug-related information and for checking presence of contraindications from the hospital information system The study procedures will be described thoroughly during the first contact by the phone. The informed consent will be sought by the responsible study team member who is documented at the delegation log. There will be 2 copies of informed consent sheet: - For the study participant - For the study record 8. REQUEST FOR DEPSEUDONYMISATION We request the Estonian Committee on Bioethics and Human Research for an approval to depseudonymise the personal data (name, ID code, e-mail, regular post address, phone number) of up to 1000 EstBB participants who have the whole genome sequence or genotype data in the EstBB database. A higher number of depseudonymised participants in comparison with participants who will be recruited to the study (200±50) is required as not all subjects meet the inclusion criteria and not all subjects agree to participate in the study. Depseudonymised data is necessary for contacting participants. Legal bases for depseudonymisation and contacting gene donors It is permitted to depseudonymise data in order to identify a gene donor on the proposal of the controller of the EstBB and with the consent of the Estonian Committee on Bioethics and Human Research, to contact the gene donor and to renew, supplement or verify a description of his or her state of health with his or her written consent (HGRA §24, section (2), 4). Procedure of depseudonymisation and contacting gene donors When performing depseudonymisation, the EstBB shall comply with all requirements of the Human Gene Research Act. 9 ● The data will be released only after the approval by the Estonian Committee on Bioethics and Human Research. ● The specific persons who perform depseudonymisation shall be appointed by the director of Institute of Genomics (HGRA § 22, section (3)). There are fixed procedures in the EstBB to follow when contacting the gene donors. 9. DESCRIPTION OF THE STUDY-RELATED PROCEDURES 9.1 Study visits 1. Contacting participants (please see Table 2) Selected biobank subjects (up to 1000 people) will be contacted and invited to participate in the study first by e-mail or regular post if email address is not available (please see Invitation letter Appendix 2). In case of nonresponse one reminder will be sent after 1 week, and a phone call will be made 1 week after the reminder. The initial contact will only be made by personnel at the EstBB who are specifically authorized by the director of the Institute of Genomics to handle personal data. 2. All participants, who give positive response to the first invitation are scheduled for a phone call with the authorized personnel at the EstBB in the course of which  introduction of the study and  pre-screening interview takes place Pre-screening interview includes mapping of inclusion criteria. Suitable subjects are offered to participate at the study and invited to the study centre (Tartu University Hospital or North Estonia Medical Centre) for a pre-scheduled pre-dosing visit. 3. Pre-dosing visit at the hospitals: Duration of the visit is approximately 1 hour (time spent at the hospital). During this visit following procedures will be performed:  verify the inclusion criteria  sign informed consent  collect medical history (previous and current medical conditions, surgical history, prior and concomitant medications, allergies) and baseline characteristics  perform local laboratory tests o haematological parameters: WBC, haemoglobin, haematocrit, platelets o renal function measurements: urea, creatinine o other tests: Na, K, Ca, glucose, transaminases  perform clinical examination (weight, height, blood pressure, heart rate) At the pre-dosing visit patient's eligibility for the study will be ascertained, including possible contraindications to the probe drugs. Relevant medical history will be documented to the electronic medical record. If necessary, the participant's previous medical history is reviewed. Only the past electronic medical records will be examined that are relevant in the context of the 10 study (information on diagnoses, medications used and allergies) and with the consent of the participant. Eligible study subjects will be invited to receive a dose of the probe drugs at a separate visit (Dosing and PK sampling visit) at the study centre (Tartu University Hospital (TUH) or North Estonia Medical Centre (NEMC)). 4. Probe drugs administration and PK sampling visit Duration of the visit is up to 10 hours (time spent in hospital). During this visit following procedures will be performed: ● recheck eligibility according to the study inclusion and exclusion criteria ● verify the inclusion criteria ● perform clinical examination (evaluation of core body temperature, weight, height, blood pressure, heart rate) ● pregnancy test from urine (for female participants until menopause) ● recording the concomitant medications (all OTC and prescription medications taken 24 hours before study dose) The following contraindications exist for using phenotyping probe drugs and participants with these conditions shall be excluded: o known hypersensitivity for the study medicines o severe hepatic impairment (ChildPugh Class C) o uncontrolled heart failure (metoprolol) o bradycardia (metoprolol) o sick-sinus syndrome (metoprolol) o Prinzmetal's angina (metoprolol) o untreated phaeochromocytoma (metoprolol) o metabolic acidosis (metoprolol) o severe peripheral arterial disease (metoprolol) o history of bronchospasm and asthma (metoprolol) o hypotension (metoprolol) o diabetes if associated with frequent episodes of hypoglycaemia (metoprolol) o chronic obstructive pulmonary disease (metoprolol) o renal or hepatic failure (metoprolol) o therapy resistant hypokalaemia and hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia, anuria (metoprolol) ● single dose administration of probe drugs: o 20 mg omeprazole (full 20mg capsule) o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is measured and packed according to the standard procedures (SOP) of the 11 hospital pharmacy of Tartu University Hospital). The reason to use extemporaneous product is caused by the fact that no marketed product of metoprolol is available at such a low dose. ● proceed to PK procedures o 5 ml blood, 10 timepoints (altogether 50ml) will be taken from the inserted venous cannula ● observation and monitoring of the patient during PK sampling period (8 hours) ● recording of the vital parameters (blood pressure, heart rate) and adverse events (ADR) Participants will be asked not to eat in the morning before the study visit when probe drugs are administered in order to assess the PK profile at fasting state. After probe drug administration and first PK analyses, a breakfast will be served at the study centres. The participants will be served a hot lunch. If requested, the subjects will receive one additional light meal. Administration of participant’s regular medicines in the morning before administration of probe drugs will be discussed and agreed during the pre-dose visit at the study centres. Specific instructions will be given to every participant. 5. Follow-up phone call 1 week after the phenotyping probe drugs administration to document possible ADRs that have occurred since Day1. The call will be made a week after the study medication is given as side effects are unlikely to occur later. The subject has the opportunity to contact investigators by telephone throughout the study and to inform the investigator of any adverse drug reaction. Table 2. Schedule of study assessment Contacting Phone Pre-dose Dosing and PK Follow-up phone call contact, visit sampling visit pre- screening interview Invitation letter, e-mail (phone call) x Inclusion criteria x x x Medical history and patient x characteristics Informed consent x Recheck eligibility x Clinical examination x x Immediately before the Study Dose Haematological parameters x Na, K, Ca, glucose, transaminases x Renal function (urea, creatinine) x Urine pregnancy test for female x participants 12 Study medicines administration x PK Sampling x Concomitant medications x documentation Adverse event reporting x x 9.2 Pharmacokinetic analysis Blood samples for pharmacokinetic analysis of probe drugs and metabolites will be collected before dosing and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6 and 8 h after drug administration from an antecubital vein into ethylenediaminetetraacetic acid tubes. A cannula is used for blood sampling. The tubes will be centrifuged (1500g for 10 min at 4 °C) and plasma will be stored at −80 °C until analysis. Sampling schedule is based on the results of a previous phenotyping cocktail study (Donzelli et al, 2014) that included slow metabolizers and showed that a shorter (8h) blood sampling period was sufficient to describe the pharmacokinetic profile of the studied drugs. In addition, the use of a shorter study period is also in the interest of subjects who do not have to spend the night in the hospital. For the plasma concentration measurements of probe drugs and metabolites (omeprazole, metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5- hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be used at the Karolinska institute. The frozen plasma samples of all study participants will be shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2). For issuing of plasma samples to Sweden a new application will be submitted to the Estonian Committee on Bioethics and Human Research and thereafter to the Senate of the University of Tartu. Pharmacokinetic endpoints: A noncompartmental model of disposition of probe drugs and its main metabolites (CL, Vd, AUC, Cmax, Tmax). 9.3 Patient health data Volunteers will be screened and assessed to be eligible for the study by physical examination, medical history, and laboratory evaluations. The following information will be collected and recorded to the electronic case report form (CRF) (Redcap): Age, gender, weight, height, blood pressure, heart rate, medical anamnesis, known allergies to medicines, results of the physical examination, medical history, and laboratory evaluations. Side effects will be documented and reported to the State Agency of Medicines. 10. ANALYSIS OF THE ETHICAL ASPECTS RELATED TO THE STUDY 10.1 Informed consent 13 Informed consent will be obtained from the participant. This will allow the research team to commence: ● Detailed monitoring of the patient ● Collection of samples at specific times ● Access to the patient’s medical notes or clinical data The researchers will explain the risks of the study (probe drug administration and blood sampling). The information will also be available on the information sheet. The information sheet/informed consent will be provided and used to structure a discussion. Patients will be allowed ample time to make their decision. They will be asked how long they would like to consider the information and what time is convenient for them when the researcher may return to answer any questions they may have. The informed consent process will be delivered by the team member and listed on the delegation log. Subjects can withdraw consent at any time without prejudice. The investigator can withdraw a subject from the study if, in his or her clinical judgment, it was in the best interest of the subject or if the subject could not comply with elements of the protocol or what is necessary for the scientific integrity of the study. If the investigator withdraws a subject from the study, the investigators will explain the reason for withdrawing the participant. Subjects enrolled in the study who withdraw after the recruitment or who the researchers decided for any reason should not continue in the study (“dropouts”) will be replaced. 10.2 Ethical aspects related to the study procedures The study will be conducted in accordance with the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP) and the Helsinki Declaration. a) Individual autonomy respect principle All of the participants have joined EstBB voluntarily. Regulated by Human Genes Research Act (HGRA) § 9 – Voluntary nature of gene donation (https://www.riigiteataja.ee/akt/72581?leiaKehtiv). Nobody will be discriminated against upon joining or for the fact of being a participant. (HGRA chapter 5 – prohibition of discrimination). People’s rights with limited disability are regulated by HGRA § 13 – Persons with restricted active legal capacity and persons without capacity to exercise will. The participant can withdraw consent at any time (HGRA § 12 – Consent to becoming a gene donor). Participation in this study is voluntary. The gene donor shall be provided with sufficient information on the nature of the trial to assist him or her in making an informed decision. The subject may at any time opt-out or discontinue the trial without justification. The study data of the subject who discontinued the study shall be kept for 5 years, separately from the data of the other subjects and shall not be included in the analysis. If a participant asks 14 the PI to delete their data, we will give them 2 options, a) delete data + destroy sample, or b) delete the code key. The requested data will be deleted and this action will be documented. b) Non-harming principle The potential risks associated with this study are related to the phenotyping drug cocktail administration and with taking blood samples. To minimize the risk of adverse effects of the phenotyping cocktail medicines, healthy adult volunteers will be screened. The probe drugs are administered at low doses and study participants will be monitored after the administration at the hospital setting. Although the magnitude of the benefits of the study cannot be known until the results of the study are available, the risks of the study have been carefully considered. As a result of the study, it is possible to describe the effect of previously unknown gene variants on the rate of drug metabolism. The study uses drugs that are commonly used in clinical practice, for which the risks and contraindications are well known, and the doses are as low as possible. The drugs are administered in a hospital setting and are monitored by study physicians throughout the study. Experienced nurses perform all examination procedures. Taking blood samples can (rarely) cause pain, bleeding, bruises, or local infection at the site. Moreover, some patients may experience vertigo or malaise during the procedure. To minimize the risks and discomfort of the patient, trained and experienced study nurses are taking the venous blood samples. According to the protocol, all participating doctors and nurses will be obliged to report any study related serious adverse effects to the State Agency of Medicines and Ethics Committee. c) The principles of justice and well-meaning The probe drug experiment has a potential value for the participants in the study group and the Estonian population in general, as it would clarify the effect of the mutations detected in their genes encoding CYP enzyme, and thereby help to adjust future treatment with medicines which are metabolised via the respective CYP enzymes and further estimate the participants’ personal metabolic activity for the studied drug metabolizing enzymes while taking into account the patient’s lifestyle and environmental influences in addition to their personal genetic background. By the request the participants (please see consent form) results of the pharmacokinetic analysis will be given in the form of a personal drug metabolism profile and genetic report. This feedback will be prepared and delivered separately as “Feedback to the gene donors” (“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the University of Tartu 271/T-2, 19.06.2017). The results are expected to benefit all participants of the EstBB, other Estonian residents and other populations as well. 15 The current proposal is important because it helps to promote the advancement of science and raises the importance of the EstBB. The compiled statistics of this work will be shared with a wider audience through the publication of scientific papers in international peer-reviewed journals to further the advances in scientific fields. Data confidentiality During the interaction with the study participants their personal data will be handled by authorized personnel at the biobank or participating clinicians only. All collected and handled data will remain confidential. Investigators who are mandated to access participant past electronic medical records are documented at the study delegation log, are also employees of the study centres (NEMC or TUH) and have access to electronic health systems of the hospitals. Once all data has been collected, it will be submitted to the EstBB where it will only be used in pseudonymized form. All documents related to the trial will be archived for 15 years after the end of the trial by the investigator sites and the sponsor. Investigators will ensure that records sources, including medical charts, are available during this trial storage period. No trial document shall be destroyed by the investigator sites after the deadline without prior written consent of the sponsor or her representative. All generated individual level data will be submitted to the EstBB for coding and incorporation into the biobank database at the end of the study. Auditing / monitoring of the study Regulatory authorities may conduct a regulatory inspection of this study. Such inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the inspector to discuss findings and any relevant issues. 10.3 Monitoring of the patients Subjects will be on study for up to 1 week after administration of study medicines. All of the possible adverse effects will be documented. 11. ANALYSIS OF DATA PROTECTION ASPECTS OF THE STUDY 11.1 Issuing pseudonymised data Legal basis for issuing data Descriptions of DNA are issued from the Gene Bank only in pseudonymised form, as a set of data and on the condition that data concerning at least five gene donors are issued at a time (HGRA § 22, section (4)). 16 Procedure for issuing data When issuing data, the biobank shall comply with all requirements of the Human Gene Research Act. ● The prerequisite for issuing data is the approval by the Estonian Committee on Bioethics and Human Research. ● The Director of the Institute of Genomics of the University of Tartu will appoint the responsible people for the procedures of releasing the data and give the order to release the data. ● The contract for the data release will be signed. ● The data transfer protocol will be signed by the parties. Genetic data is transmitted to the data analysts using the sapu.cs.ut.ee (https://sapu.cs.ut.ee) virtual environment. Obligations of the principal investigator The director of the institute responsible for the research will guarantee the confidentiality of the data and follow all of the data protection regulations according to the signed contract and general data protection regulations. The use of the data is limited to the project’s goals and scope. The distribution of data to third parties is prohibited without the written consent of the EstBB. It is the obligation of the principal investigator to send the data resulting from the analysis conducted during the research to the EstBB. The research results enrich the database of the EstBB. 11.2 Storage of the paper forms containing personal data of participants The consent forms will be stored at the North Estonia Medical Centre in the investigators room in a locked drawer. At Tartu University Hospital the consent forms will be stored in the special locked clinical research room, which is located on the premises of the hospital pharmacy. After completion of the study the consent forms will be transferred to the EstBB and stored in similar conditions and during the same time period as it is stated by the law for the consents of the gene donors (HGRA, §12, section (6)). 11.3 Storage of data collected during study The EstBB senior data encoder will depseudonymise the personal data of participants that is necessary for contacting the study subjects. The initial contact and invitation to participate in the study will only be done by the EstBB staff authorized to handle personal data. Once the individuals have agreed to participate in the study, their first visit will be scheduled by the EstBB staff. At this point, the personal data of the participants will be visible for the investigators at the study centre. During the first visit at the study centres (hospital) participants personal information (name, id code) will be used for documenting the study visit to the 17 electronic medical systems and for ordering study related medical analyses (blood tests) from the local laboratories. For the study participants unique study codes will be designated and these codes will be used for the further study related procedures. Same codes will be documented on the consent form, used in the screening logs, and on each blood sample taken for PK analysis. Plasma samples for the PK analyses will be sent to the laboratory at Karolinska Institute marked with the same unique codes and no personal information (ID codes, names) will be sent out from the study centres (TUC, NEMC). The samples will be analysed and the results will be sent to the EstBB using the same codes. All study records, measurements, sample results will be submitted to the EstBB and entered into the biobank database. The final results will then be coded for research use and made accessible through the EstBB database for the researchers of the study. 11.4 Storage of the blood samples PK samples are stored after centrifugation at the study centres at −80 °C until shipment. The samples are marked with the subject code and nr of the sample. 12. INFORMATION ABOUT THE SIMULTANEOUS ASSESSMENTS OR APPROVALS OF THIS PROJECT No other approvals will be sought. 13. Appendices 13.1 Informed consent forms Informed consent form (Estonian) Informed consent form (Russian) 13.2 Invitation letter in Estonian and in Russian 13.3 CVs of the investigators (included in separate files) 13.3 Liability insurance policy offer 18 Alar Irs ORCID 0000-0002-2244-9699 E-post [email protected] Töökohad ja ametid 01.01.2018–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi radioloogiakliinik, arst-õppejõud kardioloogia erialal (0,50) 2017–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi Südamekliinik, arst-õppejõud kardioloogia erialal (0,50) 01.01.2012–... Ravimiamet, meditsiininõunik 01.02.2009– Tartu Ülikool, Kliinilise farmakoloogia lektor (0,25) 31.12.2017 03.08.2004– Newcastle-i Ülikool, Austraalia, kliinilise farmakoloogia 03.11.2004 külalisteadur (1,00) 2004–31.01.2009 Tartu Ülikool, kliinilise farmakoloogia assistent (0,25) 01.01.2003– Ravimiamet, peadirektori asetäitja (1,00) 31.12.2011 01.01.2001– Ravimiamet, registreerimisosakonna juhataja 31.12.2003 01.01.1998– Ravimiamet, kliiniliste ravimiuuringute spetsialist 31.12.2001 01.09.1997– Tartu Ülikool, lepinguline õppetöö kliinilise farmakoloogia alal 31.12.2003 (0,50) Teadusorganisatsiooniline ja -administratiivne tegevus 2018−... Eesti Kardioloogide Seltsi juhatuse liige 2017−... Eesti Haigekassa ravimikomisjoni esimees 2017−... Riikliku Siirdemeditsiini ja Kliiniliste Teadusuuringute Keskuse kliiniliste uuringute keskuse juhtkomitee liige 2012−... Eesti ravijuhendite nõukoja liige 2010−... Euroopa Ravimiameti kardiovaskulaartöörühma liige (2017 asejuhataja) 2009−... Ravimiameti ravimite müügilubade komisjoni ase-esimees 2004−... Euroopa Ravimiameti inimravimite komitee liige 2013−2016 TÜ arstiteaduse programminõukogu liige 2013−2017 Programmi „Tervishoiuteaduste võimekuse edendamine“ (TerVE) tervisetehnoloogiate hindamise (TTH) nõukogu, liige 2011−2016 Ravimiinfo Assotsiatsiooni Euroopa nõukoja liige 2010−2013 Eesti Farmakoloogia Selts, juhatuse liige (president) 2009−2017 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni hariduse alakomitee, liige 2008−2013 Maailma Terviseorganisatsiooni esmavajalike ravimite komitee liige 2008−2013 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni nõukogu liige 2004−2017 Sotsiaalministeeriumi ravimikomisjoni liige Teadustöö põhisuunad ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B530 Südame-veresoonkonna haigused ; TÄPSUSTUS: Aterosklerootilise kardiovaskulaarhaiguse ennetus ja ravi Jooksvad projektid • (RITA1/01-42-01) "Personaalmeditsiini kliinilised juhtprojektid rinnavähi ja südame- veresoonkonna haiguste täppisennetuses (1.01.2018−31.12.2020)", Peeter Padrik, SA Tartu Ülikooli Kliinikum. Publikatsioonid 2019 Alver, Maris; Palover, Marili; Saar, Aet; Läll, Kristi; Zekavat, Seyedeh Maryam; Tõnisson, Neeme; Leitsalu, Liis; Reigo, Anu; Nikopensius, Tiit; Ainla, Tiia; Kals, Mart; Mägi, Reedik; Gabriel, Stacey B; Eha, Jaan; Lander, Eric S; Irs, Alar; Philippakis, Anthony; Marandi, Toomas; Natarajan, Pradeep; Metspalu, Andres ... Esko, Tõnu (2019). Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine, 1−8.10.1038/s41436-018-0311-2. Freemantle, Nick; Irs, Alar; De Paulis, Ruggero; Pagano, Domenico; Falk, Volkmar; Beyersdorf, Friedhelm (2019). Transcatheter versus surgical aortic valve replacement: what does the latest evidence tell us? European Journal of Cardio-thoracic Surgery, 56 (1), 7−9.10.1093/ejcts/ezz163. 2016 Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. (2016). Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open, 2016 (6, 6), e011666.10.1136/bmjopen-2016-011666. Bueno H, de Graeff P, Richard-Lordereau I, Emmerich J, Fox KA, Friedman CP, Gaudin C, El-Gazayerly A, Goldman S, Hemmrich M, Henderson RA, Himmelmann A, Irs A, Jackson N, James SK, Katus HA, Laslop A, Laws I, Mehran R, Ong S, Prasad K, Roffi M, Rosano GM, Rose M, Sinnaeve PR, Stough WG, Thygesen K, Van de Werf F, Varin C, Verheugt FW, de Los Angeles Alonso García M. (2016). Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European Heart Journal, 2016 (Jun 29, Eur Heart J Acute Cardiovasc Care), pii: 2048872616649859.10.1177/2048872616649859 [ilmumas]. Sonn, K.; Irs, A.; Laius, O. (2016). Clinical pharmacology and trends in use of sedative-hypnotic and anxiolytic medications in Estonia. 25. HOBOKEN: Wiley-blackwell, 188−188. (25). 2013 Hoebert, J; Irs, A; Mantel-Teeuwisse, A; Leufkens, H. (2013). Future of the European Union regulatory network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology, 76 (1), 1−6.10.1111/j.1365-2125.2012.04476.x. Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124. Pintson, Madli; Irs, Alar (2013). Involvement of Residents in the National Guideline Development Process in Estonia. 10th EACPT Summer School, Edinburgh, UK, 4-6.07.2013. 2012 Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe; Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit; Habicht, Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe, Erki; Esnar, Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend. Eesti Haigekassa, Tartu Ülikool 2012. 2011 Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20 (5), 474−481.10.1002/pds.2125. Raudsepp, D.; Lass, J.; Saar, M.; Kuld, L.; Irs, A. (2011). Ravimite koos- või kõrvaltoimed erakorralise meditsiini osakonda pöördumise põhjusena - prospektiivne vaatlusuuring. Eesti Arst, 3, 122−128. 2010 Irs, A.; Salupere, R.; Sinisalu, V. (2010). Mittesteroidsete põletikuvastaste ravimite ohutu kasutamine. Eesti Arst, 89 (6), 417−422. Kirss, Anne; Maipuu, Lea; Eelmäe, Imbi; Metsvaht, Tuuli; Sirotkina, Meeli; Irs, Alar (2010). Angiotensiini konverteeriva ensüümi inhibiitori ja angiotensiini II retseptori blokaatori kasutamise ohud raseduse ajal: haigusjuhu kirjeldus ja kirjanduse ülevaade. Eesti Arst, 89, 502−509. Lass, J.; Iljuhhina, J.; Laius, O.; Pisarev, H.; Irs, A. (2010). Retseptiravimite raseduseaegne kasutamine Eestis. Eesti Arst: TÜ Arstiteaduskonna teaduskonverents, 7-8.okt. 2010. 2009 Laius, O.; Irs, A.; Kiivet, R. -A. (2009). FROM USSR TO EU - LONG-TERM TRENDS IN ESTONIAN DRUG UTILIZATION. 105. MALDEN: Wiley-blackwell Publishing, Inc, 96−96. (105). Lass, J.; Laius, O.; Leinemann, T.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Availability of paediatric information in Summaries of Product Characteristics of drugs prescribed to children in Estonia. 12th Congress of European Society for Developmental Perinatal & Paediatric Pharmacology, Chamonix, Prantsusmaa, 17-20.06.2009. Lass, J.; Laius, O.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Substantial proportion of ambulatory prescribing for children is off-label in Estonia. 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, Šotimaa, 12-15.07.2009. 2008 Freemantle, N.; Irs, A. (2008). Observational evidence for determining drug safety. British Medical Journal, 336 (7645), 627−628.10.1136/bmj.39491.493252.80. Zarkovski, Aleksander; Kalda, Anti; Gavronski, Maia; Hartikainen, Sirpa; Irs, Alar (2008). Kliinik 2008 : ravimitest tulenevad ohud [Videosalvestis]. Kliinik 2008, Tartu Ülikooli Kliinikumi õenduskonverents; Tartu; 4.-6. veebruar 2008. Tartu: TÜ IT Multimeedia talitus,. (TÜ filmiarhiiv). 2006 Johnson, K.R.; Ringland, C.; Stokes, B.J.; Anthony, D.M.; Freemantle, N.; Irs, A.; Hill, S.R.; Ward, R.L. (2006). Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology, 7 (9), 741−746. Raal, A.; Fischer, K.; Irs, A. (2006). Determination of drug information needs of health care professionals in Estonia. Medicina (Kaunas), 42 (12), 1030−1034. 2005 Ristimäe, T.; Irs, A.; Teesalu, R. (2005). Arteriaalne hüpertensioon kui südame-veresoonkonnahaiguste oluline riskitegur. Eesti Arst, 4, 277−282. Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2005). Tervisesüsteem muutustes: Eesti. Tallinn: World Health Organization. 2004 Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2004). Health care systems in transition: Estonia. Copenhagen: World Health Organization. 2001 Rootslane, L.; Irs, A.; Kiivet, R. (2001). ATC/DDD methodology: a country perspective. WHO Drug Information, 15 (1), 26−30. Irs, A.; Rootslane, Ly (2001). The use of antihypertensive drugs in in Estonia compared to the Nordic countries. Pharmacology & Toxicology, 89, suppl.. 50. 1999 Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380. Kask, A.; Pahkla, R.; Irs, A.; Rago, L.; Wikberg, JES.; Schioth, HB. (1999). Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport, 10 (4), 707−711. 2019‐11‐25 Curriculum vitae Anton Pohanka Karolinska University Hospital Department of Clinical Pharmacology S‐141 86 Stockholm Sweden Telephone: +46‐8‐58581195 E‐mail: [email protected] Profile Analytical chemist with expertise of quantitative and qualitative bioanalysis. Leadership position for eight years for the SWEDAC/CAP/WADA accredited Karolinska Pharmacology Laboratory, Stockholm. Long experience in alternative biomatrices as DBS, saliva and breath. Teaching merits Mentor for Laboratory Managers through the Karolinska University Hospital Mentor Supervision Program. 2019‐ PhD supervision: Currently co‐supervisor for Fadiea Al‐Aieshy. Evaluation of biomarkers for the new oral anticoagulants apixaban and rivaroxaban, to increase safety and efficacy in individual patients. Department of Medicine, Karolinska Institute Main supervisor for PhD/student Camilla Linder, dissertation 20190614. Possibilities of dried blood spots as a matrix in therapeutic drug monitoring of antiepileptic drugs in children., Department of Laboratory Medicine, Karolinska Institute. Co‐supervisor for Dr Rana Said, dissertation 20100922. Application of new technology: MEPS and LC‐ MS/MS for determination of therapeutic drugs. Department of Laboratory Medicine, Karolinska Institute. Main supervisor for several Master thesis projects. Karolinska Institute, Uppsala University, Stockholm University. Research merits Co‐applicant ALF Medicine 2013 ”Concept study for individualized treatment of children with epilepsy: a micromethod for monitoring drug levels in a home environment by dried blood spots on filter paper”. The application received a two‐year grant of a total of 1,8 million SEK. Co‐applicant HMT (Health, Medicine, Technique) project funds 2014 ” Enabling Therapeutic Drug Monitoring from Home through Dried Blood Spot (DBS) Sampling”, The application received a two‐ year grant of a total of 2 million SEK. Co‐applicant ALF Medicine 2016 ”Individualized treatment of children with epilepsy of children with epilepsy and at immunosuppression “with filter paper kit” for sampling and analysis of drug levels and laboratory parameters at home”. The application received a three‐year grant of a total of 1,85 million SEK. 2019‐11‐25 Work experience Sept 2019‐ Acting Interim Director, Swedish Doping Control Laboratory Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. Aug 2017‐ Head of Pharmacological Laboratory, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. Aug 2017 – Dec 2017 Acting Head of Drugs of Abuse and Therapeutic Drug Monitoring Laboratory, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden Apr 2011‐Jul 2017 Head of Therapeutic Drug Monitoring Laboratory, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden Nov 2007‐Mar 2011 1st Hospital Chemist, Therapeutic Drug Monitoring Laboratory, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden Feb 1999‐Mar 2000 Laboratory Engineer, Quality Assurance, Fresenius Kabi AB, Stockholm, Sweden Positions and memberships 2014‐ Member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology 2017‐ Scientific Director of the Drugs of Abuse Laboratory under the current CAP Accreditation Education 2000 ‐2006 PhD in Chemistry. Departement of Chemistry, Swedish Agricultural University. Dissertation: ”Antimicrobial Antibiotics from Potential Biocontrol Microorganisms” 1993‐1999 MSc. in Biology, Uppsala University, Sweden. Profile of analytical chemistry and pharmacognosy. Master thesis: Minor Field Study, Sri Lanka: ”Identification of Ayurvedic Medicinal Plants ‐ with Special Reference to Plants Used Against Atopic Dermatitis” International Scientific conferences last five years WADA World Conference on Doping in Sports, Katowice, 2019 USADA Symposium on Anti‐Doping Science, Tokyo 2019 MSACL, Stuttgart, 2018 IATDMCT 15 Kyoto, 2017, 5 posters IATDMCT 14 Rotterdam, 2015, 3 posters Publications Part of 31 peer reviewed articles. Curriculum vitae Name Jana Lass Place and date of birth Tallinn, Estonia, 30.10.1979 Citizenship Estonian Address, Phone, e-mail Tähtvere 18a-3, Tartu 51007 533 18 333 [email protected] Education Tartu University Medical Faculty, Institute of Microbiology, 2013, Phd The Queen`s University Belfast, 2006, MSc Clin Pharm Tartu Univeristy Medical Faculty, Institute of Pharmacy, 2003, Msc Languages English, russian, finnish, passive german Career 2020-…Lecturer (0.1p), University of Tartu, Institute of Pharmacy 2018 - …. Research Fellow of Clinical pharmacology (0.4 p), University of Tartu, Institute of Genomics, Estonian Genome Center Science Center 2016 - 2019 Research Fellow of Medical Microbiology (0.1 p), University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Department of Microbiology 01.01.2013–... European Medicines Agency, Paediatric Committee, alternate member 2007–... Tartu University Hospital, clinical pharmacist (1,0 p) 01.01.2016–31.01.2016 University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Faculty of Medicine, Department of Microbiology, Specialist (0,75) 01.01.2012–31.03.2014 University of Tartu, Faculty of Medicine, Department of Pediatrics, Specialist (0,15) 01.01.2004–31.12.2007 North Estonia Regional Hospital, pharmacist Academic degree Jana Lass, Doctor's Degree, 2013, (sup) Irja Lutsar, Epidemiological and clinical aspects of medicines use in children in Estonia, University of Tartu. 1 Honours & awards The Association of Pharmaceutical Manufacturers in Estonia (APME) research price „Hospitalised neonates in Estonia commonly receive potentially harmful excipients“ 2012 Academic projects in progress PRG184 (PRG184) "Role of Rare and Common Genetic Variants in Adverse Drug Reactions (1.01.2018−31.12.2022)", Lili Azin Milani, University of Tartu, Institute of Genomics. IUT34-24 "Management of infections in the immunocompromised host – from bench to bedside (1.01.2015−31.12.2020)", Irja Lutsar, University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational PUT718 (PUT718) "The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of selected ß-lactam antibiotics in children and young adults with cancer (1.01.2015−31.08.2019)", Lenne-Triin Kõrgvee, University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine. Completed projects SF0180004s12 "Infection and immunocompromised host - from mechanisms to translation into clinical practice (1.01.2012−31.12.2014)", Irja Lutsar, University of Tartu, Faculty of Medicine. SARLA11077E "Paediatric Accelerator Mass Spectrometry Evaluation Research Study (1.04.2011−31.12.2014)", Heili Varendi, University of Tartu, University of Tartu, Faculty of Medicine, Department of Pediatrics. ETF8799 "Pharmacokinetics of meropenem in very low birth weight infants - short vs long infusion (1.01.2011−31.12.2012)", Irja Lutsar, University of Tartu, Faculty of Medicine. SF0182726s06 "HIV infection in Estonia: molecular and clinical implications of host and virus interactions. (1.01.2006−31.12.2011)", Irja Lutsar, University of Tartu, Faculty of Medicine. Dissertations under supervision Inge Mesek, Phd student, (sup) Irja Lutsar; Jana Lass, Euroopas kasutusel olevate ravimvormide sobilikkus vastsündinutele ja väikelastele (Availability of age-appropriate drug formulations and extent of extemporaneous medicines use in hospitalised), University of Tartu. Recent publications  Kogermann, Karin; Lass, Jana et al. (2018). Age-appropriate formulations including pharmaceutical excipients in neonatal medicines. Current Pharmaceutical Design, 23, 5779−5789.10.2174/1381612823666170926122613.  Takkis, Kalev; Aro, Rudolf; Kõrgvee, Lenne-Triin; Varendi, Heili; Lass, Jana; Herodes, Koit; Kipper, Karin (2017). Signal Enhancement in the HPLC-ESI-MS/MS 2 Analysis of Spironolactone and its Metabolites Using HFIP and NH4F as Eluent Additives. Analytical and Bioanalytical Chemistry, 409 (12), 3145−3151.s00216-017- 0255-4.  Lass, Jana; Tamme, Kadri; Kipper, Karin; Starkopf, Joel (2017). Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient. Case Reports in Critical Care, 1−3.10.1155/2017/5310768.  Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Lass, Jana; Duncan, Jennifer; Nunn, Anthony J; Turner, Mark A; Lutsar, Irja (2016). Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates. Paediatric drugs, 18 (3), 221−230.10.1007/s40272-016-0173-5.  Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja (2016). The impact of gestational age and geographical region on anti-infectives’ use in European neonatal intensive care units (NICU). In: .34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 10.-14.05.2016, Brighton, UK.  Garner, RC.; Park, BK.; French, NS.; Earnshaw, C.; Schipani, A.; Selby, AM.; Byrne, L.; Siner, S.; Crawley, FP.; Vaes, WH.; van Duijn, E.; deLigt, RA.; Varendi, H.; Lass, J.; Grynkiewicz, G.; Maruszak, W.; Turner, MA. (2015). Observational infant exploratory [14 C]paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. British Journal of Clinical Pharmacology, 80 (1), 157−167.10.1111/bcp.12597.  Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Toompere, Karolin; Lass, Jana; Mesek, Inge; Nunn, Anthony; Turner, Mark; Lutsar, Irja (2015). Potentially harmful excipients in neonatal medicines: a pan-European observational study. Archives of Disease in Childhood, 100 (7), 694−699.10.1136/archdischild-2014-307793.  Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2014). Age-appropriateness of cardiovascular medicine’s formulations for neonates. 43rd ESCP Symposium on Clinical Pharmacy, Copenhagen, Denmark 22-24 October.  Turner, MA.; Park, BK.; French, NS.; Earnshaw, A.; Schipani, A.; Selby, AM.; Byrne, L.; Siner, S.; Vaes, WHJ.; Van Dujin, E.; De Ligt, RAF.; Varendi, H.; Lass, J.; Grynkiewicz, G.; Maruszak, W.; Crawley, FP.; Garner, RC. (2014). Comparative pediatric acetaminophen pharmacokinetics between a microdose and a therapeutic dose using accelerator mass spectrometry bioanalysis. 5th congress of the European Academy of Paediatric Societies. October 17-21, Barcelona, Spain. Other academic activities  Estonian Society of Hospital Pharmacists (ESHP), member of the board since 2006  Estonian Society of Pharmacology, member since2013 Teaching activities ARFA.01.104 Clinical pharmacy (pharmacy students) since 2016 ARAI.00.009 Clinical Pharmacology Club (pharmacy and medical students) 2016/2017 ARFR.02.052 Pharmacotherapy (medical students) since 2016 Jana Lass 03.01.2020 3 Curriculum Vitae, Erik Eliasson Born 1963 in Stockholm, Swedish citizen, married, family 1. University degree 1994, Medical doctor, Karolinska Institutet (KI), Stockholm, Sweden 2. PhD 1992, KI, Physiological Chemistry, supervisor prof Magnus Ingelman-Sundberg 3. Post-doctoral visits 1994-95 Imperial College School of Medicine, Pharmacology & Toxicology, London, UK 1996, KI, Institute of Environmental Medicine, Molecular Toxicology, Stockholm 4. Associate professor/Docent at Karolinska Institutet 2000, Drug toxicology, switch to Clinical Pharmacology in 2006 5. Clinical specialist competence 2004, Clinical Pharmacology, certified by the National Board of Health & Welfare 6. Current position and employer(s) Professor and senior physician, a joint affiliation since 2012, at Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, and Karolinska University Hospital, Stockholm. Medical head of the Karolinska University Hospital Pharmacology Laboratory (including therapeutic drug monitoring and clinical pharmacogenetics) since 2004, and in the steering board of the Clinical Pharmacology Department since 2009. Line manager with staff responsibility as section head. 7. Previous position and employments National Expert on Secondment, European Medicines Agency, Scientific Advice Office, London, UK 2016-2017 Senior lecturer (KI) since 2010, and clinical specialist since 2004, Karolinska University Hospital, Clinical Pharmacology Research physician, AstraZeneca R&D, Södertälje, 2007-2008 Resident in Clinical Pharmacology, Huddinge University Hospital 2000-2004, including internal medicine service in Gastroenterology and Nephrology Clinical Houseman, Huddinge/KI 1997-2000 9. PhD-student supervision at Karolinska Institutet Main supervisor for: Mia Sandberg-Lundblad (MPharmSci) completed PhD 2005, Staffan Rosenborg (MD) completed PhD 2010, Johan Holm (MD) expected completion of PhD in 2020, Gustaf Beijer (MD), registration as PhD-student spring 2020. Co-supervision of: Etienne Neve (MSc) completed PhD in 2000, Ümit Yasar (MD) completed PhD 2002, Buster Mannheimer (MD) completed PhD 2009, Jessica Mwinyi (MD) completed PhD in 2010, Cristine Skogastierna (MSc) completed PhD in 2012, Linda Thorén (MD), ongoing since 2015 10. Teaching Annual teaching since the mid-1980s of Medical students at KI (medical biochemistry, pharmacology, clinical pharmacology). Additional teaching of graduate students or MD- residents in toxicology and clinical pharmacology. 11. Commissions of trust a. Vice-chairman in the Genomic Medicine Sweden Pharmacogenetics subsection since 2018 b. KI-representantive in the Laboratory Medicine-section of the Stockholm County Council, since 2010 c. Steering group member of the Karolinska Laboratory Medicine metabolomics platform d. Member of the Swedish Reference Group on Antibiotics, since 2010 e. Member of the Swedish Reference Group on Antimycotics, since 2004 f. Member of the Regional Ethics Committee, Stockholm, 2010-16 g. Member of the Stockholm County Council Expert group on infectious diseases, 2010-2016 h. Board member of the Swedish Foundation for Clinical Pharmacology, 2001-10 i. Board member of the Swedish Association for Clinical Pharmacology 2003- 2006 j. Member of the KI internal grants groups, 2003-2006 k. Local representative for the Swedish Medical Association, 2004 12. Publications In total, 90 published articles in PubMed and among these around 75 original papers or reviews, and accepted manuscripts or reviews in peer-reviewed journals 77 peer- reviewed-publikationer with 2910 citations and h-index of 29, in average 38 citations per article (source Web of Science Feb 2019). Swedish textbooks co-authorships: Sepsis på akuten och IVA, 2013, (Hanberger H, Editor), and Att lyckas med läkemedel, by Böttiger, Eliasson, and Lindh (Studentlitteratur, 2014). Five recent references on the topic: Hallberg P, Yue Q-Y, Eliasson E, Ås J, Melhus H, Wadelius M. SWEDEGENE – a national DNA biobank for pharmacogenomic studies of adverse drug reactions. Pharmacogenomics J 2019, in press. He W, Grassmann F, Eriksson M, Eliasson E, Thorén L, Margolin S, Hall P, Czene K, CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in breast cancer patients. J Clin Oncol, 2019, Dec 4 Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 - A study on therapeutic drug monitoring data from 1,003 genotyped Scandinavian patients. Br J Clin Pharmacol. 2019;85:194-201 Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol, 2014;70:1375-83 Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl M-L, Eliasson E. CYP2D6 and adjuvant tamoxifen: Possible differences of outcome in pre- and postmenopausal patients. Pharmacogenomics, 2013;14:613-22 13. Other merits • Editorial Board member of Therapeutic Drug Monitoring since 2005, Clinical Pharmacokinetics since 2006, Frontiers in Pharmacogenetics since 2010. Additional referee-work for Nature Med, Mol Pharmacol, Brit J Clin Pharmacol, Basic Clin Pharmacol Toxicol, Hepatology, J Hepatol, Chem Biol Interact, Pharmacogenetics & Genom, Eur J Clin Pharmacol, Clin Pharmacol Ther, etc • Recent research funding Stockholm County Council, Vinnova Swe Innovation Agency (Platinea), Public Health Agency Sweden 14. EC-related collaborations, previous experiences EUROHEPATOX – drug induced liver injury (associate partner, to PI JG Kenna, 1996-1999) EUDRAGENE - a biobank to study the genetic basis for serious drug toxicity (associate contractor, PI M Molokhia, 2003-07) SWEDEGENE - ongoing DNA collection of Swe ADR cases reported to the MPA (www.swedegene.se) Üldandmed Isiku kontaktandmed Eesnimi Lili Azin Telefon 737 4039 Perenimi Milani E-post [email protected] Sünniaeg 27.11.1981 Teine telefon 5304 5400 (5400) Researcher ID C-8759-2011 Lisainfo Keeled: rootsi keel - emakeel, inglise keel - ORCID 0000-0002-5323-3102 väga hea, eesti keel - väga hea, pärsia keel - väga hea, prantsuse keel - hea, vene keel - vähe. Töökohad ja ametid Periood Kirjeldus 01.11.2018–... Tartu Ülikool, Tartu Ülikooli genoomika instituut, epi- ja farmakogenoomika juhtivteadur (1,00) 2017 -2018 Uppsala ülikool, meditsiiniteaduste teaduskond, Associate Senior Lecturer & SciLifeLab teadur 2013–01.06.2018 Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Vanemteadur (1,00) 01.06.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, epi- ja 31.10.2018 farmakogenoomika juhtivteadur (0,50) 01.01.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, farmakogenoomika 31.05.2018 vanemteadur (0,50) 01.02.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, farmakogenoomika 31.12.2017 vanemteadur (1,00) 01.01.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, farmakogenoomika 31.01.2016 peaspetsialist (1,00) 01.04.2013– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, vanemteadur (1,00) 31.12.2015 01.01.2013– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, vanemteadur (0,60) 31.03.2013 01.12.2012– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,50) 31.12.2012 10.09.2012– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, direktori kohusetäitja 30.11.2012 01.09.2011– Eesti Biokeskus, Erakorraline vanemteadur (0,50) 31.12.2012 2011– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Sekveneerimise ja 31.03.2017 genotüpiseerimise tuumiklabori juhataja (0,20) 01.12.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (1,00) 30.11.2012 01.02.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,20) 30.11.2010 2010–2012 Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Järeldoktor (1,00) 01.01.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,50) 31.01.2010 01.01.2009– Uppsala Ülikool, Lapsepuhkus (0.80) 31.12.2010 01.01.2009– Uppsala Ülikool, Teadur (0.20) 31.12.2010 01.01.2004– Uppsala Ülikool, doktorant 31.12.2009 01.01.2004– Uppsala Ülikooli WCN SNP genotüpiseerimise osakond, laborant 31.12.2004 2001–2003 Tartu Ülikool, Arstiteaduskond, Patoloogilise anatoomia ja kohtuarstiteaduse instituut, Patoloogilise anatoomia õppetool, laborant (0,50) Haridustee Periood Kirjeldus 2004–2009 Uppsala ülikool, Meditsiiniliste Teaduste Osakond, Molekulaarne Meditsiin; PhD 2000–2004 Tartu Ülikool, Molekulaar- ja Rakubioloogia Instituut; BSc 1994–2000 Tallinna Inglise Kolledz; keskkool Teadusorganisatsiooniline ja -administratiivne tegevus Periood Kirjeldus 2005−2007 WCN praktilise kursuse “Applied bioinformatics and methodologies in SNP genotyping” juhendaja, Uppsala Ülikool 2004−2006 EU/EMBO praktilise kursuse “Advanced techniques in molecular medicine” korraldaja ja juhendaja, Uppsala Ülikool Teaduskraadid Lili Azin Milani, doktorikraad, 2009, (juh) Ann-Christine Syvänen, Gene Expression in Cancer Cells: Detection of Splice Variants, Allele-specific Expression and DNA Methylation, Uppsala Ülikool. Teaduspreemiad ja tunnustused Aasta Kirjeldus 2015 Vabariigi Presidendi kultuurirahastu noore teadlase preemia 2012 Eesti Teadusfondi uurimistoetus (4 aastaks) 2011 MOBILITAS Järeldoktori uurimistoetus (3 aaastaks) 2008 Anna Lundins stipendium väljapaistvatele doktorantidele 2008 Keystone Symposia stipendium: Vähi genoomika ja epigenoomika konverentsiks 2008 Hedströms stipendium väljapaistavatele vanem doktorantidele 2007 Anna Lundins stipendium väljapaistvatele doktorantidele Teadustöö põhisuunad VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika; PÕHISUUND: epigeneetika, geeniekspressioon, molekulaarne meditsiin VALDKOND: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatika; CERCS ERIALA: B220 Geneetika, tsütogeneetika Lisainfo Osalemine WCN kursustel “Applied bioinformatics and methodologies in SNP genotyping”, Uppsala ja Stockholm, Rootsi 13-19 november, 2004 Osalemine J.D. Terwilliger kursustel “Study design issues for gene mapping in complex traits”, Tartu, Estonia 24-26 mai, 2004 Osalemine CSHL kursustel “Eukaryotic gene expression”, Cold Spring Harbor Laboratory, USA 25. juuni - 15. august, 2005 Jooksvad projektid SLTMR16142T "Genoomika ja Siirdemeditsiini Tippkeskus (TK142) (1.01.2016−1.03.2023)", Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu. PRG184 (PRG184) "Haruldaste ja sagedaste geenivariantide mõju ravimite kõrvaltoimetele (1.01.2018−31.12.2022)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikooli genoomika instituut. MP1GI18442R "Personaalne meditsiin parema elukvaliteedi tagamiseks insuldi ennetava modelleerimise kaudu (1.05.2018−30.04.2022)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikooli genoomika instituut. IUT20-60 "Oomiksi põhised meetodid terviseuuringutes: integreeritud lähenemine haiguste tekkeprotsesside mõistmiseks ja prognoosimiseks (1.01.2014−31.12.2019)", Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikool, Tartu Ülikooli genoomika instituut. Lõppenud projektid MLTAT18497R "Ühistaristu loomine Euroopa, Kanada ja Aafrika rahvuslike kohortide jaoks (1.01.2019−31.12.2022)", Kaur Alasoo, Tartu Ülikool, Loodus- ja täppisteaduste valdkond, arvutiteaduse instituut. ETF9293 "Ravimite metabolismiga seotud geenide põhjalik geneetiline ja epigeneetiline analüüs uue põlvkonna sekveneerimistehnoloogiaga (1.01.2012−31.12.2015)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu. MJD71 "IN-DEPTH GENETIC AND EPIGENETIC ANALYSIS OF THE CYTOCHROME P450 SYSTEM BY NEXT-GENERATION SEQUENCING (1.03.2011−28.02.2014)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu. SF0180142Cs08 "Geneetiline varieeruvus, elustiil ja keskkonnategurid kui peamised tervise mõjurid - EGV (1.01.2008−31.12.2013)", Andres Metspalu, Tartu Ülikool, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu. Juhendamisel väitekirjad Anu Tammiste, doktorant, (juh) Andres Metspalu; Eduard Maron; Lili Azin Milani, Genetic factors influencing antidepressant response (Antidepressantide toimet ennustavad geneetilised tegurid), Tartu Ülikool. Kristi Krebs, doktorant, (juh) Lili Azin Milani; Andres Metspalu, Genome wide analysis of genetic and epigenetic variants associated with drug metabolism using modern sequencing technology (Ravimite lagundamisega seotud geenide põhjalik geneetiline ja epigeneetiline analüüs uue põlvkonna sekveneerimisetehnoloogiaga), Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu. Epp Kaleviste, doktorant, (juh) Kai Kisand; Pärt Peterson; Lili Azin Milani, The impact of transcription factors STAT1 and AIRE on immune cells and cytokine signaling pathways (Transkriptsioonifaktorite STAT1 ja AIRE mõju immuunrakkudele ja tsütokiinide signaaliradadele), Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut. Kelli Grand, doktorant, (juh) Lili Azin Milani; Pärt Peterson; Andres Metspalu, Investigating immune related diseases using high-throughput methods (Immuunsüsteemiga seotud haiguste uurimine uue põlvkonna meetoditega), Tartu Ülikool. Tõnis Tasa, doktorant, (juh) Jaak Vilo; Lili Azin Milani, Management and analysis of massive full-scale genome data. (Suuremahuline täisgenoomsete andmete haldus ja analüüs), Tartu Ülikool, Loodus- ja täppisteaduste valdkond, arvutiteaduse instituut. Juhendatud väitekirjad Kaie Lokk, doktorikraad, 2017, (juh) Neeme Tõnisson; Lili Azin Milani, Comparative genome- wide DNA methylation studies of healthy human tissues and non-small cell lung cancer tissue (Inimese tervete kudede ja mitteväikerakulise kopsuvähi võrdlevad ülegenoomsed DNA metülatsiooni uuringud), Tartu Ülikool, Loodus- ja täppisteaduste valdkond, molekulaar- ja rakubioloogia instituut. Riin Tamm, doktorikraad, 2017, (juh) Andres Metspalu; Lili Azin Milani, In-depth analysis of factors affecting variability in thiopurine methyltransferase activity (Uute tiopuriinmetüültransferaasi aktiivsust mõjutavate biomarkerite otsingul), Tartu Ülikool, Loodus- ja täppisteaduste valdkond, molekulaar- ja rakubioloogia instituut. Silva Kasela, doktorikraad, 2017, (juh) Lili Azin Milani; Krista Fischer; Andres Metspalu, Genetic regulation of gene expression: detection of tissue- and cell type-specific effects, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut, Biotehnoloogia õppetool. Liis Haljasmägi, magistrikraad, 2018, (juh) Kai Kisand; Lili Azin Milani; Pärt Peterson, I tüüpi interferoonide vastased neutraliseerivad autoantikehad süsteemse erütematoosse luupuse patsientidel, Tartu Ülikool, Loodus- ja täppisteaduste valdkond, molekulaar- ja rakubioloogia instituut. Marili Palover, magistrikraad, 2016, (juh) Lili Azin Milani; Silva Kasela, Telomeeride pikkuste seosed DNA metülatsiooniga, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut. Hanna Rein, magistrikraad, 2016, (juh) Kai Kisand; Lili Azin Milani, TaqMan tehnoloogia põhine metülatsioonimustri tuvastamine enneaegselt vananeva immuunsüsteemi monitoorimiseks, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut. Kelli Grand, magistrikraad, 2016, (juh) Lili Azin Milani; Pärt Peterson, Funktsioonikaoga mutatsioonide analüüs 2300 inimese genoomi ja terviseandmete põhjal, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut. Epp Kaleviste, magistrikraad, 2015, (juh) Lili Azin Milani; Kai Kisand, STAT1 geeni uudikfunktsiooniga mutatsiooni mõju JAK-STAT signaalirajale, Tartu Ülikool. Liina Pappa, magistrikraad, 2014, (juh) Lili Azin Milani; Tiit Nikopensius, Eksoomide sekveneerimine kahel unilateraalse neeru hüpoplaasiaga patsiendil, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut. Mari-Liis Reim, magistrikraad, 2013, (juh) Riin Tamm; Lili Azin Milani; Andres Metspalu, Inimese tiopuriinmetüültransferaasi aktiivsust mõjutavad faktorid maksas, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut, Biotehnoloogia õppetool. Silva Kasela, magistrikraad, 2013, (juh) Krista Fischer; Lili Azin Milani, DNA metülatsioon: normaliseerimine ja analüüs, Tartu Ülikool, Matemaatika-informaatikateaduskond, Matemaatilise statistika instituut. Publikatsioonid 2019 Tasa, T,; Krebs, K.; Kals, M.; Mägi, R.; Lauschke, V.M.; Haller, T.; Puurand, T.; Remm, M.; Esko, T.; Metspalu, A.; Vilo, J.; Milani, L. (2019). Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records. European Journal of Human Genetics, 0−0.10.1038/s41431-018-0300-6 [ilmumas]. Virtanen, V.B.; Salo, P.P.; Cao, J.; Löf-Granström, A.; Milani, L.; Metspalu, A.; Rintala, R.J.; Saarenpää-Heikkilä, O.; Paunio, T.; Wester, T.; Nordenskjöld, A.; Perola, M.; Pakarinen, M.P. (2019). Noncoding RET variants explain the strong association with Hirschsprung disease in patients without rare coding sequence variant. European Journal of Medical Genetics.10.1016/j.ejmg.2018.07.019 [_isbeingpublished]. 2018 Sung, Yun J.; Winkler, Thomas W.; de las Fuentes, Lisa; Bentley, Amy R.; Brown, Michael R.; Kraja, Aldi T.; Schwander, Karen; Ntalla, Ioanna; Guo, Xiuqing; Franceschini, Nora; Lu, Yingchang; Cheng, Ching-Yu; Sim, Xueling; Vojinovic, Dina; Marten, Jonathan; Musani, Solomon K.; Li, Changwei; Feitosa, Mary F.; Kilpelainen, Tuomas O.; Richard, Melissa A. ... Chasman, Daniel I. (2018). A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. American Journal of Human Genetics, 102 (3), 375−400.10.1016/j.ajhg.2018.01.015. Lee, James J; Wedow, Robbee; Okbay, Aysu; Kong, Edward; Maghzian, Omeed; Zacher, Meghan; Nguyen-Viet, Tuan Anh; Bowers, Peter; Sidorenko, Julia; Karlsson Linnér, Richard; Fontana, Mark Alan; Kundu, Tushar; Lee, Chanwook; Li, Hui; Li, Ruoxi; Royer, Rebecca; Timshel, Pascal N; Walters, Raymond K; Willoughby, Emily A; Yengo, Loïc ... Cesarini, David (2018). Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nature genetics, 50 (8), 1112−1121.10.1038/s41588-018-0147-3. Evangelou, Evangelos; Warren, Helen R; Mosen-Ansorena, David; Mifsud, Borbala; Pazoki, Raha; Gao, He; Ntritsos, Georgios; Dimou, Niki; Cabrera, Claudia P; Karaman, Ibrahim; Ng, Fu Liang; Evangelou, Marina; Witkowska, Katarzyna; Tzanis, Evan; Hellwege, Jacklyn N; Giri, Ayush; Velez Edwards, Digna R; Sun, Yan V; Cho, Kelly; Gaziano, J Michael ... Caulfield, Mark J (2018). Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature genetics, 50 (10), 1412−1425.10.1038/s41588-018-0205-x. Zhou, Yitian; Mägi, Reedik; Milani, Lili; Lauschke, Volker M (2018). Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. Journal of lipid research, 59 (10), 1987−2000.10.1194/jlr.P086710. Feitosa, Mary F; Kraja, Aldi T; Chasman, Daniel I; Sung, Yun J; Winkler, Thomas W; Ntalla, Ioanna; Guo, Xiuqing; Franceschini, Nora; Cheng, Ching-Yu; Sim, Xueling; Vojinovic, Dina; Marten, Jonathan; Musani, Solomon K; Li, Changwei; Bentley, Amy R; Brown, Michael R; Schwander, Karen; Richard, Melissa A; Noordam, Raymond; Aschard, Hugues ... Levy, Daniel (2018). Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. PLoS ONE, 13 (6), e0198166−e0198166.10.1371/journal.pone.0198166. Reisberg, Sulev; Krebs, Kristi; Lepamets, Maarja; Kals, Mart; Mägi, Reedik; Metsalu, Kristjan; Lauschke, Volker M.; Vilo, Jaak; Milani, Lili; (2018). Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in medicine.10.1038/s41436-018-0337-5. Lauschke, Volker M.; Milani, Lili; Ingelman-Sundberg, Magnus (2018). Pharmacogenomic Biomarkers for Improved Drug Therapy- Recent Progress and Future Developments. Aaps Journal, 20 (1), UNSP 4.10.1208/s12248-017-0161-x. Wray, Naomi R.; Ripke, Stephan; Mattheisen, Manuel; Trzaskowski, Maciej; Byrne, Enda M.; Abdellaoui, Abdel; Adams, Mark J.; Agerbo, Esben; Air, Tracy M.; Andlauer, Till M. F.; Bacanu, Silviu-Alin; Baekvad-Hansen, Marie; Beekman, Aartjan F. T.; Bigdeli, Tim B.; Binder, Elisabeth B.; Blackwood, Douglas R. H.; Bryois, Julien; Buttenschon, Henriette N.; Bybjerg- Grauholm, Jonas; Cai, Na ... Sullivan, Patrick F. (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 50 (5), 668−684.10.1038/s41588-018-0090-3. Wahl, Annika; Kasela, Silva; Carnero-Montoro, Elena; van Iterson, Maarten; Stambuk, Jerko; Sharma, Sapna; van den Akker, Erik; Klaric, Lucija; Benedetti, Elisa; Razdorov, Genadij; Trbojevic-Akmacic, Irena; Vuckovic, Frano; Ugrina, Ivo; Beekman, Marian; Deelen, Joris; van Heemst, Diana; Heijmans, Bastiaan T.; Wuhrer, Manfred; Plomp, Rosina; Keser, Toma ... Gieger, Christian (2018). IgG glycosylation and DNA methylation are interconnected with smoking. Biochimica et Biophysica Acta - General Subjects, 1862 (3), 637−648.10.1016/j.bbagen.2017.10.012. Lu, Y.; Pouget, J. G.; Andreassen, O. A.; Djurovic, S.; Esko, T.; Hultman, C. M.; Metspalu, A.; Milani, L.; Werge, T.; Sullivan, P. F. (2018). Genetic risk scores and family history as predictors of schizophrenia in Nordic registers. Psychological Medicine, 48 (7), 1201−1208.10.1017/S0033291717002665. Ruderfer, Douglas M.; Ripke, Stephan; McQuillin, Andrew; Boocock, James; Stahl, Eli A.; Pavlides, Jennifer M. Whitehead; Mullins, Niamh; Charney, Alexander W.; Ori, Anil P. S.; Loohuis, Loes M. Olde; Domenici, Enrico; Di Florio, Arianna; Papiol, Sergi; Kalman, Janos L.; Trubetskoy, Vassily; Adolfsson, Rolf; Agartz, Ingrid; Agerbo, Esben; Akil, Huda; Albani, Diego ... Kendler, Kenneth S. (2018). Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 173 (7), ARTN 1715.e16−1732.10.1016/j.cell.2018.05.046. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2018). Mis tunne on olla (noor) naisteadlane? Sirp : Eesti kultuurileht, 8−9. Turcot, Valerie; Lu, Yingchang; Highland, Heather M.; Schurmann, Claudia; Justice, Anne E.; Fine, Rebecca S.; Bradfield, Jonathan P.; Esko, Tonu; Giri, Ayush; Graff, Mariaelisa; Guo, Xiuqing; Hendricks, Audrey E.; Karaderi, Tugce; Lempradl, Adelheid; Locke, Adam E.; Mahajan, Anubha; Marouli, Eirini; Sivapalaratnam, Suthesh; Young, Kristin L.; Alfred, Tamuno ... Loos, Ruth J. F. (2018). Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (vol 50, pg 26, 2018). Nature Genetics, 50 (5), 766−767.10.1038/s41588-018-0082-3. Flannick, Jason; Fuchsberger, Christian; Mahajan, Anubha; Teslovich, Tanya M; Agarwala, Vineeta; Gaulton, Kyle J; Caulkins, Lizz; Koesterer, Ryan; Ma, Clement; Moutsianas, Loukas; McCarthy, Davis J; Rivas, Manuel A; Perry, John R B; Sim, Xueling; Blackwell, Thomas W; Robertson, Neil R; Rayner, N William; Cingolani, Pablo; Locke, Adam E; Tajes, Juan Fernandez ... McCarthy, Mark I (2018). Erratum: Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 5, 180002−180002.10.1038/sdata.2018.2. 2017 Wahl, Simone; Drong, Alexander; Lehne, Benjamin; Loh, Marie; Scott, William R; Kunze, Sonja; Tsai, Pei-Chien; Ried, Janina S; Zhang, Weihua; Yang, Youwen; Tan, Sili; Fiorito, Giovanni; Franke, Lude; Guarrera, Simonetta; Kasela, Silva; Kriebel, Jennifer; Richmond, Rebecca C; Adamo, Marco; Afzal, Uzma; Ala-Korpela, Mika ... Chambers, John C (2017). Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature, 541 (7635), 81−86.10.1038/nature20784. Hinney A, Kesselmeier M, Jall S, Volckmar AL, Föcker M, Antel J; GCAN; WTCCC3, Heid IM, Winkler TW; GIANT, Grant SF; EGG, Guo Y, Bergen AW, Kaye W, Berrettini W, Hakonarson H; Price Foundation Collaborative Group; Children’s Hospital of Philadelphia/Price Foundation, Herpertz-Dahlmann B, de Zwaan M, Herzog W, Ehrlich S, Zipfel S, Egberts KM, Adan R, Brandys M, van Elburg A, Boraska Perica V, Franklin CS, Tschöp MH, Zeggini E, Bulik CM, Collier D, Scherag A, Müller TD, Hebebrand J. (2017). Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index. Molecular Psychiatry, 22 (2), 192−201.10.1038/mp.2016.71. Guha M, Saare M, Maslovskaja J, Kisand K, Liiv I, Haljasorg U, Tasa T, Metspalu A, Milani L, Peterson P. (2017). DNA breaks and chromatin structural changes enhance the transcription of Autoimmune Regulator target genes. Journal of Biological Chemistry, 292 (16), 6542−6554.jbc.M116.764704. Guo, Michael H.; Nandakumar, Satish K.; Ulirsch, Jacob C.; Zekavat, Seyedeh M.; Buenrostro, Jason D.; Natarajan, Pradeep; Salem, Rany M.; Chiarle, Roberto; Mitt, Mario; Kals, Mart; Parn, Kalle; Fischer, Krista; Milani, Lili; Magi, Reedik; Palta, Priit; Gabriel, Stacey B.; Metspalu, Andres; Lander, Eric S.; Kathiresan, Sekar; Hirschhorn, Joel N. ... Sankaran, Vijay G. (2017). Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. Proceedings Of The National Academy Of Sciences Of The United States Of America, 114 (3), E327−E336.10.1073/pnas.1619052114. R Tamm, R Mägi, R Tremmel, S Winter, E Mihailov, A Smid, A Möricke, K Klein, M Schrappe, M Stanulla, R Houlston, R Weinshilboum, Irena Mlinarič Raščan, A Metspalu, L Milani, M Schwab, E Schaeffeler. (2017). Polymorphic Variation in TPMT Is the Principal Determinant of TPMT Phenotype: A Meta-Analysis of Three Genome-Wide Association Studies. Clinical Pharmacology & Therapeutics, 101 (5), 684−695.10.1002/cpt.540. Nath, Artika P.; Ritchie, Scott C.; Byars, Sean G.; Fearnley, Liam G.; Havulinna, Aki S.; Joensuu, Anni; Kangas, Antti J.; Soininen, Pasi; Wennerstrom, Annika; Milani, Lili; Metspalu, Andres; Mannisto, Satu; Wurtz, Peter; Kettunen, Johannes; Raitoharju, Emma; Kahonen, Mika; Juonala, Markus; Palotie, Aarno; Ala-Korpela, Mika; Ripatti, Samuli ... Inouye, Michael (2017). An interaction map of circulating metabolites, immune gene networks, and their genetic regulation. Genome Biology, 18, ARTN 146.10.1186/s13059-017-1279-y. Robinson, Matthew R.; English, Geoffrey; Moser, Gerhard; Lloyd-Jones, Luke R.; Triplett, Marcus A.; Zhu, Zhihong; Nolte, Ilja M.; van Vliet-Ostaptchouk, Jana V.; Snieder, Harold; Esko, Tonu; Milani, Lili; Magi, Reedik; Metspalu, Andres; Magnusson, Patrik K. E.; Pedersen, Nancy L.; Ingelsson, Erik; Johannesson, Magnus; Yang, Jian; Cesarini, David; Visscher, Peter M. (2017). Genotype-covariate interaction effects and the heritability of adult body mass index. Nature Genetics, 49 (8), 1174−1186.10.1038/ng.3912. Mihailov, E.; Nikopensius, T.; Reigo, A.; Nikkolo, C.; Kals, M.; Aruaas, K.; Milani, L.; Seepter, H.; Metspalu, A. (2017). Whole-exome sequencing identifies a potential TTN mutation in a multiplex family with inguinal hernia. Hernia, 21 (1), 95−100.10.1007/s10029-016-1491-9. Manning, Alisa; Highland, Heather M.; Gasser, Jessica; Sim, Xueling; Tukiainen, Taru; Fontanillas, Pierre; Grarup, Niels; Rivas, Manuel A.; Mahajan, Anubha; Locke, Adam E.; Cingolani, Pablo; Pers, Tune H.; Vinuela, Ana; Brown, Andrew A.; Wu, Ying; Flannick, Jason; Fuchsberger, Christian; Gamazon, Eric R.; Gaulton, Kyle J.; Im, Hae Kyung ... Lindgren, Cecilia M. (2017). A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes, 66 (7), 2019−2032.10.2337/db16-1329. Marshall, Christian R.; Marshall, Christian R.; Howrigan, Daniel P.; Merico, Daniele; Thiruvahindrapuram, Bhooma; Wu, Wenting; Greer, Douglas S.; Antaki, Danny; Shetty, Aniket; Holmans, Peter A.; Pinto, Dalila; Gujral, Madhusudan; Brandler, William M.; Malhotra, Dheeraj; Wang, Zhouzhi; Fajarado, Karin V. Fuentes; Maile, Michelle S.; Ripke, Stephan; Agartz, Ingrid; Albus, Margot ... Sebat, Jonathan (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 1, 27−35.10.1038/ng.3725. Mandaviya PR, Aïssi D, Dekkers KF, Joehanes R, Kasela S, Truong V, Stolk L, Heemst DV, Ikram MA, Lindemans J, Slagboom PE, Trégouët DA, Uitterlinden AG, Wei C, Wells P, Gagnon F, van Greevenbroek MM, Heijmans BT, Milani L, Morange PE, van Meurs JB, Heil SG; BIOS Consortium. (2017). Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. Epigenomics, 9 (11), 1403−1422.10.2217/epi- 2017-0038. Kasela, Silva; Kisand, Kai; Tserel, Liina; Kaleviste, Epp; Remm, Anu; Fischer, Krista; Esko, Tõnu; Westra, Harm-Jan; Fairfax, Benjamin P; Makino, Seiko; Knight, Julian C; Franke, Lude; Metspalu, Andres; Peterson, Pärt; Milani, Lili (2017). Pathogenic implications for autoimmune mechanisms derived by comparative eQTL analysis of CD4(+) versus CD8(+) T cells. PLoS genetics, 13 (3, 3), ARTN e1006643.10.1371/journal.pgen.1006643. Flannick, Jason; Fuchsberger, Christian; Mahajan, Anubha; Teslovich, Tanya M.; Agarwala, Vineeta; Gaulton, Kyle J.; Caulkins, Lizz; Koesterer, Ryan; Ma, Clement; Moutsianas, Loukas; McCarthy, Davis J.; Rivas, Manuel A.; Perry, John R. B.; Sim, Xueling; Blackwell, Thomas W.; Robertson, Neil R.; Rayner, N. William; Cingolani, Pablo; Locke, Adam E.; Tajes, Juan Fernandez ... McCarthy, Mark I. (2017). Data Descriptor: Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 4, ARTN 170179.10.1038/sdata.2017.179. Day, Felix R.; Thompson, Deborah J.; Helgason, Hannes; Chasman, Daniel I.; Finucane, Hilary; Sulem, Patrick; Ruth, Katherine S.; Whalen, Sean; Sarkar, Abhishek K.; Albrecht, Eva; Altmaier, Elisabeth; Amini, Marzyeh; Barbieri, Caterina M.; Boutin, Thibaud; Campbell, Archie; Demerath, Ellen; Giri, Ayush; He, Chunyan; Hottenga, Jouke J.; Karlsson, Robert ... Perry, John R. B. (2017). Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nature Genetics, 49 (6), 834−845.10.1038/ng.3841. Linner, R. Karlsson; Marioni, R. E.; Rietveld, C. A.; Simpkin, A. J.; Davies, N. M.; Watanabe, K.; Armstrong, N. J.; Auro, K.; Baumbach, C.; Bonder, M. J.; Buchwald, J.; Fiorito, G.; Ismail, K.; Iurato, S.; Joensuu, A.; Karell, P.; Kasela, S.; Lahti, J.; Mcrae, A. F.; Mandaviya, P. R. ... Benjamin, D. J. (2017). An epigenome-wide association study meta-analysis of educational attainment. Molecular Psychiatry, 22 (12), 1680−1690.10.1038/mp.2017.210. Gupta, R; Qaiser, B; He, L; Hiekkalinna, T S; Zheutlin, A B; Therman, S; Ollikainen, M; Ripatti, S; Perola, M; Salomaa, V; Milani, L; Cannon, T D; Madden, P A F; Korhonen, T; Kaprio, J; Loukola, A (2017). Neuregulin signaling pathway in smoking behavior. Translational psychiatry, 7 (8), e1212−e1212.10.1038/tp.2017.183. Kantojärvi, Katri; Liuhanen, Johanna; Saarenpää-Heikkilä, Outi; Satomaa, Anna-Liisa; Kylliäinen, Anneli; Pölkki, Pirjo; Jaatela, Julia; Toivola, Auli; Milani, Lili; Himanen, Sari- Leena; Porkka-Heiskanen, Tarja; Paavonen, Juulia; Paunio, Tiina (2017). Variants in calcium voltage-gated channel subunit Alpha1 C-gene (CACNA1C) are associated with sleep latency in infants. PLoS ONE, 12 (8), e0180652−e0180652.10.1371/journal.pone.0180652. Joshi, P. K., Pirastu, N., Kentistou, K. A., Fischer, K., Hofer, E., Schraut, K. E., Clark D.W., Nutile T., Barnes C.L.K., Timmers P.R.H.J., Shen X., Gandin I., McDaid A.F., Hansen T.F., Gordon S.D., Giulianini F., Boutin T.S., Abdellaoui A., Zhao W., Medina-Gomez C., Bartz T.M., Trompet S., Lange L.A., Raffield L., van der Spek A.,/.../,Bertram L., Pendleton N., Kardia S.L.R., Ciullo M., Becker D.M., Wong A., Psaty B.M., van Duijn C.M., Wilson J.G., Jukema J.W., Kiemeney L., Uitterlinden A.G, Franceschini N., North K.E., Weir D.R., Metspalu A., Boomsma D.I., Hayward C., Chasman D., Martin N.G., Sattar N., Campbell H., Esko T., Kutalik Z., Wilson J.F. (2017). Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nature Communications, 8, 910.10.1038/s41467-017-00934-5. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2017). Teadlaste koostöö ettevõtetega – kellele seda vaja on? Sirp : Eesti kultuurileht, 37−37. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2017). Põlevkivist elektri tootmisest on kujunemas piinlik igand. Sirp : Eesti kultuurileht, 28−29. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2017). Teadus kui haridusuuenduse toetuspunkt, vundament, vaade ja garantii. Sirp : Eesti kultuurileht, 34−35. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2017). Teadlaste otselepingud ja vaesus. Sirp : Eesti kultuurileht, 33−35. Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin; Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli; Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa ... Voll, Hendrik (2017). Kuhu viib teadlaste karjääriredel? Sirp : Eesti kultuurileht, 7−8. Lokk, Kaie; Vooder, Tõnu; Kolde, Raivo; Välk, Kristjan; Võsa, Urmo; Roosipuu, Retlav; Milani, Lili; Fischer, Krista; Koltsina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres; Tõnisson, Neeme (2017). Correction: Methylation Markers of Early-Stage Non-Small Cell Lung Cancer. PLoS ONE, 12 (1), e0170833−e0170833.10.1371/journal.pone.0170833. Lokk, Kaie; Vooder, Tonu; Kolde, Raivo; Valk, Kristjan; Vosa, Urmo; Roosipuu, Retlav; Milani, Lili; Fischer, Krista; Koltsina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres; Tonisson, Neeme (2017). Methylation Markers of Early-Stage Non-Small Cell Lung Cancer (vol 7, e39813, 2012). PLoS ONE, 1, ARTN e0170833.10.1371/journal.pone.0170833. 2016 Lessard, Samuel; Manning, Alisa K; Low-Kam, Cécile; Auer, Paul L; Giri, Ayush; Graff, Mariaelisa; Schurmann, Claudia; Yaghootkar, Hanieh; Luan, Jian'an; Esko, Tonu; Karaderi, Tugce; Bottinger, Erwin P; Lu, Yingchang; Carlson, Chris; Caulfield, Mark; Dubé, Marie-Pierre; Jackson, Rebecca D; Kooperberg, Charles; McKnight, Barbara; Mongrain, Ian ... Lettre, Guillaume (2016). Testing the role of predicted gene knockouts in human anthropometric trait variation. Human Molecular Genetics, 25 (10), 1−11.10.1093/hmg/ddw055. Ivanov, Maxim; Kals, Mart; Lauschke, Volker; Barragan, Isabel; Ewels, Philip; Käller, Max; Axelsson, Tomas; Lehtiö, Janne; Milani, Lili; Ingelman-Sundberg, Magnus (2016). Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. Nucleic acids research, 44 (14), 6756−6769.doi:10.1093/nar/gkw316. Franke, B; Stein, JL; Ripke, S; Anttila, V; Hibar, DP; van, Hulzen, KJ; Arias-Vasquez, A; Smoller, JW; Nichols, TE; Neale, MC; McIntosh, AM; Lee, P; McMahon, FJ; Meyer- Lindenberg, A; Mattheisen, M; Andreassen, OA; Gruber, O; Sachdev, PS; Roiz-Santiañez, R; Saykin, AJ ... Sullivan, PF . (2016). Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience, 19 (3), 420−433.10.1038/nn.4228. Pettai, Kristi; Milani, Lili; Tammiste, Anu; Võsa, Urmo; Kolde, Raivo; Eller, Triin; Nutt, David; Metspalu, Andres; Maron, Eduard (2016). Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26 (9), 1475−1483.10.1016/j.euroneuro.2016.06.007. Limbach, Maia; Saare, Mario; Tserel, Liina; Kisand, Kai; Eglit, Triin; Sauer, Sascha; Axelsson, Tomas; Syvänen, Ann-Christine; Metspalu, Andres; Milani, Lili; Peterson, Pärt (2016). Epigenetic profiling in CD4+ and CD8+ T cells from Graves' disease patients reveals changes in genes associated with T cell receptor signaling. Journal of Autoimmunity, 67, 46−56.10.1016/j.jaut.2015.09.006. Thiéry, Odile; Vasar, Martti; Jairus, Teele; Davison, John; Roux, Christophe; Kivistik, Paula- Ann; Metspalu, Andres; Milani, Lili; Saks, Ülle; Moora, Mari; Zobel, Martin; Öpik, Maarja (2016). Sequence variation in nuclear ribosomal small subunit, internal transcribed spacer and large subunit regions of Rhizophagus irregularis and Gigaspora margarita is high and isolate- dependent. Molecular ecology, 25 (12), 2816−2832.10.1111/mec.13655. Fuchsberger, Christian; Flannick, Jason; Teslovich, Tanya M; Mahajan, Anubha; Agarwala, Vineeta; Gaulton, Kyle J; Ma, Clement; Fontanillas, Pierre; Moutsianas, Loukas; McCarthy, Davis J; Rivas, Manuel A; Perry, John R B; Sim, Xueling; Blackwell, Thomas W; Robertson, Neil R; Rayner, N William; Cingolani, Pablo; Locke, Adam E; Tajes, Juan Fernandez; Highland, Heather M ... McCarthy, Mark I (2016). The genetic architecture of type 2 diabetes. Nature, 536 (7614), 41−47.10.1038/nature18642. Okbay, Aysu; Beauchamp, Jonathan P; Fontana, Mark Alan; Lee, James J; Pers, Tune H; Rietveld, Cornelius A; Turley, Patrick; Chen, Guo-Bo; Emilsson, Valur; Meddens, S Fleur W; Oskarsson, Sven; Pickrell, Joseph K; Thom, Kevin; Timshel, Pascal; de Vlaming, Ronald; Abdellaoui, Abdel; Ahluwalia, Tarunveer S; Bacelis, Jonas; Baumbach, Clemens; Bjornsdottir, Gyda ... Benjamin, Daniel J (2016). Genome-wide association study identifies 74 loci associated with educational attainment. Nature, 533 (7604), 539−542.10.1038/nature17671. Gormley, Padhraig; Anttila, Verneri; Winsvold, Bendik S; Palta, Priit; Esko, Tonu; Pers, Tune H; Farh, Kai-How; Cuenca-Leon, Ester; Muona, Mikko; Furlotte, Nicholas A; Kurth, Tobias; Ingason, Andres; McMahon, George; Ligthart, Lannie; Terwindt, Gisela M; Kallela, Mikko; Freilinger, Tobias M; Ran, Caroline; Gordon, Scott G; Stam, Anine H ... Palotie, Aarno (2016). Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature genetics, 48 (8), 856−866.10.1038/ng.3598. Barban N, Jansen R, de Vlaming R, Vaez A, Mandemakers JJ, Tropf FC, Shen X, Wilson JF, Chasman DI, Nolte IM, Tragante V, van der Laan SW, Perry JR, Kong A; BIOS Consortium, Ahluwalia TS, Albrecht E, Yerges-Armstrong L, Atzmon G, Auro K, Ayers K, Bakshi A, Ben- Avraham D, Berger K, Bergman A, Bertram L, Bielak LF, Bjornsdottir G, Bonder MJ, Broer L, Bui M, Barbieri C, Cavadino A, Chavarro JE, Turman C, Concas MP, Cordell HJ, Davies G, Eibich P, Eriksson N, Esko T, Eriksson J, Falahi F, Felix JF, Fontana MA, Franke L, Gandin I, Gaskins AJ, Gieger C, Gunderson EP, Guo X, Hayward C, He C, Hofer E, Huang H, Joshi PK, Kanoni S, Karlsson R, Kiechl S, Kifley A, Kluttig A, Kraft P, Lagou V, Lecoeur C, Lahti J, Li- Gao R, Lind PA, Liu T, Makalic E, Mamasoula C, Matteson L, Mbarek H, McArdle PF, McMahon G, Meddens SF, Mihailov E, Miller M, Missmer SA, Monnereau C, van der Most PJ, Myhre R, Nalls MA, Nutile T, Kalafati IP, Porcu E, Prokopenko I, Rajan KB, Rich-Edwards J, Rietveld CA, Robino A, Rose LM, Rueedi R, Ryan KA, Saba Y, Schmidt D, Smith JA, Stolk L, Streeten E, Tönjes A, Thorleifsson G, Ulivi S, Wedenoja J, Wellmann J, Willeit P, Yao J, Yengo L, Zhao JH, Zhao W, Zhernakova DV, Amin N, Andrews H, Balkau B, Barzilai N, Bergmann S, Biino G, Bisgaard H, Bønnelykke K, Boomsma DI, Buring JE, Campbell H, Cappellani S, Ciullo M, Cox SR, Cucca F, Toniolo D, Davey-Smith G, Deary IJ, Dedoussis G, Deloukas P, van Duijn CM, de Geus EJ, Eriksson JG, Evans DA, Faul JD, Sala CF, Froguel P, Gasparini P, Girotto G, Grabe HJ, Greiser KH, Groenen PJ, de Haan HG, Haerting J, Harris TB, Heath AC, Heikkilä K, Hofman A, Homuth G, Holliday EG, Hopper J, Hyppönen E, Jacobsson B, Jaddoe VW, Johannesson M, Jugessur A, Kähönen M, Kajantie E, Kardia SL, Keavney B, Kolcic I, Koponen P, Kovacs P, Kronenberg F, Kutalik Z, La Bianca M, Lachance G, Iacono WG, Lai S, Lehtimäki T, Liewald DC; LifeLines Cohort Study, Lindgren CM, Liu Y, Luben R, Lucht M, Luoto R, Magnus P, Magnusson PK, Martin NG, McGue M, McQuillan R, Medland SE, Meisinger C, Mellström D, Metspalu A, Traglia M, Milani L, Mitchell P, Montgomery GW, Mook-Kanamori D, de Mutsert R, Nohr EA, Ohlsson C, Olsen J, Ong KK, Paternoster L, Pattie A, Penninx BW, Perola M, Peyser PA, Pirastu M, Polasek O, Power C, Kaprio J, Raffel LJ, Räikkönen K, Raitakari O, Ridker PM, Ring SM, Roll K, Rudan I, Ruggiero D, Rujescu D, Salomaa V, Schlessinger D, Schmidt H, Schmidt R, Schupf N, Smit J, Sorice R, Spector TD, Starr JM, Stöckl D, Strauch K, Stumvoll M, Swertz MA, Thorsteinsdottir U, Thurik AR, Timpson NJ, Tung JY, Uitterlinden AG, Vaccargiu S, Viikari J, Vitart V, Völzke H, Vollenweider P, Vuckovic D, Waage J, Wagner GG, Wang JJ, Wareham NJ, Weir DR, Willemsen G, Willeit J, Wright AF, Zondervan KT, Stefansson K, Krueger RF, Lee JJ, Benjamin DJ, Cesarini D, Koellinger PD, den Hoed M, Snieder H, Mills MC. (2016). Genome-wide analysis identifies 12 loci influencing human reproductive behavior. Nature Genetics, 48 (12), 1462−1472.10.1038/ng.3698. Ried JS, Jeff M J, Chu AY, Bragg-Gresham JL, van Dongen J, Huffman JE, Ahluwalia TS, Cadby G, Eklund N, Eriksson J, Esko T, Feitosa MF, Goel A, Gorski M, Hayward C, Heard- Costa NL, Jackson AU, Jokinen E, Kanoni S, Kristiansson K, Kutalik Z, Lahti J, Luan J, Mägi R, Mahajan A, Mangino M, Medina-Gomez C, Monda KL, Nolte IM, Pérusse L, Prokopenko I, Qi L, Rose LM, Salvi E, Smith MT, Snieder H, Stančáková A, Ju Sung Y, Tachmazidou I, Teumer A, Thorleifsson G, van der Harst P, Walker RW, Wang SR, Wild SH, Willems SM, Wong A, Zhang W, Albrecht E, Couto Alves A, Bakker SJ, Barlassina C, Bartz TM, Beilby J, Bellis C, Bergman RN, Bergmann S, Blangero J, Blüher M, Boerwinkle E, Bonnycastle LL, Bornstein SR, Bruinenberg M, Campbell H, Chen YI, Chiang CW, Chines PS, Collins FS, Cucca F, Cupples LA, D'Avila F, de Geus EJ, Dedoussis G, Dimitriou M, Döring A, Eriksson JG, Farmaki AE, Farrall M, Ferreira T, Fischer K, Forouhi NG, Friedrich N, Gjesing AP, Glorioso N, Graff M, Grallert H, Grarup N, Gräßler J, Grewal J, Hamsten A, Harder MN, Hartman CA, Hassinen M, Hastie N, Hattersley AT, Havulinna AS, Heliövaara M, Hillege H, Hofman A, Holmen O, Homuth G, Hottenga JJ, Hui J, Husemoen LL, Hysi PG, Isaacs A, Ittermann T, Jalilzadeh S, James AL, Jørgensen T, Jousilahti P, Jula A, Marie Justesen J, Justice AE, Kähönen M, Karaleftheri M, Tee Khaw K, Keinanen-Kiukaanniemi SM, Kinnunen L, Knekt PB, Koistinen HA, Kolcic I, Kooner IK, Koskinen S, Kovacs P, Kyriakou T, Laitinen T, Langenberg C, Lewin AM, Lichtner P, Lindgren CM, Lindström J, Linneberg A, Lorbeer R, Lorentzon M, Luben R, Lyssenko V, Männistö S, Manunta P, Leach IM, McArdle WL, Mcknight B, Mohlke KL, Mihailov E, Milani L, Mills R, Montasser ME, Morris AP, Müller G, Musk AW, Narisu N, Ong KK, Oostra BA, Osmond C, Palotie A, Pankow JS, Paternoster L, Penninx BW, Pichler I, Pilia MG, Polašek O, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rayner NW, Ribel-Madsen R, Rice TK, Richards M, Ridker PM, Rivadeneira F, Ryan KA, Sanna S, Sarzynski MA, Scholtens S, Scott RA, Sebert S, Southam L, Sparsø TH, Steinthorsdottir V, Stirrups K, Stolk RP, Strauch K, Stringham HM, Swertz MA, Swift AJ, Tönjes A, Tsafantakis E, van der Most PJ, Van Vliet-Ostaptchouk JV, Vandenput L, Vartiainen E, Venturini C, Verweij N, Viikari JS, Vitart V, Vohl MC, Vonk JM, Waeber G, Widén E, Willemsen G, Wilsgaard T, Winkler TW, Wright AF, Yerges-Armstrong LM, Hua Zhao J, Carola Zillikens M, Boomsma DI, Bouchard C, Chambers JC, Chasman DI, Cusi D, Gansevoort RT, Gieger C, Hansen T, Hicks AA, Hu F, Hveem K, Jarvelin MR, Kajantie E, Kooner JS, Kuh D, Kuusisto J, Laakso M, Lakka TA, Lehtimäki T, Metspalu A, Njølstad I, Ohlsson C, Oldehinkel AJ, Palmer LJ, Pedersen O, Perola M, Peters A, Psaty BM, Puolijoki H, Rauramaa R, Rudan I, Salomaa V, Schwarz PE, Shudiner AR, Smit JH, Sørensen TI, Spector TD, Stefansson K, Stumvoll M, Tremblay A, Tuomilehto J, Uitterlinden AG, Uusitupa M, Völker U, Vollenweider P, Wareham NJ, Watkins H, Wilson JF, Zeggini E, Abecasis GR, Boehnke M, Borecki IB, Deloukas P, van Duijn CM, Fox C, Groop LC, Heid IM, Hunter DJ, Kaplan RC, McCarthy MI, North KE, O'Connell JR, Schlessinger D, Thorsteinsdottir U, Strachan DP, Frayling T, Hirschhorn JN, Müller-Nurasyid M, Loos RJ. (2016). A principal component meta-analysis on multiple anthropometric traits identifies novel loci for body shape. Nature Communications, e13357, 1−11.10.1038/ncomms13357. Guerra, D.; Ghiselli, F.; Milani, L.; Breton, S.; Passamonti, M. (2016). Early replication dynamics of sex-linked mitochondrial DNAs in the doubly uniparental inheritance species Ruditapes philippinarum (Bivalvia Veneridae). Heredity, 116 (3), 314−322.10.1038/hdy.2015.105. Marioni RE, Ritchie SJ, Joshi PK, Hagenaars SP, Okbay A, Fischer K, Adams MJ, Hill WD, Davies G; Social Science Genetic Association Consortium, Nagy R, Amador C, Läll K, Metspalu A, Liewald DC, Campbell A, Wilson JF, Hayward C, Esko T, Porteous DJ, Gale CR, Deary IJ. (2016). Genetic variants linked to education predict longevity. PNAS, 113 (47), 13366−13371.10.1073/pnas.1605334113. Sekar, Aswin; Bialas, Allison R.; de Rivera, Heather; Davis, Avery; Hammond, Timothy R.; Kamitaki, Nolan; Tooley, Katherine; Presumey, Jessy; Baum, Matthew; Van Doren, Vanessa; Genovese, Giulio; Rose, Samuel A.; Handsaker, Robert E.; Daly, Mark J.; Carroll, Michael C.; Stevens, Beth; McCarroll, Steven A. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530 (7589), 177−194.10.1038/nature16549. Tasa, Tonis; Metsvaht, Tuuli; Kalamees, Riste; Milani, Lili; Vilo, Jaak; Lutsar, Irja (2016). Personalised Bayesian Dose Adjustment of Vancomycin in Neonates. Human Heredity, 81 (4), 236−236. Peterson, P.; Tserel, L.; Kolde, R.; Limbach, M.; Tretyakov, K.; Kasela, S.; Kisand, K.; Saare, M.; Vilo, J.; Metspalu, A.; Milani, L. (2016). Age-related profiling of DNA methylation in CD8+T cells reveals changes in immune response and transcriptional regulator genes. European Journal of Immunology, 879−879. Kantojarvi, K.; Liuhanen, J.; Saarenpaa-Heikkila, O.; Satomaa, A. -L; Kylliainen, A.; Polkki, P.; Jaatela, J.; Milani, L.; Himanen, S. -L.; Porkka-Heiskanen, T.; Paavonen, J.; Paunio, T. (2016). Variants in CACNA1C are associated with sleep regulation in infants. European Neuropsychopharmacology, 192−192.WOS:000413843800345. Gormley, Padhraig; Anttila, Verneri; Winsvold, Bendik S; Palta, Priit; Esko, Tonu; Pers, Tune H; Farh, Kai-How; Cuenca-Leon, Ester; Muona, Mikko; Furlotte, Nicholas A; Kurth, Tobias; Ingason, Andres; McMahon, George; Ligthart, Lannie; Terwindt, Gisela M; Kallela, Mikko; Freilinger, Tobias M; Ran, Caroline; Gordon, Scott G; Stam, Anine H ... Palotie, Aarno. (2016). Corrigendum: Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature genetics, 48 (10), 1296−1296.10.1038/ng1016-1296c. Nikopensius, T.; Saag, M.; Jagomagi, T.; Annilo, T.; Kals, M.; Kivistik, P. A.; Milani, L.; Metspalu, A. (2016). A missense mutation in DUSP6 is associated with Class III malocclusion (vol 92, pg 893, 2013). Journal Of Dental Research, 8, 955−955.10.1177/0022034516651438. 2015 Westra, HJ; Arends, D; Esko, T; Peters, MJ; Schurmann, C; Schramm, K; Kettunen, J; Yaghootkar, H; Fairfax, BP; Andiappan, AK; Li, Y; Fu, J; Karjalainen, J; Platteel, M; Visschedijk, M; Weersma, RK; Kasela, S; Milani, L; Tserel, L; Peterson, P ... Franke, L. (2015). Cell Specific eQTL Analysis without Sorting Cells. Plos Genetics, 11 (5), e1005223.10.1371/journal.pgen.1005223. Bulik-Sullivan, BK.; Loh, PR.; Finucane, HK.; Ripke, S.; Yang, J.; Schizophrenia Working Group of the Psychiatric, Genomics Consortium; Patterson, N.; Daly, MJ.; Price, AL.; Neale, BM. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature Genetics, 47 (3), 291−295.10.1038/ng.3211. Peyrot, WJ; Lee, SH; Milaneschi, Y; Abdellaoui, A; Byrne, EM; Esko, T; de, Geus, EJ; Hemani, G; Hottenga, JJ; Kloiber, S; Levinson, DF; Lucae, S; Martin, NG; Medland, SE; Metspalu, A; Milani, L; Noethen, MM; Potash, JB; Rietschel, M; Rietveld, CA ... SSGAC, Corporate, Collaborator. (2015). The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25 000 subjects. Molecular Psychiatry, 20 (6), 735−743.10.1038/mp.2015.50. Huan, Tianxiao; Esko, Tõnu; Peters, Marjolein J; Pilling, Luke C; Schramm, Katharina; Schurmann, Claudia; Chen, Brian H; Liu, Chunyu; Joehanes, Roby; Johnson, Andrew D; Yao, Chen; Ying, Sai-Xia; Courchesne, Paul; Milani, Lili; Raghavachari, Nalini; Wang, Richard; Liu, Poching; Reinmaa, Eva; Dehghan, Abbas; Hofman, Albert ... Levy, Daniel. (2015). A Meta- analysis of Gene Expression Signatures of Blood Pressure and Hypertension. Plos Genetics, 11 (3), e1005035.10.1371/journal.pgen.1005035. Zhu, Z; Bakshi, A; Vinkhuyzen, AA; Hemani, G; Lee, SH; Nolte, IM; van, Vliet-Ostaptchouk, JV; Snieder, H; The, LifeLines, Cohort, Study; Esko, T; Milani, L; Mägi, R; Metspalu, A; Hill, WG; Weir, BS; Goddard, ME; Visscher, PM; Yang, J. (2015). Dominance Genetic Variation Contributes Little to the Missing Heritability for Human Complex Traits. American Journal of Human Genetics, 96 (3), 377−85.10.1016/j.ajhg.2015.01.001. Shungin, D; Winkler, TW; Croteau-Chonka, DC; Ferreira, T; Locke, AE; Mägi, R; Strawbridge, RJ; Pers, TH; Fischer, K; Justice, AE; Workalemahu, T; Wu, JM; Buchkovich, ML; Heard- Costa, NL; Roman, TS; Drong, AW; Song, C; Gustafsson, S; Day, FR; Esko, T ... Mohlke, KL. (2015). New genetic loci link adipose and insulin biology to body fat distribution. Nature, 518 (7538), 187−196.10.1038/nature14132. Putku, Margus; Kals, Mart; Inno, Rain; Kasela, Silva; Org, Elin; Kožich, Viktor; Milani, Lili; Laan, Maris (2015). CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs. Human Genetics, 134 (3), 291−303.10.1007/s00439- 014-1521-6. Milani, Lili; Leitsalu, Liis; Metspalu, Andres (2015). An epidemiological perspective of personalized medicine: the Estonian experience. Journal of Internal Medicine, 277 (2), 188−200.10.1111/joim.12320. The, Coffee, and, Caffeine, Genetics, Consortium; Cornelis, MC; Byrne, EM; Esko, T; Nalls, MA; Ganna, A; Paynter, N; Monda, KL; Amin, N; Fischer, K; Renstrom, F; Ngwa, JS; Huikari, V; Cavadino, A; Nolte, IM; Teumer, A; Yu, K; Marques-Vidal, P; Rawal, R; Manichaikul, A ... Chasman, DI. (2015). Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Molecular Psychiatry, 20 (5), 647−656.10.1038/mp.2014.107. Joshi, PK; Esko, T; Mattsson, H; Eklund, N; Gandin, I; Nutile, T; Jackson, AU; Schurmann, C; Smith, AV; Zhang, W; Okada, Y; Stančáková, A; Faul, JD; Zhao, W; Bartz, TM; Concas, MP; Franceschini, N; Enroth, S; Vitart, V; Trompet, S ... Wilson, JF. (2015). Evidence for directional dominance on complex traits relating to size and cognition in a wide range of human populations. Nature, 46 (11), 1173−1186.10.1038/nature14618. Yang, J; Bakshi, A; Zhu, Z; Hemani, G; Vinkhuyzen, AAE; Lee, SH (; Robinson, MR; Perry, JRB; Nolte, IM; van Vliet-Ostaptchouk, JV; Snieder, H; Esko, T; Milani, L; Magi, R; Metspalu, A; Hamsten, A; Magnusson, PKE; Pedersen, NL; Ingelsson, E; Soranzo, N ... Visscher, PM. (2015). Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nature Genetics, 47 (10), 1114−1120.10.1038/ng.3390. Peters, MJ; Joehanes, R; Pilling, LC; Schurmann, C; Conneely, KN; Powell, J; Reinmaa, E; Sutphin, GL; Zhernakova, A; Schramm, K; Wilson, YA; Kobes, S; Tukiainen, T; NABEC/UKBEC, Consortium; Ramos, YF; Göring, HH; Fornage, M; Liu, Y; Gharib, SA; Stranger, BE ... Johnson, AD. (2015). The transcriptional landscape of age in human peripheral blood. Nature Communications, 6 (8570), 1−14.10.1038/ncomms9570. Kato, N; Loh, M; Takeuchi, F; Verweij, N; Wang, X; Zhang, W; Kelly, TN; Saleheen, D; Lehne, B; Mateo, Leach, I; Drong, AW; Abbott, J; Wahl, S; Tan, ST; Scott, WR; Campanella, G; Chadeau-Hyam, M; Afzal, U; Ahluwalia, TS; Bonder, MJ ... Chambers, JC. (2015). Trans- ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 47 (11), 1282−1293.10.1038/ng.3405. Winkler, T.W.; Justice, A.E.; Graff, M.; Barata, L.; Feitosa, M.F.; Chu, S; Czajkowski, J.; Esko, T.; Fall, T.; Kilpeläinen, T.O.; Lu, Y.; Mägi, R.; Mihailov, E.; ... Milani, L.; Nelis, M.; Pervjakova, N.; Perola, M.; ... Loos, RJF. (2015). The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. Plos Genetics, 11 (10), e1005378−42.10.1371/journal.pgen.1005378. Locke, AE.; Kahali, B.; Berndt, SI.; Justice, AE.; Pers, TH.; Day, FR.; Powell, C.; Vedantam, S.; Buchkovich, ML.; Yang, J.; Croteau-Chonka, DC.; Esko, T.; Fall, T.; Ferreira, T.; Gustafsson, S.; Kutalik, Z.; Luan, J.; Mägi, R.; Randall, JC.; Winkler, TW. ... Speliotes, EK. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature, 518 (7538), 197−206.10.1038/nature14177. Day, Felix R; Ruth, Katherine S; Thompson, Deborah J; Lunetta, Kathryn L; Pervjakova, Natalia; Chasman, Daniel I; Stolk, Lisette; Finucane, Hilary K; Sulem, Patrick; Bulik-Sullivan, Brendan; Esko, Tõnu; Johnson, Andrew D; Elks, Cathy E; Franceschini, Nora; He, Chunyan; Altmaier, Elisabeth; Brody, Jennifer A; Franke, Lude L; Huffman, Jennifer E; Keller, Margaux F ... Murray, Anna (2015). Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 47 (11), 1294−303.10.1038/ng.3412. Peters, Marjolein J; Joehanes, Roby; Pilling, Luke C; Schurmann, Claudia; Conneely, Karen N; Powell, Joseph; Reinmaa, Eva; Sutphin, George L; Zhernakova, Alexandra; Schramm, Katharina; Wilson, Yana A; Kobes, Sayuko; Tukiainen, Taru; ,; Ramos, Yolande F; Göring, Harald H H; Fornage, Myriam; Liu, Yongmei; Gharib, Sina A; Stranger, Barbara E ... Johnson, Andrew D (2015). The transcriptional landscape of age in human peripheral blood. Nature communications, 6, 8570−8570.10.1038/ncomms9570. Tserel, Liina; Kolde, Raivo; Limbach, Maia; Tretyakov, Konstantin; Kasela, Silva; Kisand, Kai; Saare, Mario; Vilo, Jaak; Metspalu, Andres; Milani, Lili; Peterson, Pärt (2015). Age-related profiling of DNA methylation in CD8+ T cells reveals changes in immune response and transcriptional regulator genes. Scientific Reports, 5 (13107), 1−11.10.1038/srep13107. Leitsalu, Liis; Haller, Toomas; Esko, Tõnu; Tammesoo, Mari-Liis; Alavere, Helene; Snieder, Harold; Perola, Markus; Ng, Pauline C; Mägi, Reedik; Milani, Lili; Fischer, Krista; Metspalu, Andres (2015). Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. International Journal of Epidemiology, 44 (4), 1137−1147.10.1093/ije/dyt268. Day, Felix R.; Ruth, Katherine S.; Thompson, Deborah J.; Lunetta, Kathryn L.; Pervjakova, Natalia; Chasman, Daniel I.; Stolk, Lisette; Finucane, Hilary K.; Sulem, Patrick; Bulik-Sullivan, Brendan; Esko, Tonu; Johnson, Andrew D.; Elks, Cathy E.; Franceschini, Nora; He, Chunyan; Altmaier, Elisabeth; Brody, Jennifer A.; Franke, Lude L.; Huffman, Jennifer E.; Keller, Margaux F. ... Murray, Anna (2015). Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair EDITORIAL COMMENT. Obstetrical & Gynecological Survey, 12, 758−762.10.1097/01.ogx.0000473766.71624.99. Yang, Jian; Bakshi, Andrew; Zhu, Zhihong; Hemani, Gibran; Vinkhuyzen, Anna A E; Nolte, Ilja M; van Vliet-Ostaptchouk, Jana V; Snieder, Harold; , ; Esko, Tonu; Milani, Lili; Mägi, Reedik; Metspalu, Andres; Hamsten, Anders; Magnusson, Patrik K E; Pedersen, Nancy L; Ingelsson, Erik; Visscher, Peter M (2015). Genome-wide genetic homogeneity between sexes and populations for human height and body mass index. Human Molecular Genetics, 24 (25), 7445−7449.10.1093/hmg/ddv443. Joshi, Peter K; Esko, Tonu; Mattsson, Hannele; Eklund, Niina; Gandin, Ilaria; Nutile, Teresa; Jackson, Anne U; Schurmann, Claudia; Smith, Albert V; Zhang, Weihua; Okada, Yukinori; Stančáková, Alena; Faul, Jessica D; Zhao, Wei; Bartz, Traci M; Concas, Maria Pina; Franceschini, Nora; Enroth, Stefan; Vitart, Veronique; Trompet, Stella ... Wilson, James F (2015). Directional dominance on stature and cognition in diverse human populations. Nature, 523 (7561), 459−462.10.1038/nature14618. Milani, L. (2015). Toome geenid lauale. Sirp : Eesti kultuurileht. Benyamin, B; Esko, T; Ried, JS; Radhakrishnan, A; Vermeulen, SH; Traglia, M; Gögele, M; Anderson, D; Broer, L; Podmore, C; Luan, J; Kutalik, Z; Sanna, S; van, der, Meer, P; Tanaka, T; Wang, F; Westra, HJ; Franke, L; Mihailov, E; Milani, L ... Whitfield, JB. (2015). Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 6, 6542.10.1038/ncomms7542. Benyamin, Beben; Esko, Tonu; Ried, Janina S.; Radhakrishnan, Aparna; Vermeulen, Sita H.; Traglia, Michela; Goegele, Martin; Anderson, Denise; Broer, Linda; Podmore, Clara; Luan, Jianan; Kutalik, Zoltan; Sanna, Serena; van der Meer, Peter; Tanaka, Toshiko; Wang, Fudi; Westra, Harm-Jan; Franke, Lude; Mihailov, Evelin; Milani, Lili ... Whitfield, John B. (2015). Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis (vol 5, 4926, 2014). Nature Communications, ARTN 6542.10.1038/ncomms7542. 2014 Benyamin, B; Esko, T; Ried, JS; Radhakrishnan, A; Vermeulen, SH; Traglia, M; Gögele, M; Anderson, D; Broer, L; Podmore, C; Luan, J; Kutalik, Z; Sanna, S; van, der, Meer, P; Tanaka, T; Wang, F; Westra, HJ; Franke, L; Mihailov, E; Milani, L ... Whitfield, JB. (2014). Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 5 (4926), 1−7.10.1038/ncomms5926. Knappskog, S.; Gansmo, L.B.; Dibirova, K.; Metspalu, A.; Cybulski, C.; Peterlongo, P.; Aaltonen, L.; Vatten, L.; Romundstad, P.; Hveem, K.; Devilee, P.; Evans, G.D.; Lin, D.; Van, Camp, G.; Manolopoulos, V.G.; Osorio, A.; Milani, L.; Ozcelik, T.; Zalloua, P.; Mouzaya, F. ... Lønning, P.E. (2014). Population, distribution, and, ancestry, of, the, cancer, protective, MDM2, SNP285, (rs117039649). Oncotarget, 5 (18), 8224−8234. Bonder, MJ; Kasela, S; Kals, M; Tamm, R; Lokk, K; Barragan, I; Buurman, WA; Deelen, P; Greve, J-W; Ivanov, M; Rensen, SS; van Vliet-Ostaptchouk, JV; Wolfs, MG; Fu, J; Hofker, MH; Wijmenga, C; Zhernakova, A; Ingelman-Sundberg, M; Lude Franke, L; Milani, L. (2014). Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics, 15 (860), 1−28.10.1186/1471-2164-15-860. Dumas, O.; Laurent, E.; Bousquet, J.; Metspalu, A.; Milani, L.; Kauffmann, F.; Le Moual, N. (2014). Occupational irritants and asthma: an Estonian cross-sectional study of 34 000 adults. European Respiratory Journal, 44 (3), 647−656.10.1183/09031936.00172213. González, JR; Cáceres, A; Esko, T; Cuscó, I; Puig, M; Esnaola, M; Reina, J; Siroux, V; Bouzigon, E; Nadif, R; Reinmaa, E; Milani, L; Bustamante, M; Jarvis, D; Antó, JM; Sunyer, J; Demenais, F; Kogevinas, M; Metspalu, A; Cáceres, M ... Pérez-Jurado, LA. (2014). A Common 16p11.2 Inversion Underlies the Joint Susceptibility to Asthma and Obesity. American Journal of Human Genetics, 94 (3), 361−372.10.1016/j.ajhg.2014.01.015. Perry, J.R.B.; Day, F.; Elks, C.E.; Sulem, P.; Thompson, D.J.; Ferreira, T.; He, C.; Chasman, D.I.; Esko, T.; Thorleifsson, G.; Albrecht, E.; Ang, W.Q.; Corre, T.; Cousminer, D.L.; Feenstra, B.; Franceschini, N.; Ganna, A.; Johnson, A.D.; Kjellqvist, S.; Lunetta, K.L. ... Ong, K.K. (2014). Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 514 (7520), 92.10.1038/nature13545. Schizophrenia Working Group of the Psychiatric Genomics Consortium ... Metspalu, A; Milani, L; Nelis, M; Esko, T. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511 (7510), 421−427.10.1038/nature13595. Metsalu, Tauno; Viltrop, Triin; Tiirats, Airi; Rajashekar, Balaji; Reimann, Ene; Kõks, Sulev; Rull, Kristiina; Milani, Lili; Acharya, Ganesh; Basnet, Purusotam; Vilo, Jaak; Mägi, Reedik; Metspalu, Andres; Peters, Maire; Haller-Kikkatalo, Kadri; Salumets, Andres (2014). Using RNA sequencing for identifying gene imprinting and random monoallelic expression in human placenta. Epigenetics, 9 (10), 1397−1409.10.4161/15592294.2014.970052. Winkler, T.W.; Day, FR.; Croteau-Chonka, DC.; Wood, AR.; Locke, AE.; Magi, R.; Ferreira, T.; Fall, T.; Graff, M.; Justice, AE.; Luan, JA.; Gustafsson, S.; Randall, JC.; Vedantam, S.; Workalemahu, T.; Kilpelainen, TO.; Scherag, A.; Esko, T.; Kutalik, Z.; Heid, IM. ... Loos, RJF (2014). Quality control and conduct of genome-wide association meta-analyses. Nature Protocols, 9 (5), 1192−1212.10.1038/nprot.2014.071. Tserel, Liina; Limbach, Maia; Saare, Mario; Kisand, Kai; Metspalu, Andres; Milani, Lili; Peterson, Pärt (2014). CpG sites associated with NRP1, NRXN2 and miR-29b-2 are hypomethylated in monocytes during ageing. Immunity and Ageing, 11 (1), Article Number: 1 (1-5). Evangelou, E; Kerkhof, HJ; Styrkarsdottir, U; Ntzani, EE; Bos, SD; Esko, T; Evans, DS; Metrustry, S; Panoutsopoulou, K; Ramos, YF; Thorleifsson, G; Tsilidis, KK; arcOGEN, Consortium; Arden, N; Aslam, N; Bellamy, N; Birrell, F; Blanco, FJ; Carr, A; Chapman, K ... Valdes, AM. (2014). A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Annals of the Rheumatic Diseases, 73 (12), 2130−2136.10.1136/annrheumdis-2012-203114. Wood, AR; Esko, T; Yang, J; Vedantam, S; Pers, TH; Gustafsson, S; Chu, AY; Estrada, K; Luan, J; Kutalik, Z; Amin, N; Buchkovich, ML; Croteau-Chonka, DC; Day, FR; Duan, Y14; Fall, T; Fehrmann, R; Ferreira, T; Jackson, AU; Karjalainen, J ... Frayling, TM. (2014). Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 46 (11), 1173−1186.10.1038/ng.3097. Knappskog, Stian; Gansmo, Liv B.; Dibirova, Khadizha; Metspalu, Andres; Cybulski, Cezary; Peterlongo, Paolo; Aaltonen, Lauri; Vatten, Lars; Romundstad, Pal; Hveem, Kristian; Devilee, Peter; Evans, Gareth D.; Lin, Dongxin; Van Camp, Guy; Manolopoulos, Vangelis G.; Osorio, Ana; Milani, Lili; Ozcelik, Tayfun; Zalloua, Pierre; Mouzaya, Francis ... Lonning, Per E. (2014). Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 5 (18), 8223−8234. Kretschmer, A.; Moeller, G.; Lee, H.; Laumen, H.; von Toerne, C.; Schramm, K.; Prokisch, H.; Eyerich, S.; Wahl, S.; Baurecht, H.; Franke, A.; Claussnitzer, M.; Eyerich, K.; Teumer, A.; Milani, L.; Klopp, N.; Hauck, S. M.; Illig, T.; Peters, A.; Waldenberger, M. ... Weidinger, S. (2014). A common atopy-associated variant in the Th2 cytokine locus control region impacts transcriptional regulation and alters SMAD3 and SP1 binding. Allergy, 69 (5), 632−642.10.1111/all.12394. Viltrop, T.; Metsalu, T.; Tiirats, A.; Rajashekar, B.; Reimann, E.; Koks, S.; Rull, K.; Milani, L.; Vilo, J.; Maegi, R.; Metspalu, A.; Peters, M.; Haller-Kikkatalo, K.; Salumets, A. (2014). Imprinting landscape of human placenta as discovered by whole transcriptome RNA-sequencing and exome variant data analysis. Human Reproduction, 29, 72−72. 2013 Ivanov, M; Kals, M; Kacevska, M; Barragan, I; Kasuga, K; Rane, A; Metspalu, A; Milani, L; Ingelman-Sundberg, M. (2013). Ontogeny, distribution and potential roles of 5- hydroxymethylcytosine in human liver function. Genome Biology, 14 (8), R83. Westra, HJ; Peters, MJ; Esko, T; Yaghootkar, H; Schurmann, C; Kettunen, J; Christiansen, MW; Fairfax, BP; Schramm, K; Powell, JE; Zhernakova, A; Zhernakova, DV; Veldink, JH; Van den Berg, LH; Karjalainen, J; Withoff, S; Uitterlinden, AG; Hofman, A; Rivadeneira, F; 't Hoen, PA ... Franke, L. (2013). Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature Genetics, 45 (10), 1238−U195.10.1038/ng.2756. Nikopensius, T; Saag, M; Jagomägi, T; Annilo, T; Kals, M; Kivistik, P.A; Milani, L; Metspalu, A. (2013). A Missense Mutation in DUSP6 is Associated with Class III Malocclusion. Journal of Dental Research, 92 (10), 893−898.10.1177/0022034513502790. Rietveld, CA; Medland, SE; Derringer, J; Yang, J; Esko, T; Martin, NW; Westra, HJ; Shakhbazov, K; Abdellaoui, A; Agrawal, A; Albrecht, E; Alizadeh, BZ; Amin, N; Barnard, J; Baumeister, SE; Benke, KS; Bielak, LF; Boatman, JA; Boyle, PA; Davies, G ... Koellinger, PD. (2013). GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment. Science, 340 (6139), 1467−1471.10.1126/science.1235488. den Hoed, M; Eijgelsheim, M; Esko, T; Brundel, BJ; Peal, DS; Evans, DM; Nolte, IM; Segrè, AV; Holm, H; Handsaker, RE; Westra, HJ; Johnson, T; Isaacs, A; Yang, J; Lundby, A; Zhao, JH; Kim, YJ; Go, MJ; Almgren, P; Bochud, M ... Loos, RJ. (2013). Identification of heart rate- associated loci and their effects on cardiac conduction and rhythm disorders. Nature Genetics, 45 (6), 621. Berndt, SI; Gustafsson, S; Mägi, R; Ganna, A; Wheeler, E; Feitosa, MF; Justice, AE; Monda, KL; Croteau-Chonka, DC; Day, FR; Esko, T; Fall, T; Ferreira, T; Gentilini, D; Jackson, AU; Luan, J; Randall, JC; Vedantam, S; Willer, CJ; Winkler, TW ... Ingelsson, E. (2013). Genome- wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nature Genetics, 45 (5), 501−U69.10.1038/ng.2606. Ivanov, Mart; Kals, Mart; Kacevska, Marina; Metspalu, Andres; Ingelman-Sundberg, Magnus; Milani, Lili. (2013). In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. Nucleic Acids Research, 2013/01/15, 1−9. Perry, JR; Corre, T; Esko, T; Chasman, DI; Fischer, K; Franceschini, N; He, C; Kutalik, Z; Mangino, M; Rose, LM; Smith, AV; Stolk, L; Sulem, P; Weedon, MN; Zhuang, WV; Arnold, A; Ashworth, A; Bergmann, S; Buring, JE; Burri, A ... Murray, A (2013). A genome-wide association study of early menopause and the combined impact of identified variants. Human Molecular Genetics, 22(7) (1), 1465−1472.10.1093/hmg/dds551. 2012 Kacevska, Marina; Ivanov, Maxim; Wyss, Annika; Kasela, Silva; Milani, Lili; Rane, Anders; Ingelman-Sundberg, Magnus (2012). DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie, 94 (11), 2338−2344.10.1016/j.biochi.2012.07.013. McQuillan, R.; Eklund, N.; Pirastu, N.; Kuningas, M.; McEvoy, BP.; Esko, T.; Corre, T.; Davies, G.; Kaakinen, M.; Lyytikäinen, LP.; Kristiansson, K.; Havulinna, AS.; Gögele, M.; Vitart, V.; Tenesa, A.; Aulchenko, Y.; Hayward, C.; Johansson, A.; Boban, M.; Ulivi, S. ... on behalf of the ROHgen, Consortium. (2012). Evidence of Inbreeding Depression on Human Height. Plos Genetics, 8 (7), e1002655.10.1371/journal.pgen.1002655. Lokk, Kaie; Vooder, Tõnu; Kolde, Raivo; Välk, Kristjan; Võsa, Urmo; Roosipuu, Retlav; Milani, Lili; Fischer, Krista; Koltšina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres; Tõnisson, Neeme (2012). Methylation Markers of Early-Stage Non-Small Cell Lung Cancer. PLoS ONE, 7 (6), e39813− .10.1371/journal.pone.0039813. Nordlund, J.; Milani, L.; Lundmark, A.; Lönnerholm, G.; Syvänen, AC. (2012). DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission. PLoS ONE, 7 (4), e34513. Tserel, L.; Saare, M.; Kisand, K.; Milani, L.; Metspalu, A.; Peterson, P. (2012). Patterns of DNA methylation in the T-cells and monocytes from the elderly and the young. Immunology, 137, 432−433. Tõnisson, N.; Lokk, K.; Vooder, T.; Kolde, R.; Välk, K.; Roosipuu, R.; Võsa, U.; Milani, L.; Fischer, K.; Koltšina, M.; Urgard, E.; Annilo, T.; Metspalu, A. (2012). Altered DNA methylation in early-stage non-small-cell lung cancer. European Journal of Human Genetics: European Human Genetics Conference; Nürnberg, Saksamaa; 23.–26. juuni, 2012. Nature Publishing Group, 174−174. (20; Suppl 1). Kaasik, Aidula-Taie; Keis, Aime; Metspalu, Andres; Allik, Annely; Mölder, Ene; Leego, Erkki; Alavere, Helene; Lilienthal, Kadri Fischer, Krista; Leitsalu-Moynihan, Liis; Milani, Lili; Tammesoo, Mari-Liis; Väli-Täht, Maris; Leego, Merike; Hass, Merli; Tamm, Riin; Nikopensius, Tiit; Esko, Tõnu; Haller, Toomas (2012). Estonian Genome Center : 2001-2011. Tartu: University of Tartu. 2011 Metspalu, A.; Leitsalu, L.; Milani, L.; Esko, T.; Allik, A.; Lilienthal, M.-L.; Haller, T.; Kaasik, A.-T.;Nelis, M.; Hass, M.; Fischer, K.; Krjutškov, K.; Leego, E.; Alavere, H.; Perola, M. (2011). The Estonian biobank - the gateway for the stratified medicine. In: Engelbrecht, J. (_EditorsAbbr). Research in Estonia. Present and future. (283−301).. Tallinn: Estonian Academy of Sciences. 2010 Milani, L.; Lundmark, A.; Kiialainen, A.; Nordlund, J.; Flaegstad, T.; Forestier, E.; Heyman, M.; Jonmundsson, G.; Kanerva, J.; Schmiegelow, K.; Söderhäll, S.; Gustafsson, M. G.; Lönnerholm, G.; Syvänen, A. C. (2010). DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood, 115 (6), 1214−1225.10.1182/blood-2009-04-214668. 2009 Mukonzo, J. K.; Roshammar, D.; Waako, P.; Andersson, M.; Fukasawa, T.; Milani, L.; Svensson, J. O.;Ogwal-Okeng, J.;Gustafsson, L. L.;Aklillu, E. (2009). A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. British Journal of Clinical Pharmacology, 68, 690−699. Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen A-C, Bertilsson L, Ingelman-Sundberg M, Aklillu E (2009). Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. The pharmacogenomics journal, 9 (3), 208−217.10.1038/tpj.2009.4. Milani, L.; Lundmark, A.; Nordlund, J.; Kiialainen, A.; Flaegstad, T.; Jonmundsson, G.; Kanerva, J.; Schmiegelow, K.; Gunderson, K.L.; Lönnerholm, G.; Syvänen, A-C. (2009). Allele- specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Research, 19 (1), 1−11.10.1101/gr.083931.108. Milani, Lili; Syvänen, Ann-Christine. (2009). Genotyping single nucleotide polymorphisms by multiplex minisequencing using tag-arrays. In: DNA Microarrays for Biomedical Research (215−229).. Humana Press. (Methods in Molecular Biology). 2008 Schnorrer, F.; Ahlford, A.; Chen, D.; Milani, L.; Syvänen, AC. (2008). Positional cloning by fast-track SNP-mapping in Drosophila melanogaster. Nature Protocols, 3 (11), 1751−1765.10.1038/nprot.2008.175. Kristjansdottir, G.; Sandling, JK.; Bonetti, A.; Roos, IM.; Milani, L.; Wang, C.; Gustafsdottir, SM.; Sigurdsson, S.; Lundmark, A.; Tienari, PJ.; Koivisto, K.; Elovaara, I.; Pirttilä, T.; Reunanen, M.; Peltonen, L.; Saarela, J.; Hillert, J.; Olsson, T.; Landegren, U.; Alcina, A. ... Syvänen, A-C. (2008). Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. Journal of Medical Genetics, 45 (6), 362−369. Sigurdsson, S.; Goring, HH.; Kristjansdottir, G.; Milani, L.; Nordmark, G.; Sandling, JK.; Eloranta, ML.; Feng, D.; Sangster-Guity, N.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.; Jonsen, A.; Truedsson, L.; Barnes, BJ.; Alm, G.; Rönnblom, L.; Syvänen, A-C.. (2008). Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Human Molecular Genetics, 17 (6), 872−881.10.1093/hmg/ddm359. Gupta M, Milani L, Hermansson M, Simonsson B, Markevarn B, Syvänen A-C, Barbany G. (2008). Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. Biochemical and Biophysical Research Communications, 366 (3), 848−851.10.1016/j.bbrc.2007.12.029. 2007 Dideberg, V; Kristjansdottir, G; Milani, L; Libioulle, C; Sigurdsson, S; Louis, E; Wiman, AC; Vermeire, S; Rutgeerts, P; Belaiche, J; Franchimont, D; Van Gossum, A; Bours, V; Syvänen, A- C. (2007). An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Human Molecular Genetics, 16 (24), 3008−3016.10.1093/hmg/ddm259. Milani L, Gupta M, Andersen M, Dhar S, Fryknäs M, Isaksson A, Larsson R, Syvänen A-C. (2007). Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Research, 35, e34−e34.10.1093/nar/gkl1152. 2006 Milani L, Fredriksson M, Syvänen A-C. (2006). Detection of alternatively spliced transcripts in leukemia cell lines by minisequencing on microarrays. Clinical Chemistry, 52, 202−211.10.1373/clinchem.2005.062042. Tööstusomand Patentne leiutis: Marker BMP5 geenis SSRI klassi ravimite toimet ennustava tegurina; Omanikud: Tartu Ülikooli Eesti Geenivaramu; Autorid: Anu Tammiste, Lili Azin Milani, Krista Fischer, Tõnu Esko, Kristi Pettai, Kaarel Krjutškov, Reedik Mägi, Merike Leego, Eduard Maron, Andres Metspalu; Prioriteedi number: US61/546.607; Prioriteedi kuupäev: 13.10.2011. ELULOOKIRJELDUS Nimi: Tuuli Jürgenson Sünniaeg: 18. mai 1997 E-post: [email protected] Haridus: 2019–... Tartu Ülikool, matemaatika ja statistika magistriõpe 2016–2019 Tartu Ülikool, BSc matemaatilise statistika erialal (cum laude) 2013–2016 Hugo Treffneri Gümnaasium (kuldmedal) Teenistuskäik: 06.2019–... Tartu Ülikooli Eesti Geenivaramu, statistik (0,5) 09.2018–02.2019 Tartu Ülikooli matemaatika ja statistika instituut, õppeassistent aines Analüütiline geomeetria 09.2017–02.2018 Tartu Ülikooli matemaatika ja statistika instituut, õppeassistent aines Matemaatiline maailmapilt Curriculum Vitae Isiklik informatsioon Nimi: Kristi Krebs Sünniaeg: 09.01.1990, Tallinn, Estonia Aadress: Vaksali 21-20, 50409, Tartu Telefon, email: +372 56 47 3303, [email protected] Teenistuskäik Haridustee: 2015–... Doktoriõpe molekulaarse biomeditsiini eralal, Tartu Ülikool, Eesti Geenivaramu 15.01.2018–17.12.2018 Uppsala Ülikool, Molekulaarse meditsiini õppetool, külalisdoktorant 2012–2014 Magistriõpe geenitehnoloogia erialal, Tallinna Tehnikaülikool, cum laude 2009–2012 Bakalaureuseõpe geenitehnoloogia erialal,Tallinna Tehnikaülikool Töökohad ja ametid: 01.01.2018–... Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist (0,30) 01.01.2017–... Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, spetsialist (0,30) 2014–2015 Repforce, Tervisenõustaja/ravimiesitleja (1,00) 2012–2014 Tallinna Tehnikaülikool, Matemaatika-loodusteaduskond, Geenitehnoloogia instituut, Molekulaarbioloogia õppetool, Spetsialist (0,75) Teadusorganisatsiooniline ja -administratiivne tegevus 2016 (aprill) -2016(aprill) Biotehnoloogia praktikumi juhendamine 2012- ....Inimesegeneetika ühingu liige Teenistuskäigu lisainfo: 2018, kursus “Genetic Analysis of Population-based Association Studies”, Wellcome Genome Campus Advanced Course, Hinxton, Inglismaa 2017, Bioinformaatika suvekool, Wellcome Genome Campus, Hinxton, Inglismaa 2016, kursus “Statistical Practice in Epidemiology using R”, Eesti Geenivaramu ja Tartu Ülikooli Matemaatika ja Statistika instituut 2013, English for Science and Research, Tallinna Tehnikaülikool, B2/C1 2012, 2012, Laboratory Animal Techniques, Tallinna Tehnikaülikool 2007, Keelepraktika: Berlin Humboldt (Saksamaa) Kvalifikatsioon Teaduskraadid Kristi Krebs, doktorant 2015- …, (juh) Lili Milani; Andres Metspalu, Ravimite lagundamisega seotud geenide põhjalik geneetiline ja epigeneetiline analüüs uue põlvkonna sekveneerimisetehnoloogiaga, Tartu Ülikool, Tartu Ülikool Eesti Geenivaramu. Kristi Krebs, Magistrikraad, 2014, (juh) Teet Velling, Filamiin A roll PKB/Akt’i lokalisatsiooni ja kineetika regulatsioonis integriinide ja retseptor türosiinkinaaside poolt, Tallinna tehnikaülikool, geenitehnoloogia instituut Teaduspreemiad ja tunnustused 2017 Dora Pluss doktorantide õpirände stipendium 2017 Kristi Krebs, Kristjan Jaagu välissõidu stipendium: ettekandega esinemine konverentsil 2017 ESHG konverentsi stipendium Euroopa riikidele 2016 ECNP seminari auhind 2016 Eesti Teaduste Akadeemia "Teadus 3 minutiga" loengute konkursi finalist ja laureaat (loengu teema "Ravimiretsept – allkirjastatud geneetikaga") 2016 Kõrghariduse erialastipendium nutika spetsialiseerumise kasvuvaldkondades Teadustöö põhisuunad VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika; CERCS ERIALA: B220 Geneetika, tsütogeneetika; PÕHISUUNAD: Farmakogenoomika Jooksvad projektid PRG184 (PRG184) "Haruldaste ja sagedaste geenivariantide mõju ravimite kõrvaltoimetele (1.01.2018−31.12.2022)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikooli genoomika instituut. IUT20-60 "Oomiksi põhised meetodid terviseuuringutes: integreeritud lähenemine haiguste tekkeprotsesside mõistmiseks ja prognoosimiseks (1.01.2014−31.12.2019)", Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikool, Tartu Ülikooli genoomika instituut. Publikatsioonid 2019 Tasa, T & Krebs, K.; Kals, M.; Mägi, R.; Lauschke, V.M.; Haller, T.; Puurand, T.; Remm, M.; Esko, T.; Metspalu, A.; Vilo, J.; Milani, L. (2019). Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records. European Journal of Human Genetics, 0−0.10.1038/s41431-018-0300-6 [ilmumas]. 2018 Reisberg, Sulev; Krebs, Kristi; Lepamets, Maarja; Kals, Mart; Mägi, Reedik; Metsalu, Kristjan; Lauschke, Volker M.; Vilo, Jaak; Milani, Lili; (2018). Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in medicine.10.1038/s41436-018-0337-5. 2015 Krebs, Kristi; Ruusmann, Anu; Simonlatser, Grethel; Velling, Teet (2015). Expression of FLNa in human melanoma cells regulates the function of integrin α1β1 and phosphorylation and localisation of PKB/AKT/ERK1/2 kinases. European Journal of Cell Biology, 564−575. Kersti Oselin https://www.etis.ee/CV/Kersti_Oselin/est E-post [email protected] ORCID 0000-0002-3862-3882 Teenistuskäik Töökohad ja ametid 28.09.2015–... North Estonian Medical Centre, onkoloog (keemiaraviarst) (0,90) 2003 - 2004 AS EGeen farmakogeneetiliste uuringute projektijuht 2002 - 2003 TÜ farmakoloogia instituut assistent 2000 - 2002 Humboldti Ülikool Charité Kliinik kliinilis farmakoloogia instituut teadur 1999 - 2000 TÜ farmakoloogia instituut assistent 01.09.2012–31.08.2015 Tartu Ülikool, Arstiteaduskond, Anestesioloogia ja intensiivravi kliinik, anestesioloogia ja intensiivravi teadur (0,25) 2012–01.09.2015 SA Tartu Ülikooli Kliinikum, Teadur (0,25) 01.09.2011–31.08.2015 SA Tartu Ülikooli Kliinikum, arst-resident onkoloogias (1,00) 01.09.2007–01.09.2007 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia vanemteadur (1,00) 01.02.2007–31.08.2007 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00) 2007–30.04.2007 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, Farmakoloogia ja toksikoloogia õppetool, farmakoloogia vanemteadur (1,00) 01.01.2007–31.12.2011 Suurbritannia Ravimiamet, kliiniline hindaja 2006–2007 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00) 01.09.2004–31.01.2007 Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia teadur (1,00) Haridustee 1998 - 2003 TÜ arstiteaduskond kliiniline farmakoloogia doktorantuur 1997 - 1998 SA TÜ Kliinikum internatuur 1991 - 1997 TÜ arstiteaduskond ravi eriala 01.09.2011–31.08.2015 Arstiteaduse residentuur onkoloogia erialal Teadusorganisatsiooniline ja -administratiivne tegevus 2016−... American Society of Clinical Oncology, liige 2015−... European Society of Medical Oncology, liige 2015−... EORTC Lung Cancer Group 2009−... Eesti Farmakoloogia Selts, liige 1999−... Eesti Onkoteraapia Ühing, juhatuse liige Loometöö PK, PD, kliiniliste uuringute disain, onkoloogia. Kvalifikatsioon Teaduskraadid Kersti Oselin, doktorikraad, 2003, (juh) Lembit Rägo; Rein Pähkla, Studies on the human MDR1, MRP1 and MRP2 ABC transporters: Functional relevance of the genetic polymorphism in the MDR1 and MRP1 gene (MDR1, MRP1 ja MRP2 ABC transporterid: geneetilise polümorfismi tähtsus MDR1 ja MRP1 geenides), Tartu Ülikool, Arstiteaduskond. Teadustöö põhisuunad ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: Kliiniline farmakoloogia, farmakokineetika, farmakogeneetika ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B200 Tsütoloogia, onkoloogia, kantseroloogia; TÄPSUSTUS: Infektsioonide nõrgestatud organisms, farmaokineetilised ja farmakogeneetilised uuringud onkoloogiliste ravimitega ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B726 Kliiniline bioloogia ; TÄPSUSTUS: onkoloogia, kartsinogenees Lisainfo meditsiinidoktor Tartu Ülikool, 2003 Jooksvad projektid IUT34-24 "Infektsioonid langenud immuunsusega isikutel – eksperimendist kliinilisse praktikasse (1.01.2015−31.12.2020)", Irja Lutsar, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut. Lõppenud projektid SARAI120119T "Antibiootikumide doseerimine raskete infektsioonide korral (1.01.2012−31.08.2015)", Joel Starkopf, Tartu Ülikool, Tartu Ülikool, Arstiteaduskond. SF0180004s12 "Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani (1.01.2012−31.12.2014)", Irja Lutsar, Tartu Ülikool, Arstiteaduskond. ETF8799 "Meropeneemi farmakokineetika enneaegsetel vastsündinutel (1.01.2011−31.12.2012)", Irja Lutsar, Tartu Ülikool, Arstiteaduskond. SF0180059s07 "Uued ravistrateegiad neurodegeneratsiooni ja psüühiliste häirete ravis (1.01.2007−31.12.2012)", Aleksandr Žarkovski, Tartu Ülikool, Arstiteaduskond. SF0182726s06 "HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil (1.01.2006−31.12.2011)", Irja Lutsar, Tartu Ülikool, Arstiteaduskond. ETF6691 "Tiopuriinravimite farmakokineetikat ja -dünaamikat mõjutavad geneetilised ja mitte-geneetilised faktorid. (1.01.2006−31.12.2007)", Kersti Oselin, Tartu Ülikool, Arstiteaduskond. SF0182587s03 "Müokardiinfarkti-järgne südamepuudulikkus : raskusastme determinandid, ravi ja prognoos (1.01.2003−31.12.2006)", Rein Teesalu, Tartu Ülikool, Arstiteaduskond. SF0182135As02 "Afektiivsete häirete ja neurodegeneratiivsete haiguste farmakoteraapia alused (1.01.2002−31.12.2006)", Aleksandr Žarkovski, Tartu Ülikool, Arstiteaduskond. Juhendatud väitekirjad  Katrina Talpsepp, magistrikraad, 2008, (juh) Annika Vaarmann; Kersti Oselin, Glükokortikosteroidravi mõju inimese tiopuriini metüültransferaasi ekspressioonile ja aktiivsusele, Tartu Ülikool, Arstiteaduskond.  Karin Kipper, magistrikraad, 2008, (juh) Kersti Oselin; Ivo Leito; Annika Vaarmann, HPLC-UV meetod kesknärvisüsteemi ravimite määramiseks inimese vereplasmas, Tartu Ülikool, Füüsika- keemiateaduskond.  Riin Tamm, magistrikraad (teaduskraad), 2007, (juh) Kersti Oselin; Andres Metspalu, Inimese tiopuriinmetüültransferaasi farmakogeneetika: genotüübi-fenotüübi võrdlus ja haplotüübianalüüs eestlaste populatsioonis, Tartu Ülikool, Bioloogia-geograafiateaduskond.  Kaili Anier, magistrikraad (teaduskraad), 2006, (juh) Uno Mäeorg; Kersti Oselin, HPLC põhise meetodi väljatöötamine tiopuriini metüültransferaasi aktiivsuse määramiseks Eesti populatsioonis ja raviminteraktsioonide ennustamine in vitro eksperimentide põhjal, Tartu Ülikool, Füüsika-keemiateaduskond, Orgaanilise ja bioorgaanilise keemia instituut. Publikatsioonid Klass Aasta Publikatsioon 1.1. 2019 Oselin, Kersti; Girard, Nicolas; Lepik, Karlin; Adamson-Raieste, Aidi; Vanakesa, Tõnu; Almre, Ingemar; Leismann, Tiina; Chalabreysse, Lara (2019). Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience. Journal of Thoracic Disease, 11 (2), 456−464.10.21037/jtd.2018.12.123. 1.1. 2018 Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing, Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17. 5.2. 2017 Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Kals, Mart; Lokk, Kaie; Keerma, Katrin; Saare, Margot; Roosipuu, Retlav; Leismann, Tiina; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2017). Monitoring cancer related mutations in cell-free DNA of lung cancer patients. European Journal of Human Genetics: European Human Genetics Conference, Copenhagen, Denmark, May 27–30, 2017. Nature Publishing Group,. 1.1. 2016 Tamme, K.; Oselin, K.; Kipper, K.; Tasa, T.; Metsvaht, T.; Karjagin, J; Herodes, K.; Kern, H.; Starkopf J. (2016). Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. Acta Anaesthesiologica Scandinavica, 60 (2), 230−240.10.1111/aas.12629. 1.1. 2016 Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16 (1), 206−206.10.1186/s12887-016-0753-0. 5.2. 2016 Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Keerma, Katrin; Roosipuu, Retlav; Saare, Margot; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2016). Detecting EGFR and related mutations in the cfDNA of lung cancer patients. European Journal of Human Genetics, 24: European Human Genetics Conference, Barcelona, Spain May 21-24, 2016. Nature Publishing Group, 313−313. (Supplement 1). 1.1. 2012 Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12. 1.1. 2011 Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115. 1.1. 2008 Tamm, R.; Oselin, K.; Kallassalu, K.; Magi, R.; Anier, K.; Remm, M.; Metspalu, A. (2008). Thiopurine S- methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clinical Chemistry and Laboratory Medicine, 46 (7), 974−979. 1.1. 2008 Karjagin, J.; Lefeuvre, S.; Oselin, K.; Kipper, K.; Marchand, S.; Tikkerberi, A.; Starkopf, J.; Couet, W.; Sawchuk, R.J. (2008). Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock. Clinical Pharmacology & Therapeutics, 83 (3), 452−459.10.1038/sj.clpt.6100312. 1.1. 2007 Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low- birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000. 1.1. 2007 Oselin, K.; Anier, K. (2007). Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti- inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metabolism and Disposition, 35 (9), 1452−1454. 3.3. 2007 Brilene, T.; Hedman, A.; Kirss, A.; Kullamaa, A.; Kõrv, J.; Oselin, K.; Otter, K.; Ristimäe, T.; Visnapuu, P.; Peet, K. (2007). Rasedate farmakoteraapia. Tallinn: Medicina. 1.1. 2006 Oselin, K.; Anier, K.; Tamm, R.; Kallassalu, K.; Mäeorg, U. (2006). Determination of thiopurine S- methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 77−83.10.1016/j.jchromb.2006.02.031. 5.1. 2006 Metsvaht, T.; Ilmoja, ML.; Oselin, K.; Anier, K.; Lutsar, I. (2006). Pharmacokinetics of penicillin G(Pen) 'steady-state' in very low birth weight premature newborns. BIOLOGY OF THE NEONATE, 90. 281−281. 5.2. 2006 Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Intensive Care Medicine, 1. 132. 5.2. 2006 Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Proceedings of 2nd International Baltic Congress of Anaesthesiology and Intensive Care: 2nd International Baltic Congress of Anaesthesiology and Intensive Care; Tallinn, Estonia; 26-28 October 2006. Tallinn, 127. 1.1. 2003 Oselin, K.; Nowakowski-Gashaw, I.; Mrozikiewicz, PM.; Wolbergs, D.; Pahkla, R.; Roots, I. (2003). Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. European Journal of Clinical Investigation, 33 (3), 261−267. 1.1. 2003 Oselin, K.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4(+), CD8(+), CD19(+), and CD56(+) cells. European Journal of Haematology, 71 (2), 119−123. 1.1. 2003 Oselin, K.; Mrozikiewicz, PM.; Gaikovitch, E.; Pahkla, R.; Roots, I. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. European Journal of Clinical Pharmacology, 59 (4), 347−350. 1.1. 2003 Oselin, K.; Gerloff, T.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental & Clinical Pharmacology, 17 (4), 463−469. 1.1. 2003 Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its Complications, 17 (6), 387−391. 6.6. 2003 Oselin, K. (2003). Iivelduse ja oksendamise farmakoloogiline ravi. Lege Artis, 2(16), 49−52. 1.1. 2002 Gerloff, T.; Schaefer, M.; Johne, A.; Oselin, K.; Meisel, C.; Cascorbi, I.; Roots, I. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of Clinical Pharmacology, 54 (6), 610−616. 1.3. 2002 Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69. 1.2. 2001 Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics, 9 (269), 269. 1.1. 1999 Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380. Volker M. Lauschke, 17. September 1984 [email protected] Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19 Volker M. Lauschke, Curriculum vitae Address Storängsgatan 1, 115 44 Stockholm, Sweden E-mail [email protected] Phone (+46) 76 0829199 Date of birth September 17th 1984 Nationality German Marital status Married, three children ORCID ID 0000-0002-1140-6204 Professional Experience Since 2018 Associate Professor and Group Leader in Personalized Medicine and Drug Development, Karolinska Institutet, Stockholm, Sweden My research group uses 3D cell culture systems of primary human cells, microfluidics and integrative bioinformatics approaches to identify novel therapeutic strategies for complex metabolic diseases, such as non-alcoholic fatty liver disease and type 2 diabetes. In addition, we develop machine learning tools to improve personalized pharmacological therapy and establish novel methods for the prediction of drug toxicity. Since 2018 I am the Director of the Micro- and Nanofabrication core facility. Venia legendi in Pharmacology since 2018. 2017 – 2018 Assistant Professor and Group Leader. Same as above Since 2016 Co-founder and CEO of HepaPredict AB, HepaPredict AB (www.hepapredict.com) is a contract research organization (CRO) that is part of the Karolinska Innovations life science incubator program. We offer in-house evaluations of drug metabolism, pharmacokinetic properties and safety as well as drug target validations based on our novel long-term stable microphysiological 3D spheroid culture platform and our data has been used for regulatory purposes within EFSA. I am one of two founders and during my time as CEO, we have expanded from a start-up to an established profitable service provider in the area of drug discovery and development with yearly revenue >3M SEK and customers in Europe, UK, US and Japan. 2014 - 2016 Postdoctoral Research Associate and MarieCurie Fellow Karolinska Institutet, Stockholm, Sweden, Supervisor: Prof. Magnus Ingelman-Sundberg In my postdoctoral research I contributed to the development of the hepatic spheroid model that constitutes an integral part of my group’s experimental tool kit. Furthermore, I obtained extensive experience in the integration of multiple omics data sets, which provides an important basis for our computational approaches towards understanding inter-individual differences in drug response. 2013 – 2014 Bridging Postdoctoral Research Associate European Molecular Biology Laboratory (EMBL). Same as below. 2009 – 2013 Dr. rer. nat. (PhD) Grade 1.0; Graduation Summa cum Laude (best possible grade) European Molecular Biology Laboratory (EMBL) and the joint faculty of Science and Mathematics of the Ruperto-Carola University, Heidelberg, Supervisor: Dr. Alexander Aulehla Thesis title: Scaling of embryonic patterning based on phase-gradient encoding In my PhD studies, I analyzed how the proportionality of tissues and organs is maintained in the developing embryo. To address this question, I developed an ex vivo primary cell culture assay in which tissue self-organization can be observed. Importantly, we found that positional information can be encoded through integrating information of oscillation phases from multiple oscillator systems, revealing a novel way of dynamic information encoding in biological systems. The work resulted in publications in Nature and Cell. 2007 – 2009 Scientific Assistant Ruperto-Carola University, Heidelberg, Germany; PI: Prof. Gabriele Petersen In parallel to my second cycle university education I obtained practical experiences in biochemistry, molecular biology and epigenetics. 1 Volker M. Lauschke, 17. September 1984 [email protected] Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19 University Studies 2007 – 2009 Master of Science (M.Sc.) in Molecular Biosciences Grade: 1.0 (best possible grade), Ruperto-Carola University, Heidelberg, Germany 2004 – 2007 Bachelor of Science (B.Sc.) in Molecular and Cellular Biology Grade: 1.6, Ruperto-Carola University, Heidelberg, Germany and University of Bergen, Norway Additional Academic Qualifications 2015 – present Bachelor of Laws (LL.B.) 2016 – 2018 Master of Science (M.Sc.) in Business Administration and Economics 2012 – 2016 Bachelor of Science (B.Sc.) in Business Administration and Economics Current Funding Swedish Research Foundation (VR) 3R Grant (2,205,000 SEK; PI Lauschke) ERC Synergy grant SPHERES (10,000,000 SEK; PI Langin) IMI2 EUbOPEN (1,400,000 SEK; PI Sundström) Rolf Luft Grant for Diabetes Research (1,050,000 SEK; PI Lauschke) Swedish Research Foundation (VR) Starting Grant (6,000,000 SEK; PI Lauschke) Swedish Research Foundation (VR) 3R Grant (2,265,000 SEK; PI Lauschke) Fellowships, Prizes and Awards 2017 Lennart Philipson Prize 2014 Marie Curie Fellowship 2009 EMBL International PhD Program Graduate Fellowship Top Master of Science (M.Sc.) Award 2006 Erasmus Fellowship (Ecotoxicology at the University of Bergen, Norway, Supervisor: Prof. A. Goksøyr) 2002 Fördern, Fordern, Forschen Award (Awarded by the University of Bonn, Germany for university studies in Astronomy in parallel to high-school education) Supervision of Graduate Students Current supervision: Five PhD students (Yitian Zhou, Nuria Oliva-Vilarnau, Joanne Shen, Lena Preiss and Qingyang Xiao) as main supervisor. One MD/PhD student (Mikael Kozyra) and one PhD student (Leyre Pernaute Lau) as co- supervisor. Teaching Portfolio Teaching activities include seminars and practical courses in local anaesthetics, cardiovascular pharmacology, pharmacokinetics and receptor pharmacology for biomedical, medical and dentistry students. Editorial Activities Editorial Board Member: Frontiers in Pharmacology (IF 3.8; Since 2017), Human Genomics (IF 2.5; Since 2017), Frontiers in Medicine (IF 3.1; Since 2018), Drug Metabolism Reviews (IF 4.7; Since 2019) Senior Editor: Annals of Human Genetics (IF 1.3; Since 2019) Associate Editorial Board Member: Current Drug Metabolism (IF 2.3; Since 2019) Guest Editor: Special Issue in Journal of Clinical Medicine (IF 5.7; “Importance of Genetic Variants for the Hepatic Metabolism of Xenobiotics”; June 2020) 2 Volker M. Lauschke, 17. September 1984 [email protected] Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19 Commissions of Trust and Memberships in Scientific Societies Since 2019 Member of the Management Committee of the COST Action “Prospective European Drug-Induced Liver Injury (DILI) Network” Since 2019 Board member of the Swedish Society of Medicine (Section of Pharmacology) Since 2019 Swedish delegate to the Federation of European Pharmacological Societies (EPHAR) Since 2018 Docent with venia legendi in Pharmacology Since 2018 Member of the IUPHAR (International Union of Basic & Clinical Pharmacology) Young Investigator Committee Since 2018 Director of Micro- and Nanofabrication Facility at Karolinska Institutet Since 2018 Member of the Swedish Strategic Research Program in Diabetes Since 2018 Oversea Fellow of the Royal Society of Medicine Since 2018 Member of the Pharmacogene Variation Consortium (PharmVar) Since 2018 Member of the American Society for Biochemistry and Molecular Biology (ASBMB) Since 2017 Full member of the International Society for the Study of Xenobiotics (ISSX) and Member of the ISSX Young Investigator Workgroup 2017 Member of expert panel for the discussion of scientific and regulatory opportunities and challenges of medicinal product development using genome editing technologies at EMA, London Since 2016 Member of the Ubiquitous Pharmacogenomics Consortium (UPgx) Since 2014 Full member of the Society of Bioinformatics in Northern Europe Bibliography Total publications (incl. in press): 55 publications * First and co-first authorships: 17 publications # Last and co-last authorships: 21 publications † Corresponding author: 29 publications Additional manuscripts in review/revision: 10 manuscripts Sum of ISI impact factors: 324.3 Bibliometrics Google Scholar Web of Science Citations: 1544 1034 H-index: 20 18 3 Tähis VKL-241 Viide PKL-127 Versioon 02 Teatis Eetikakomiteele Tartu Ülikooli Kliinikumi nõusolek uuringu läbiviimiseks UURINGU ANDMED Uuringu täielik nimetus: Study of the effects of previously uncharacterized rare variants in the genes of CyP450 enzymes Sponsori protokolli number, versioon ja kuupäev: Vastutav uurija: Alar Irs UURINGUKESKUSE ANDMED Uuringu läbiviimise koht: Südamekliinik KINNITUS Olen teadlik ülaltoodud kliinilisest uuringust. Kliiniliste uuringute koordinaator Katrin Kaarna juhatuse 08.08.2017 nr otsuse nr 1.3-1/296 volituse alusel Katrin Kaarna /allkirjastatud digitaalselt/ Eesti bioeetika ja inimuuringute nõukogule Suur-Ameerika 1 10122 Tallinn 28.02.2020 KAASKIRI Käesolevalt esitame avalduse Eesti bioeetika ja inimuuringute nõukogule kliinilise uuringu läbiviimise kooskõlastuse saamiseks. Plaanitava uuringu nimi: Varasemalt kirjeldamata geenivariatsioonide mõju ravimite metabolismile (Study of the effects of previously uncharacterized rare variants in the genes encoding CYP450 enzymes) Uuringuprotokolli number: Protocol 01-2020, Version 2 E-kirjaga lisatud: - Kaaskiri - Taotlus kooskõlastuse saamiseks Eesti bioeetika ja inimuuringute nõukogult - Uuringuprotokoll - Kindkustuspakkumine - Uuritava informeerimise ja teadliku nõusoleku lehed (venekeelse informeerimise ja nõusoleku lehe plaanime tõlkida siis, kui eestikeelne on heaks kiidetud) - Kiri geenidoonorite uuringusse kutsumiseks (esimene pöördumine, venekeelse informeerimise ja nõusoleku lehe plaanime tõlkida siis, kui eestikeelne on heaks kiidetud) Lugupidamisega, Jana Lass SA Tartu Ülikooli Kliinikum, apteek Puusepa 8, 51014 Tartu, Eesti Tel: +372 7318333 E-post: [email protected] Vastus Eesti bioeetika ja inimuuringute nõukogule 1. Selleks, et uuringut läbi viia, on vajalik geenidoonori isiku tuvastamine. Nõukogule ei ole esitatud vastavalt IGUS §24 lõige 4 geenidoonorite depsudonüünimiseks vajalikku taotlust. Vastus: Esitasime Nõukogule taotluse geenidoonorite depseudonüümimiseks. Taotlusesse on lisatud uus peatükk nr 8. “Request for depseudonymisation”. 2. Tegemist on kõrge riskiga sekkuva uuringuga ja antud taotlusega tutvudes on nõukogu seisukohal, et uuringust tulenevad riskid on suuremad, kui uuringust saadav kasu. Vastus: Täname Nõukogu tähelepanu juhtimast, kuid jääme seisukohale, et kuigi uuringust saadava kasu ulatust ei ole enne uuringutulemuste saamist võimalik täpselt teada, on uuringuga kaasnevad riskid põhjalikult läbi kaalutud. Uuringu tulemusel on võimalik kirjeldada seni teadmata geenivariantide mõju ravimite metaboliseerumise määrale. Uuringus kasutatakse kliinilises praktikas sageli kasutatavaid ravimeid, mille kasutamisega seotud riskid ja vastunäidustused on hästi teada ning ravimite annused on võimalikult väiksed. Ravimeid manustatakse haiglas ning kogu uuringu jooksul jälgivad osalejaid uuringuarstid. Kõiki uuringuprotseduure teevad kogenud õed. Kõik uuringusse valitud indiviidid kannavad CYP2C19 ja/või CYP2D6 geenides vähemalt ühte potentsiaalselt funktsioonikaoga mutatsiooni ja/või deletsiooni, mille mõju mitmete ravimite lagundamise kiirusele pole varem uuritud. Sellepärast võib neil inimestel olla tavapäraste raviannuste kasutamisel suurem risk ravimite kõrvaltoimete tekkeks. Tavaliselt otsitakse selliseid mutatsioone peale ravimi tõsiste kõrvaltoimete avaldumist või ebatavalise ravimi plasmakontsentratsiooni leidmist. Näiteks leiti neerusiirdamise järgselt patsiendil erakordselt kõrged immuunosuppressant takroliimuse plasmakontsentratsioonid, mille tõttu uuriti tema eksoomi ja leiti üliaeglase metabolismi põhjusena funktsioonikaoga mutatsioon CYP3A4 geenis1. Sarnaseid leide on ka ensüümide CYP2C19 ja CYP2D6 puhul, mis metaboliseerivad vastavalt 15% ja 25% ravimitest2. Lisasime täiendava lõigu taotluses punkti 10.2: The probe drug experiment has a potential value for the participants in the study group and the Estonian population in general, as it would clarify the effect of the mutations detected in their genes encoding CYP enzyme, and thereby help to adjust future treatment with medicines which are metabolised via the respective CYP enzymes and further estimate the participants’ personal metabolic activity for the studied drug metabolizing enzymes while taking into account the patient’s lifestyle and environmental influences in addition to their personal genetic background. By the request the participants (please see consent form) results of the pharmacokinetic analysis will be given in the form of a personal drug metabolism profile and genetic report. 1 Werk et al 2013: https://doi.org/10.1038/clpt.2013.210 2 Guengerich et al 2006: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751428/ 1 This feedback will be prepared and delivered separately as “Feedback to the gene donors” (“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the University of Tartu 271/T-2, 19.06.2017). The results are expected to benefit all participants of the EstBB, other Estonian residents and other populations as well. Nõukogu esitas taotlusele järgmised kommentaarid ja küsimused: 3. Tegemist on tervete vabatahtlike uuringuga. Kas on plaanis ka nende vabatahtlike osalemist kompenseerida? Kui jah, siis kuidas ja missuguses ulatuses. Kas kompenseerimine toimub või ei toimu, peaks kajastuma informeeritud nõusolekul. Nõukogu on seisukohal, et 50 eurot ei ole piisav kompensatsioon. Palume uuringu meeskonnal tutvuda Euroopa Ravimiameti poolt uuritavatele kompensatsiooni tasumise nõuetega. Vastus: Vastavalt EU kliiniliste uuringute regulatsioonile „Clinical trials regulation (eu) no 536/2014“ https://ec.europa.eu/health/sites/health/files/files/eudralex/vol- 10/regulation5362014_qa_en.pdf ei tohiks uuringus osalemise kompensatsioon ületada otseseid töötasu vähenemisega ja otseselt uuringus osalemisega seotud kulusid. Vastav lõik regulatsioonist: „compensation should not cover more than expenses and loss of earning, directly related to the participation in the clinical trials. Examples of expenses directly related to the participation in the clinical trials are travel costs for the participating subject and the legally designated representative (if applicable) or (if applicable) the person accompanying the subject, costs for accommodation, or additional costs due to participation in the clinical trial collected by the subjects’ health insurance (compulsory patient contributions/own risk). Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning osalejale sobival ajal. Uuringu ajal on plaanis katta kuludokumentide alusel osaleja transpordikulud. Kuna uuringukeskused on nii Tallinnas kui Tartus, ei ületa transpordikulud Eestis tõenäoliselt väga palju 50.-. Kui osalejal ei ole võimalik uuringukeskusesse tulla uuringuravimi manustamise päeva hommikul või lahkuda uuringupäeva järgsel õhtul, siis tasustatakse ka ööbimiskulud. Vastav lõik on lisatud taotlusesse: The study drug administration is scheduled for the weekend. During the study, it is planned to cover the participant's transportation costs on the basis of expense receipt(s). As the research centers are located in both Tallinn and Tartu, transport costs in Estonia are unlikely to exceed 50€/visit. As the participant has to come to the study center twice during the study, altogether the travel compensation is up to 100€. If the subject is unable to come to the study center in the morning on the day when the drug will be administered or travel home in the evening after the day of the study, accommodation costs will also be reimbursed. As participants are healthy subjects we do not foresee necessity for involving an accompanying person. Lisatud ka järgnevad lõigud informeeritud nõusoleku lehele: 2 Uuringus osalejatel on vaja käia kahel uuringuvisiidil, mis toimuvad haiglas (Tartu Ülikooli Kliinikum või Põhja Eesti Regionaalhaigla). Haiglasse sõitmise kulud kompenseeritakse Teile sõidudokumentide alusel, maksimaalselt kuni 50 € ulatuses visiidi kohta. Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning Teile sobival ajal. Uuringu ajal on plaanis katta kuludokumentide alusel Teie transpordikulud. Kui Teil ei ole võimalik uuringukeskusesse tulla uuringuravimi manustamise päeva hommikul või lahkuda uuringupäeva järgsel õhtul, siis tasutakse ka Teie ööbimiskulud. 4. Tegemist on väga suure farmakokineetilise uuringuga tervetel vabatahtlikel, kus plaanitakse hõlmata 200+/-50 isikut (informeeritud nõusoleku vormis 250) erinevate CYP450 (ilmselt CYP2D6 ja CYP2C19) geenivariantidega. Samas ei ole kirjeldatud, miks nii suurt valimit on tarvis, kas on mingid piirarvud teatud geeni variantidele jne. Uurijad peaksid põhjendama valimi suuruse kujunemist ja analüüsima, missuguseid meetodeid kasutatakse tagamaks, et oleks piisav arv uuritavaid erinevate geenivariantidega. Kas sarnase uuringu saaks läbi viia ka oluliselt väiksema isikute hulgaga? Uuringusse kutsutakse osalema 200+/-50 isikut, aga neist kõik ei pruugi sobida või nõustuda. Pole aga selge, kui palju uuritavaid on vajalik hõlmata uuringu farmakokineetilisse perioodi, et tõestada/ümber lükata püstitatud hüpoteese. Vastus: Uuringusse on plaanis kutsuda geenidoonorid, kellel esineb potentsiaalselt funktsioonikaoga mutatsioon või deletsioon (geneetika leid) ravimeid metaboliseerivates ensüümides. Sellliste isikute arv geenivaramu andmebaasis on 984 ja kõiki neid kutsutakse uuringus osalema. Seega on plaanis kirjeldada üksikjuhtude (erinevate mutatsioonidega isikute) põhjal statistilisi PK parameetreid ning vajalikku uuritavate arvu (sample size) hinnangut ei ole asjakohane teha. Lisasime allpool oleva küsimuse nr 7 juurde tabeli erinevate genotüüpidega isikute arvu kohta, keda on plaanis uuringusse kutsuda. Lisasime taotlusele punkti nr 7 lause: It is planned to describe the statistical PK parameters on a case-by-case basis (individuals with different mutations) and the sample size estimate is therefore not applicable. 5. Ravimitele on palju vastunäidustusi. Kas need tehakse kindlaks patsiendi sõnade põhjal või vaadatakse ka haiguslugusid? Vastus: Vastavalt uuringuprotokollile tuvastatakse patsiendi sobivus uuringus osalemiseks esimesel uuringu visiidil (pre-dosing visit) haiglas, sealjuures ka võimalikud vastunäidustused ravimitele. Selleks võetakse patsiendilt suuline meditsiiniline anamnees ning vajadusel vaadatakse ka osaleja eelmisi haiguslugusid. Uurijad vaatavad varasemaid haiguslugusid vaid osaleja nõusolekul ning vaadatakse vaid neid haiguslugusid, mis on antud uuringu kontekstis olulised – sellised, kust saab vajadusel kinnitust osaleja sobivuse kohta uuringus osalema (nt ravimite vastunäidustused). Varasematest haiguslugudest võib olla vaja vaadata infot varasemate diagnooside, kasutatavate ravimite ja allergiate kohta. 3 6. Taotluses on vaja palju selgemat lahti kirjutamist uuringusse kaasamise protsess – kes helistab ja kust telefoninumbrid saadakse, kas kõik, kellele helistatakse kutsutakse ka esimesele visiidile või jäävad mõned isikud juba pärast telefoni kontakti välja? Kui palju isikuid ja milliseid haaratakse farmakokineetilisse faasi? Vt ka eelmist kommentaari. Vastus: Kirjeldame täpsemalt uuritavate kaasamise protsessi punktis 9 „Description of the study-related procedures”. Taotlusele on lisatud ka uuringusse kutsumise kiri, mis esmalt geenidoonoritele saadetakse. 7. Kas uuring sellise formaadiga omab piisavat teaduslikku kvaliteeti? Miks ei ole rakendatud lisaks ka populatsiooni kineetika uuringut lisaks parameetrilisele farmakokineetilisele analüüsile. Vastus: Kuna uuringusse kaasatakse varem kirjeldamata geneetilise mutatsiooniga inimesed, ei ole teada, kas mutatsioon üldse mõjutab ravimite farmakokineetikat. Uuringu eeldus on, et uuringusse kaasatud isikute metabolismivõime on väga erinev ning erineva genotüübiga indiviide, keda uuringusse soovime kaasata, on vähe. Lisatud on tabel erinevate genotüüpidega osalejate numbritega. Leiame, et antud uuringus ei anna populatsiooni farmakokineetika lisaväärtust. Allele 1 Allele 2 N Nmax Coordinate CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1 CYP2C19_del CYP2C19_del 1 1 CYP2C19_del CYP2C19_Increased 162 10 CYP2C19_del CYP2C19_LoF 54 10 CYP2C19_del CYP2C19_Normal 324 10 CYP2C19_Novel_missense 1 1 chr10:96535248 CYP2C19_Novel_missense 1 1 chr10:96580257 CYP2C19_Novel_missense 4 4 chr10:96540331 CYP2C19_Novel_missense 1 1 chr10:96541688 CYP2C19_Novel_missense 1 1 chr10:96580323 CYP2C19_Novel_missense 1 1 chr10:96602648 CYP2C19_Novel_missense 1 1 chr10:96535156 CYP2C19_Novel_missense 1 1 chr10:96602634 CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820 CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820 CYP2D6_Novel_LoF 6 10 22:42522982 CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847 CYP2D6_Novel_LoF 1 1 chr22:42522916 CYP2D6_Novel_missense 1 1 chr22:42523889 CYP2D6_Novel_missense 1 1 chr22:42523916 4 CYP2D6_Novel_missense 2 2 chr22:42523928 CYP2D6_missense? * 109 10 chr22:42522613 CYP2D6_missense? * 86 10 chr22:42523943 CYP2D6_missense? * 45 10 chr22:42526694 CYP2D6_missense? * 33 10 chr22:42524814 CYP2D6_missense? * 30 10 chr22:42526763 CYP2D6_missense? * 23 10 chr22:42525811 CYP2D6_missense? * 23 10 chr22:42525821 CYP2D6_missense? 10 10 chr22:42524947 CYP2D6_missense? 6 10 chr22:42523558 CYP2D6_missense? 4 4 chr22:42523613 CYP2D6_missense? 3 3 chr22:42523567 CYP2D6_missense? 3 3 chr22:42524310 CYP2D6_missense? 2 2 chr22:42523897 CYP2D6_missense? 2 2 chr22:42525115 CYP2D6_missense? 1 1 chr22:42522601 CYP2D6_missense? 1 1 chr22:42523844 CYP2D6_missense? 1 1 chr22:42526712 Total 984 197 *) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3. Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid change, missense? = amino acid change with unknown function 8. Kas uuringus on ülemine vanusepiir? Kui on, siis tuleks see taotluses märkida. Vastus: ülemist vanusepiiri ei ole, lisame selle info taotlusele punktis 7. Inclusion criteria: Biobank participants (> 18 years, no upper limit of age) 9. Milliseid haiguslugusid vaadatakse (Access to medical records is only allowed to people mandated by the sponsor....)? Vastus: Uurijad vaatavad vaid uuringu jaoks asjakohaseid haiguslugusid, mis on potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega. Lisasime taotlusesse: Punkti nr 9: At the pre-dosing visit patient's eligibility for the study will be ascertained, including possible contraindications to the probe drugs. Relevant medical history will be documented in the electronic medical record. If necessary, the participant's previous medical history is reviewed. Only the past electronic medical records will be examined that are relevant 5 in the context of the study (information on diagnoses, medications used and allergies) and with the consent of the participant. Punkti nr 10: All collected data will remain confidential and anonymous. Investigators who are mandated to access the participants’ past electronic medical records are documented in the study delegation log, are also employees of the study centres (NEMC or TUH) and have access to electronic health systems of the hospitals. 10. Ei ole selge, kui kaua uuring kestab ja kui kaua sellest uuritav haiglas veedab. Kas uuringu kestvus uuritava jaoks on 72 tundi või 10 tundi? Vastus: uuring kestab kuni viimase kontakteerumiseni telefoni teel. Esimese uuringuvisiidi pikkus on umbes 1 tund ja teise uuringuvisiidi kestus on 10 tundi. Lisasime vastava info taotluses punkti nr 9.1. Informeeritud nõusoleku lehel on juba kirjas lause: Teine visiit kestab kuni 10 tundi ja seetõttu toimub see nädalavahetusel. Lisasime informeeritud nõusoleku lehele: Uuringu esimesel visiidil kulub haiglas aega umbes 1 tund. 11. Nõukogu on seisukohal, et 10 tunnise haiglas viibimise kohta ainult hommikusöök on ebapiisav. Uuringus osalejale tuleb tagada toitlustamine. Vastus: Uuritavatele tagatakse toitlustamine terve päeva jooksul, mil uuring toimub. Tegime vastava muudatuse taotluses ja patsiendi infolehel. Lisatud lause taotlusele: After probe drug administration and the first PK analyses a breakfast will be served at the study centres. The participants will be served a hot lunch. If requested, the subjects will receive one additional light meal. Lisatud lõik informeeritud nõusoleku lehele: Pärast uuringuravimite manustamist pakutakse Teile uuringukeskuses hommikusööki ning toitlustus tagatakse terve uuringupäeva jooksul. 12. Taotluse järgi on uuringu meeskonnas meditsiiniõed. Taotluses peavad olema vastavad isikud märgitud ja nendelt allkirjad võetud. Vastus: Saadame uuringuõdede nimed Nõukogule täiendusega siis, kui uuringu alguse aeg on selgunud. Uuringuõdedeks on mõlemas uuringukeskuses plaanitud õed, kelle igapäevatöö on uuringuprotseduuridele analoogsete meditsiiniliste tegevuste läbiviimine. Lisasime taotlusele lõigu: COMMENT: an additional application will be submitted to the Estonian Committee on Bioethics and Human Research for adding medical personnel from study centers (nurses) to the list of investigators. 6 13. Taotluses on ebaselge kui palju vereanalüüse võetakse peale ravimikokteili manustamist. Taotluse punktis 8.1 on lisaks 10 analüüsile (viimane 8 tundi pärast ravimi manustamist) ka märgitud analüüsid 12, 24, 48 ja 72 tundi pärast ravimi manustamist. Mujal taotluses ja protokollis aga mainitakse 10 analüüsi võtmist, sealjuures viimane analüüs võetakse 8 tundi pärast ravimi manustamist. Kuna metoprololi poolväärtusaeg SPC andmetel on 3.5 tundi, siis viimase analüüsi võtmine 8 tundi pärast ravimi manustamist võib osutuda ebapiisavaks ja seda eriti pidades silmas, et uuringusse kontsentreeruvad aeglased metaboliseerijad. Uurijad peaksid seda selgitama ja olema veendunud, et nimetatud uuringust saadud tulemused annavad vastuse neid huvitavale küsimusele. Vastus: Lähtume uuringus farmakokineetiliste analüüside võtmisel varem fenotüpiseerimiskokteiliga tehtud uuringu (Donzelli et al) tulemustest, milles oli kaasatud ka aeglased metaboliseerijad ning kus selgus, et lühem vereproovide võtmise periood on olnud piisav uuritavate ravimite farmakokineetilise profiili kirjeldamiseks. Lühema uuringuperioodi rakendamine on lisaks ka uuritavate huvides, kes ei pea veetma haiglas ööd. Lisasime taotlusesse lõigu: The sampling schedule is based on the results of a previous phenotyping cocktail study (Donzelli et al, 2014) that included slow metabolizers and showed that a shorter blood sampling period was sufficient to describe the pharmacokinetic profile of the studied drugs. In addition, the use of a shorter study period is also in the interest of subjects who do not have to spend the night at the hospital. 14. „Side effects will be documented and reported to the State Agency of Medicines“. Selgitada oleks tarvis, kas kõik kõrvalnähud või ainult tõsised kõrvalnähud (serious adverse events) dokumenteeritakse Ravimiametis ja kas neid muudes dokumentides (haige kaart) et raporteerita. Vastus: Uuringu ajal raporteerime Ravimiametile vaid tõsistest kõrvalnähtudest. Tegime vastavad muudatused eetikakomitee taotluses. Muudatus taotluses: According to the protocol, all participating doctors and nurses will be obliged to report any study related serious adverse effects to the State Agency of Medicines and Ethics Committee. Uuringuprotokollis on punktis 11 lause: 11. Safety reporting All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged to report to State Agency of Medicines and Ethical Committee about any suspected unexpected serious adverse adverse reactions (SUSAR). 15. Taotluses on märgitud, et haigele helistatakse 1 nädal pärast uuringukokteili võtmist. Miks selline ajamääratlus? Kas on kaalutud, et võib esineda ravimite manustamisest probleeme ka esimestel päevadel . 7 Vastus: Uuritavatele helistatakse nädal pärast uuringuravimite manustamist, kuna uuringuravimite põhjustatud kõrvalnähud tõenäoliselt hiljem enam ei avaldu. Uuritaval on võimalus uurijatega telefoni teel ühendust võtta kogu uuringu ajal ja teavitada uurijat võimalikust ravimi kõrvaltoimest. Lisasime taotlusesse punkti nr 9 lõigu: Follow-up phone call 1 week after the phenotyping probe drugs administration to document possible ADRs. The call will be made a week after the study medication is given as side effects are unlikely to occur later. The subject has the opportunity to contact investigators by telephone throughout the study and to inform the investigator of any adverse drug reaction. Lisasime infolehele järgmise lause: Teil on võimalus uurijatega telefoni teel ühendust võtta kogu uuringu ajal ja teavitada uurijat võimalikust ravimi kõrvaltoimest. 16. Kuna tegemist on ravimuuringuga siis on vajalik uuritavatele rakendada eraldi kindlustuskaitse. Vastus: Uuringu ajaks küsitakse uuritavatele kindlustuspoliis. Lisas kindlustuspakkumine. 17. Taotluses 9.2 isiku autonoomia respekteerimise lõik peaks puudutama ka prospektiivset uuringut. Vastus: Täiendasime vastavat peatükki: Participation in this study is voluntary. The gene donor shall be provided with sufficient information on the nature of the trial to assist him or her in making an informed decision. The subject may at any time opt-out or discontinue the trial without justification. The study data of the subject who discontinued the study shall be kept for 5 years, separately from the data of the other subjects and shall not be included in the analysis. If a participant asks the PI to delete their data, we will give them 2 options, a) delete data + destroy sample, or b) delete the code key. The requested data will be deleted and this action will be documented. 16. Kas geenivaramust võetakse mingid koeproovid, kuna punktis 10.1 kirjutatakse: „The tissue samples, ... are issued from the Gene Bank only in pseudonymised form“ Vastus: Parandasime vea punktis 10.1. Uuringu käigus ei võeta geenivaramust koeproove. Lause uus sõnastus: Descriptions of DNA are issued from the Gene Bank only in pseudonymised form, as a set of data and on the condition that samples or data concerning at least five gene donors are issued at a time (HGRA § 22, section (4)). 8 18. Ei taotlusest ega informeeritud nõusolekust ei selgu, kuidas uuritavaid ravimeid manustatakse. Kas ravimvorm lahustatakse 50 ml kraanivees? Või uuringuks spetsiaalselt valmistatud tablettide või kapslitena. See vajab selgitust nii taotluses kui ka informeeritud nõusoleku lehel. Vastus: Kirjutasime vastava punkti täpsemalt lahti taotluses, protokollis punktis 9.2 (description of dosing): Muudetud lõik taotluses: Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs will be administered with 50 mL of tap water: 20 mg omeprazole (full 20mg capsule) 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is measured and packed according to the standard procedures (SOP) of the hospital pharmacy of Tartu University Hospital). The reason to use extemporaneous product is caused by the fact that no marketed product of metoprolol is available at such a low dose. Täiendus patsiendi infolehel: Omeprasool on kapslis valmispreparaat ja metoprolool antakse Teile puhta toimeaine pulbrina, mille uuringuõde lisab 50ml-le kraaniveele ja annab Teile sisse võtmiseks. Ka omeprasooli võtmiseks antakse teile kraanivett. 18. Informeeritud nõusolekust johtub, et haigele antakse kaasa soovitus ravimikokteili võtmiseks. Samas on aga isik samaaegselt haiglas. Niisuguses uuringus on ilmselt ohutum kui uuringuravimi valmistab ja manustab uuringuga seotud meditsiinitöötaja. Vastus: Muutsime sõnastuse täpsemaks. Informeeritud nõusoleku lehel on kirjas, et esimesel uuringuvisiidil antakse koju kaasa info selle kohta, kas uuringus osaleja võib uuringupäeva hommikul võtta oma isiklikud ravimid, mida ta regulaarselt tarvitab. Kuna uuringus osalevad terved vabatahtlikud ja täiskasvanud inimesed, siis annavad uuringuõed suu kaudu manustatava ravimi patsiendi kätte, kes selle uuringuõe järelvalve all endale ise manustab. Täiendasime vastavat lõiku informeeritud nõusoleku lehel: Kui tarvitate regulaarselt ravimeid, lepitakse Teiega esimesel visiidil kokku, kas võite uuringupäeva hommikul oma isiklikke ravimeid võtta. Selle kohta antakse Teile kaasa täpne soovitus. 19. Isikute ohutuse tagamiseks palume lisada informeeritud nõusolekule telefoninumber, kuhu ja kellele uuritav probleemide korral võib ööpäevaringselt helistada. 9 Vastus: Lisame informeeritud nõusoleku lehele telefoninumbrid mõlemast uuringukeskusest (uurijate isiklikele telefonidele suunatud kabineti telefoni numbrid), kuhu uuritavad saavad uuringu ajal ööpäevaringselt helistada. Numbrid täpsustuvad uuringu eelseks hetkeks. 20. Kui kaua ja kus säilitatakse prospektiivse uuringu andmeid ning koodi võtit? Vastus: Uuringu andmeid säilitatakse peale uuringu lõppu geenivaramus tähtajatult ning samuti säilitatakse geenivaramus ka koodi võtit. 21. Mis juhtub andmetega, kui osalemine katkestada? Vastus: Uuringu katkestanud isiku uuringuandmeid säilitatakse 5 aastat, teiste uuritavate andmetest eraldi Geenivaramus ja neid andmeid analüüsi ei kaasata. Kui osaleja palub oma andmed kustutada, anname talle 2 võimalust, andmed kustutada+ proov hävitada või koodivõti kustutada, siis andmed kustutatakse ning see tegevus dokumenteeritakse. Lisasime taotlusele punkti 10.2: The study data of the subject who discontinued the study shall be kept for 5 years, separately from the data of the other subjects and shall not be included in the analysis. If a participant asks the PI to delete their data, we will give them 2 options, a) delete data + destroy sample, or b) delete the code key. The requested data will be deleted and this action will be documented. 22. Infolehes peab olema isikuandmete kaitse osa selgitatud vastavalt IKS –le. Vastus: Lisasime infolehes isikuandmete kaitse kohta täienduse: Kõik uuringu raames kogutud andmed on konfidentsiaalsed ja uuritavate isikuandmed on kaitstud vastavalt rahvusvaheliste ja Eestis kehtestatud reeglitele (kooskõlas Isikuandmete Kaitse seadusega). 23. Mida tähendab „Info dokumenteeritakse elektroonilises haigusloos.“ Kas haigla programmis (n ESTER)? Vastus: Jah, uuringuvisiidil dokumenteeritakse info vastavalt uuringukeskusele vastava haigla elektroonilises haigusloos (Ester Põhja-Eesti Regionaalhaiglas või eHL Tartu Ülikooli Kliinikumis). Täiendasime informeeritud nõusoleku vormi: Info dokumenteeritakse elektroonilises haigusloos vastava haigla IT süsteemis sarnaselt sellele, kuidas andmeid dokumenteeritakse tavalise arstivisiidi käigus. 24. Nõusoleku vormi lause: Ma annan uuringuga seotud isikutele loa juurdepääsuks oma 10 meditsiinilistele dokumentidele – on liiga laialt formuleeritud. Kas siin on silmas peetud kõiki andmeid TISis? Vastus: Uurijad vaatavaid vaid uuringu jaoks asjakohaseid haiguslugusid, mis on potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega. Lisasime informeeritud nõusoleku vormile lõigud: Uurijad võivad vaadata ka Teie varasemaid haiguslugusid, mis on potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega. Selleks küsitakse Teilt eraldi nõusolek. Täiendasime informeeritud nõusoleku vormi lauset: 3. Ma annan uuringuga seotud isikutele loa juurdepääsuks oma meditsiinilistele dokumentidele (uuringu jaoks vajaliku ravimitega seotud info jaoks varasematest elektroonilistest haiguslugudest haigla infosüsteemis) 25. Uuritavale tuleb esitada kogu info, mis puudutab andmete kasutamist, muuhulgas ka lisada, et prospektiivse uuringu andmed edastatakse ka Biopanka. Vastus: Lisame infolehele lause, et et prospektiivse uuringu andmed edastatakse ka Biopanka, kus toimub andmete kodeerimine ja pseudonümiseeritud kujul analüüs. 26. Kuna on kaks visiiti ja üks telefonikõne kõige lõpus, ei saa uuring olla päris anonüümne, vahepeal on vaja andmeid isiku lõikes kokku viia (All information collected will remain strictly confidential and anonymous ja All generated individual level data will be submitted to the Estonian Biobank for incorporation into the biobank database at the end of the study) Infolehel on kirjas: „Visiidi käigus dokumenteeritakse Teie isikuandmed“. Vastus: Uuritavate ohutuse tagamiseks on patsiendiga otseselt kokkupuutuvatele uurijatele uuringu ajal uuritava isik teada, et oleks võimalik tutvuda uuritava asjakohaste haiguslugudega. Uuringuandmeid analüüsitakse ja avaldatakse teaduskirjanduses anonüümselt. Lisasime taotlusesse täpsustava lõigu: 11.3 Storage of data collected during study The EstBB senior data encoder will depseudonymise the personal data of participants that is necessary for contacting the study subjects. The initial contact and invitation to participate in the study will only be done by the EstBB staff authorized to handle personal data. Once the individuals have agreed to participate in the study, their first visit will be scheduled by the EstBB staff. At this point, the personal data of the participants will be visible for the investigators at the study centre. During the first visit at the study centres (hospital) participants personal information (name, id code) will be used for documenting the study visit to the electronic medical systems and for ordering study related medical analyses (blood tests) from 11 the local laboratories. For the study participants unique study codes will be designated and these codes will be used for the further study related procedures. Same codes will be documented on the consent form, used in the screening logs, and on each blood sample taken for PK analysis. Plasma samples for the PK analyses will be sent to the laboratory at Karolinska Institute marked with the same unique codes and no personal information (ID codes, names) will be sent out from the study centres (TUC, NEMC). The samples will be analysed and the results will be sent to the EstBB using the same codes. All study records, measurements, sample results will be submitted to the EstBB and entered into the biobank database. The final results will then be coded for research use and made accessible through the EstBB database for the researchers of the study. 27. Ravimikontsentratsioonide määramine tehakse Rootsis, Karolinska Instituudis. See oluline informatsioon tuleb lisada ka informeeritud nõusolekule. Vastus: Lisasime vastava info informeeritud nõusolekule: Ravimikontsentratsioonid määratakse Rootsis, Karolinska Instituudis. 28. Infolehel on lause: Selles uuringus osalemisest ei pruugi Teile olla otsest kasu. Sellest uuringut uuritavale otsest kasu ei ole ja nii tuleks seda ka öelda. Vastus: Uuringust ei pruugi olla uuritavale otsest kasu, kuid juhul kui farmakokineetiline uuring näitab, et uuritav ei ole võimeline uuringuravimeid metaboliseerima, võib sellest teadmisest olla uuritavale tulevikus kasu ka teiste CYP2D6 või CYP2C19 ensüümi poolt metaboliseeritud ravimite korral. Lisaks vaatab uuritava läbi uuringuarst ning uuringu ajal tehakse osalejale laboratoorsed analüüsid, mille interpreteerimine uurijate poolt võib samuti uuritavale kasu tuua. Lisasime taotlusele lõigu: The probe drug experiment has a potential value for the participants in study group as it could help to adjust future treatment with medicines which are metabolised via the studied CYP enzymes and further estimate the participants’ personal metabolic activity for the respective drug metabolizing enzymes while taking into account the patient’s lifestyle and environmental influences in addition to their personal genetic background. By the request the participants (please see consent form) results of the pharmacokinetic analysis will be given in the form of a personal drug metabolism profile and genetic report. This feedback will be prepared and delivered separately as “Feedback to the gene donors” (“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the University of Tartu 271/T-2, 19.06.2017). Lisasime informeeritud nõusoleku vormile täiendavalt: 12 Teil on võimalus saada teada, kas olete uuringus kasutatud ravimite kiire või aeglane metaboliseerija ning saada personaalse farmakogeneetika raporti, mis on koostatud Teie kohta Geenivaramus hoitavate geeniandmete põhjal. Farmakogeneetika raport kajastab inimese geneetiliste eripärade mõju ravimite omastamisele, sobivusele või kõrvaltoimete tekkimisele. Raportis on andmed 28 erineva toimeaine kohta. Uuringu tulemused ja raport saadetakse Teile soovi korral e-mailile või tavapostiga. Palun tehke valik ja märkige sobivasse kasti ees- ja perekonnanime esitähed Soovin teada uuringu tulemusi Soovin saada raportit Ei soovi teada uuringu tulemusi Ei soovi saada raportit Kirjutage trükitähtedega e-maili või postiaadress, kuhu saadetakse tulemused ja/või raport. Neid andmeid ei kasutata mingil muul otstarbel ja ei kanta mingisse andmebaasi, kuid nad jäävad tähtajatult hoiule Geenivaramusse. …………………………………………………………………………………………. 29. Uuritavatele esitatud tekst peab olema tavainimese jaoks arusaadav. Vastus: Hindasime uuesti üle uuritavale esitatava teksti arusaadavuse ja tegime vastavad parandused. 13 Sweden, Stockholm, Karolinska University Hospital ------------------------------------------- Date: 2020-02-25 Dr. Anton Pohanka -------------------------------------------- Date: Dr. Volker M Lauschke -------------------------------------------- Date: Prof. Erik Eliasson, MD Protocol 27.02.2020 CLINICAL STUDY PROTOCOL Protocol 1-2020, Version 2 Study of the effects of previously uncharacterized rare variants in the genes encoding CYP450 enzymes 1 Protocol 27.02.2020 Table of Contents Protocol Signature Sheet and Acknowledgement 3 1. Protocol Synopsis 4 2. Protocol team 7 3. Participating institutions and units 9 4. Background and rationale 9 5. Study objective 13 6. Study design 13 7. Study population 14 8. Study procedures 15 8.3 Pharmacokinetic sampling and sample handling 18 9. Study medications 18 9.2 Description of dosing 19 Single doses of the following probe drug combinations will be administered Error! Bookmark not defined. with 50 mL of tap water: Error! Bookmark not defined. omeprazole 20 mg for CYP2C19 Error! Bookmark not defined. metoprolol 12.5 mg for CYP2D6 Error! Bookmark not defined. 9.3 Concomitant medication 20 10. Analytical procedures 20 11. Safety reporting 20 12. Study management and monitoring 22 13. Statistical considerations 22 13.1 Pharmacokinetic analysis 22 14. Ethical considerations and confidentiality 22 14.1 Informed consent 22 15. Administrative aspects 23 15.1 Handling and storage of data and documents 23 15.2 Annual progress report 23 15.3 End of study report 24 16. Scientific communication 24 2 Protocol 27.02.2020 Protocol Signature Sheet and Acknowledgement I have read this Protocol and agree that it contains all necessary details for carrying out the study described. I understand that it must be reviewed by the Independent Ethics Committee and approved or given favourable opinion before implementation. The signature of the Principal Investigator and Sponsor or it’s representative below constitute their approval of this protocol and proved the necessary assurances that this study will be conducted according to the Declaration of Helsinki, ICH GCP guidelines and applicable regulatory requirements. _________________________________________ _________________ Sponsor’s printed name and signature Date __________________________________________ _________________ Principal investigator’s printed name and signature Date 3 Protocol 27.02.2020 1. Protocol Synopsis Sponsor InstituEstonian Genome Center Science Center, University of Tartu Principal Investigator of the Alar Irs, Tartu University Hospital, Heart Clinic clinical trial Coordinating Investigator Jana Lass, University of Tartu, Institute of Genomics, Research Fellow of Clinical pharmacology Monitoring Riina Janno, National Centre of Translational and Clinical Research Title of Study Study of the effects of previously uncharacterized rare variants in the genes encoding CYP450 enzymes Protocol Number Protocol 1-2020, Version 2 Study Centres and units 1. Institute of Genomics, University of Tartu 2. Tartu University Hospital Haematology and Oncology Clinic 3. North Estonia Medical Centre Foundation Oncology and Haematology Clinic 4. Karolinska University Hospital Department of Clinical Pharmacology Study medicines Single oral dose of: 20 mg omeprazole 12.5 mg metoprolol Study population Adult (>18 years) volunteers from the Estonian biobank population not using interfering concomitant medicines Methodology Prospective, multicentre, single dose phenotyping study. For all of the genotyped participants full pharmacokinetic profiles of the probe drugs and their main metabolites will be determined in plasma. Study timetable Study start date: 03.2020 Study completion date: 02.2025 Objectives To asses if the newly described mutations in cytochrome 2D6 and 2C19 change the metabolizing activity of these enzymes. Study design Prospective trial Inclusion criteria 1. All biobank participants (> 18 years, no upper limit of age) who have (according to performed genotyping analysis) previously not described/studied mutations or deletions in the metabolizing enzymes (CYP2D6 and CYP2C19) 4 Protocol 27.02.2020 2. Able to understand the nature of the study and content and meaning of consent. Exclusion criteria 1. Clinically relevant abnormality of renal or liver function or anemia identified at the laboratory screening 2. Pregnancy or lactation 3. History or clinical evidence of alcoholism or drug abuse within the last year period prior to screening 4. Excessive alcohol consumption within 2 days before the first drug administration 5. Previous treatment with any medicines interfering with the measurement of phenotyping probe drugs 6. Any of the probe drugs contraindicated or had a history of allergy to any study medication 7. Patient's weight 50% more or less than their ideal body weight (for assessment the on-line calculator will be used e.g.https://www.calculator.net/ideal- weight-calculator.html) Study flow - Biopank participant screening - E-mail contact - Phone contact - Pre-dose visit - Drug administration and sample collection visit - Phone follow up on Day 7 after drug administration visit Duration of subject Subjects will be on study for up to 1 week after participation administration of study medicines. Pharmacokinetics PK sampling A total of 10 blood samples will be collected: 1st – before the start of drug cocktail dosing (baseline) 2nd – 15 min after the administration of study dose 3rd – 30 min after the administration of study dose 4th – 45 min after the administration of study dose 5th – 1 h after the administration of study dose 6th – 2 h after the administration of study dose 7th – 3 h after the administration of study dose 8th – 4 h after the administration of study dose 9th – 6 h after the administration of study dose 10th – 8 h after the administration of study dose Statistical methods Descriptive statistics: PK parameters (AUC, T1/2, VD, CLt, CLr, Cmax) 5 Protocol 27.02.2020 Outcome Pharmacokinetic endpoints, area under the concentration–time curve (AUC) ratios (AUC0–24h parent / AUC0–24h metabolite) 6 Protocol 27.02.2020 2. Protocol team Principal investigator Dr. Alar Irs Tartu University Hospital Heart Clinic 511 8592 [email protected] /signed electronically/ Sub-investigators Dr. Lili Milani Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu 737 4039 [email protected] /signed electronically/ Dr. Alar Irs Tartu University Hospital Heart Clinic 511 8592 [email protected] /signed electronically/ Dr. Kersti Oselin North Estonia Regional Hospital Oncology and Haematology Clinic 617 1792 [email protected] /signed electronically/ Dr. Jana Lass Tartu University Hospital Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu731 8333 [email protected] /signed electronically/ Kristi Krebs, MSc Estonian Genome Centre Institute of Genomics University of Tartu 7 Protocol 27.02.2020 Riia 23b, 51010 Tartu737 4039 [email protected] /signed electronically/ Tuuli Jürgenson, BSc (statistics) Estonian Genome Centre Institute of Genomics University of Tartu Riia 23b, 51010 Tartu [email protected] /signed electronically/ Dr. Anton Pohanka Karolinska University Hospital Department of Clinical Pharmacology [email protected] /signature in Annex/ Dr. Volker M Lauschke Dept of Physiology and Pharmacology Karolinska Institutet [email protected] /signature in Annex/ Prof. Erik Eliasson, MD Department of Laboratory Medicine Clinical Pharmacology Karolinska Institutet [email protected] /signature in Annex/ Director of the institution or head of the structural unit of the principal investigator Katrin Kaarna Head of the Clinical Research Centre, University of Tartu Ravila 19, 50411 Tartu [email protected] 737 4119 /signed electronically/ Consent from director or authorised person of the institution(s)/partner organisation(s) Institute of Genomics University of Tartu Riia 23b, 51010 Tartu Mait Metspalu Director 737 5052 8 Protocol 27.02.2020 [email protected] /signed electronically/ 3. Participating institutions and units 1. Estonian Genome Center Science Center, University of Tartu 2. Tartu University Hospital Haematology and Oncology Clinic 3. Oncology and Haematology Clinic, North Estonia Medical Centre Foundation 5. Pharmacological laboratory, Karolinska Institute, Sweden 4. Background and rationale Cytochrome P450 (CYP) enzymes play an important role in drug metabolism by being responsible for oxidative metabolism of approximately 50 % of drugs and xenobiotics. Variation in the CYP genes can produce enzyme products with abolished, reduced, altered or increased enzyme activity. In addition to metabolizing enzymes of which the CYP genes are the by far most well studied, drug transporter proteins are important sources of pharmacokinetic variability in drug response (Kozyra et al, 2016). Considerable inter- and intra-individual variability in the expression and function of CYP enzymes exists, which is determined by multiple factors. A large degree of variability exists within any particular genotype group, which confirms that in addition to known genetic variants, novel rare genetic factors as well as non-genetic host factors (age, gender, disease states), and environmental influences (such as smoking, diet, concomitant drugs) are also important (Wilkinson et al, 2005). Consequently, each individual has its own CYP450 metabolic profile and the phenotype (i.e. the real activity) of an individual enzyme is important for predicting possible therapeutic failures or toxic reactions to medicines. Several common genetic variants have been described which lead to altered enzyme activity and thus variation in treatment outcome (Reisberg et al, 2019). However, the effect of some novel rare genetic variants is not known on drug metabolism. The aim of our study is to examine in a clinical trial the effect of novel predicted loss-of-function (LoF), missense genetic variants and large deletions that were detected in the Estonian population by analysing the whole genome sequence data of 2500 participants of the Estonian Biobank (Tasa and Krebs et al, 2018). The effect of the variants was first assessed with bioinformatic tools, incl. Variant Effect Predictor (VEP, https://www.ensembl.org/info/docs/tools/vep/index.html) and filtered for loss- of-function and missense variants. For this study, we have also included missense variants that were selected using a recently published framework for pharmacogenetic variants (Zhou et al, 2018). In order to determine the effect of the previously uncharacterized genetic variants, we will use in vivo phenotyping by using previously tested and validated phenotyping probe drugs. This will allow us to determine the enzyme activities and describe the net effect of all influencing 9 Protocol 27.02.2020 factors on CYP activity. It has been shown that using phenotyping probe drugs is an accurate and minimally invasive method for the in vivo assessment of CYP enzyme activities in a single experiment. Probe drugs can be used in various combinations (Donzelli et al, 2014; Christensen et al, 2003; Keller et al. 2017), allowing for the in vivo assessment of multiple pathways of drug metabolism in a single experiment, taking into account genetic, non-genetic and environmental influencing factors. Probe drugs should predominantly be metabolized by an individual CYP enzyme, can be safely administered to humans and have no other significant cause of variability, in addition to the one for which they will be used as a probe. There are several phenotyping cocktails used in clinical studies, each of these having their benefits and flaws. The basel phenotyping cocktail (containing caffeine, efavirenz, losartan, omeprazole, metoprolol, and midazolam as probe drugs for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, respectively) has been well tolerated and has had good correlations of metabolic ratios with AUC (Area Under The Curve - one of the most important evaluation metrics for checking any classification model’s performance) ratios of the corresponding probe drugs and their metabolites (Derungs et al. 2016). References 1. Kozyra et al. “Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response”. Genet. Med. (2016) 2. Wilkinson. “Drug metabolism and variability among patients in drug response”. N Engl J Med. 2005;352(21):2211–21 3. Reisberg et al. "Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions." Gen Medicine 21.6 (2019): 1345. 4. Tasa et al. "Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records." Eur J Human Genetics 27.3 (2019): 442. 5. Donzelli et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokin 2014, 53(3), 271-282. 6. Christensen et al. "The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes." Clin Pharmacol Therapeutics 73.6 (2003): 517-528. 7. Keller et al. "In vivo phenotyping methods: cytochrome P450 probes with emphasis on the cocktail approach." Curr pharm design 23.14 (2017): 2035-2049. 8. Derungs et al. "Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the basel cocktail: a randomized crossover study." Clin Pharmacokin 55.1 (2016) 9. Zhou et al. “Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.” Front Pharmacol 4;9:1437. (2018) 4.1 Genotyping probe drugs It has been shown that the method of using phenotyping probe drugs is accurate and minimally invasive methods for in-vivo assessment of CYP enzyme activities in a single experiment. Probe drugs can be used in various combinations allowing for the in vivo assessment of multiple pathways of drug metabolism in a single experiment, taking into account genetic, non-genetic and environmental influencing factors 10 Protocol 27.02.2020 Probe drugs should meet certain criteria - they should predominately be metabolized by an individual CYP enzyme, can be safely administered to humans and have no other significant cause of variability, in addition to the one for which they will be used as a probe. The phenotyping procedure involves following steps: 1. administration of a small dose of the probe drug(s) 2. measurement of the drug and metabolites concentration in plasma/urine 3. calculation of a specific metabolic index 4. correlation of the resulting index value with a known activity of the evaluated enzyme. There are several phenotyping cocktails used in clinical studies, each of these having their benefits and flaws. The Basel phenotyping cocktail has been well tolerated and has had good correlations of metabolic ratios with AUC ratios of the corresponding probe drugs and their metabolites (Derungs et al. 2016). The composition of the Basel cocktail is following: 100 mg caffeine, 50 mg efavirenz, 12.5 mg losartan, 10 mg omeprazole, 12.5 mg metoprolol 2 mg midazolam. Practical considerations in the selection of CYP substrates Cytochrome Probe drug CYP1A2 Caffeine Complex metabolism involving many enzymes (CYP1A1, 1A2, 2A6, 2E1, 3A, NAT-2 and XO). Metabolism rate variable and 2 to 12 h half-life in humans. Urine collection period, renal clearance, smoking and dietary/ influence PK. Disagreement about the dose, time of evaluation, sample matrix (blood /urine), and the best metabolic quotient. CYP2B6 Efavirenz Upon repeated dosing, it is a moderate inducer of CYP3A4. In vitro CYP inhibition of CYP1A2, 2C9, 2C19, 2D6 and 3A4 isoforms (no in vivo data available). Because of CYP liability, very low dose required and necessities sensitive assay. Long half-life (52-76 h) and slow plasma clearance resulting in longer sampling intervals and washout periods CYP2C9 Losartan Metabolism not specific to CYP2C9 and mediated by CYP3A4 also through metabolism rate is 4-times greater for CYP2C9 than for CYP3A4 11 Protocol 27.02.2020 CYP2C19 Omeprazole Half-life is very short (0.5-1 h), and sampling within a few hours after dosing. Omeprazole is a competitive inhibitor of p-glycoprotein. adverse effects such as headache, dizziness, cough, upset stomach etc. CYP2D6 Metoprolol Weak correlation of activity ss. urinary MR (M/HM) or urinary S/R-metoprolol ratio. Significant first-pass metabolism. Adverse reactions (hypotension, orthostatic symptoms etc.). CYP3A4/5 Midazolam Multiple- blood samples needed for AUC measurement. Metabolism is related to two different organ enzymes (hepatic and intestinal CYP3A). Oral and intravenous dosing necessary to characterize the hepatic and intestinal contributions. At increased CYP3A4/5 activity, midazolam clearance may exhibit hepatic blood flow dependence. This may present issues with the interpretation of the results. First-pass metabolism may be saturated. Side effects (i.e., dizziness and sedation). Based on the genetic profiles of the biobank patients, the composition of the cocktail was reduced to 2 components (omeprazole and metoprolol) to cover the most important and common drug metabolizing CYP enzymes (2D6 and 2C19). References ● Derungs et al. "Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the basel cocktail: a randomized crossover study." Clinical pharmacokinetics 55.1 (2016) ● Donzelli, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet., 2014, 53(3), 271-282. 4.2 Sample collection for pharmacokinetic analysis A total of 10 blood samples will be collected from antecubital veins (inserted catheters): 1st – before the start of drug cocktail dosing (baseline) 2nd – 15 min after the administration of study dose 3rd – 30 min after the administration of study dose 4th – 45 min after the administration of study dose 5th – 1 h after the administration of study dose 6th – 2 h after the administration of study dose 7th – 3 h after the administration of study dose 8th – 4 h after the administration of study dose 9th – 6 h after the administration of study dose 10th – 8 h after the administration of study dose 12 Protocol 27.02.2020 5. Study objective The aim of the study is to assess if the newly described mutations in cytochrome 2D6 and 2C19 change the metabolizing activity of these enzymes. 6. Study design A prospective study will be performed at Tartu University Clinic’s Hematology and Oncology Clinic and North Estonia Medical Centre Foundation’s Oncology and Haematology Clinic. The subjects will be selected and re-contacted based on the availability of whole genome sequencing data, the health status of the subjects and their suitability for such a study, according to standard ethical procedures regarding clinical studies involving drugs. Based on initial review of the existing whole genome sequencing data of 2500 the Estonian Biobank (EstBB) participants, we have detected the following number of individuals with previously uncharacterized genetic variants in the CYP450 genes: Table 1. Number of individuals with rare genetic variants in the CYP450 genes Allele 1 Allele 2 N Nmax Coordinate CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2 CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1 CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1 CYP2C19_del CYP2C19_del 1 1 CYP2C19_del CYP2C19_Increased 162 10 CYP2C19_del CYP2C19_LoF 54 10 CYP2C19_del CYP2C19_Normal 324 10 CYP2C19_Novel_missense 1 1 chr10:96535248 CYP2C19_Novel_missense 1 1 chr10:96580257 CYP2C19_Novel_missense 4 4 chr10:96540331 CYP2C19_Novel_missense 1 1 chr10:96541688 CYP2C19_Novel_missense 1 1 chr10:96580323 CYP2C19_Novel_missense 1 1 chr10:96602648 CYP2C19_Novel_missense 1 1 chr10:96535156 CYP2C19_Novel_missense 1 1 chr10:96602634 CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820 CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820 CYP2D6_Novel_LoF 6 10 22:42522982 CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847 CYP2D6_Novel_LoF 1 1 chr22:42522916 CYP2D6_Novel_missense 1 1 chr22:42523889 13 Protocol 27.02.2020 CYP2D6_Novel_missense 1 1 chr22:42523916 CYP2D6_Novel_missense 2 2 chr22:42523928 CYP2D6_missense? * 109 10 chr22:42522613 CYP2D6_missense? * 86 10 chr22:42523943 CYP2D6_missense? * 45 10 chr22:42526694 CYP2D6_missense? * 33 10 chr22:42524814 CYP2D6_missense? * 30 10 chr22:42526763 CYP2D6_missense? * 23 10 chr22:42525811 CYP2D6_missense? * 23 10 chr22:42525821 CYP2D6_missense? 10 10 chr22:42524947 CYP2D6_missense? 6 10 chr22:42523558 CYP2D6_missense? 4 4 chr22:42523613 CYP2D6_missense? 3 3 chr22:42523567 CYP2D6_missense? 3 3 chr22:42524310 CYP2D6_missense? 2 2 chr22:42523897 CYP2D6_missense? 2 2 chr22:42525115 CYP2D6_missense? 1 1 chr22:42522601 CYP2D6_missense? 1 1 chr22:42523844 CYP2D6_missense? 1 1 chr22:42526712 Total 984 197 *) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3. Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid change, missense? = amino acid change with unknown function Coordinate = chromosome and position according to human genome build hg37. The deletion of CYP2C19 spans exons 1-5 and the deletion of CYP2D6 the entire gene. 7. Study population 7.1 Inclusion criteria 1. All biobank participants (> 18 years, no upper limit of age) who have (according to performed genotyping analysis) previously not described/studied mutations or deletions in the metabolizing enzymes (CYP2D6 and CYP2C19) 2. Able to understand the nature of the study and content and meaning of consent. 7.2. Exclusion criteria 1. Clinically relevant abnormality of renal or liver function or anemia identified at the laboratory screening 2. Pregnancy or lactation 14 Protocol 27.02.2020 3. History or clinical evidence of alcoholism or drug abuse within the last year period prior to screening 4. Excessive alcohol consumption within 2 days before the first drug administration 5. Previous treatment with any medicines interfering with the measurement of phenotyping probe drugs 6. Any of the probe drugs contraindicated or had a history of allergy to any study medication 7. Patient's weight 50% more or less than their ideal body weight (for assessment the on- line calculator will be used e.g.https://www.calculator.net/ideal-weight- calculator.html) Informed consent will be taken from the study participants before the study-related procedures. Informed consent form allows to: - Take blood samples for the PK analysis - Administer probe drugs - Assess relevant electronic medical records The study procedures will be described thoroughly during the first contact by the phone. The informed consent will be sought by the responsible study team member who is documented at the delegation log. There will be 2 copies of informed consent sheet: - For the study participant - For the study record 7.3. Removal of subjects from the study Subjects could withdraw consent at any time without prejudice. The investigator could withdraw a subject from the study if, in his or her clinical judgment, it was in the best interest of the subject or if the subject could not comply with elements of the protocol or necessary for the scientific integrity of the study. If the investigator withdrew a subject from the study, the investigators explained the reason for withdrawing the participant 8. Study procedures 8.1 Study visits and patients monitoring 1. Contacting participants (please see Table 2) Selected biobank subjects (up to 984 people) will be contacted and invited to participate in the study first by e-mail or regular post if email address is not available (please see Invitation letter Appendix 2). In case of nonresponse one reminder will be sent after 1 week, and a phone call will be made 1 week after the reminder. The initial contact will only be made by personnel at the EstBB who are specifically authorized by the director of the Institute of Genomics to handle personal data. 15 Protocol 27.02.2020 2. All participants, who give positive response to the first invitation are scheduled for a phone call with the authorized personnel at the EstBB in the course of which  introduction of the study and  pre-screening interview takes place Pre-screening interview includes mapping of o inclusion criteria Suitable subjects are offered to participate at the study and invited to the study centre (Tartu University Hospital or North Estonia Medical Centre) for a pre-scheduled pre-dosing visit. 3. Pre-dosing visit at the hospitals: Duration of the visit is approximately 1 hour (time spent at the hospital).  verify the inclusion criteria  sign informed consent  collect medical history (previous and current medical conditions, surgical history, prior and concomitant medications, allergies) and baseline characteristics  perform local laboratory tests o haematological parameters: WBC, haemoglobin, haematocrit, platelets o renal function measurements: urea, creatinine o other tests: Na, K, Ca, glucose, transaminases  perform clinical examination (weight, height, blood pressure, heart rate) At the pre-dosing visit patient's eligibility for the study will be ascertained, including possible contraindications to the probe drugs. Relevant medical history will be documented to the electronic medical record. If necessary, the participant's previous medical history is reviewed. Only the past electronic medical records will be examined that are relevant in the context of the study (information on diagnoses, medications used and allergies) and with the consent of the participant. Eligible study subjects will be invited to receive a dose of the probe drugs at a separate visit (Dosing and PK sampling visit) at the study centre (Tartu University Hospital (TUH) or North Estonia Medical Centre (NEMC)). 4. Probe drugs administration and PK sampling visit Duration of the visit is up to 10 hours (time spent in hospital) ● Recheck eligibility according to the study inclusion and exclusion criteria ● Verify the inclusion criteria ● Perform clinical examination (evaluation of core body temperature, weight, height, blood pressure, heart rate) ● Pregnancy test from urine (for female participants until menopause) o Single dose administration of probe drugs: o 20 mg omeprazole (full 20mg capsule) o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is measured and packed according to the standard procedures (SOP) of the hospital pharmacy of Tartu University Hospital). The reason to use extemporaneous product is caused by the fact that no marketed product of metoprolol is available at such a low dose. 16 Protocol 27.02.2020 ● Proceed to PK procedures o 5 ml blood, 10 timepoints (altogether 50ml) will be taken from the inserted venous cannula ● Observation and monitoring of the patient during PK sampling period (8 hours) ● Recording of the vital parameters (blood pressure, heart rate) and adverse events (ADR) ● Recording the concomitant medications (all OTC and prescription medications taken 24 hour before study dose) Participants will be asked not to eat in the morning before the study visit when probe drugs are administered in order to assess the PK profile at fasting state. After probe drug administration and first PK analyses, a breakfast will be served at the study centres. The participants will be served a hot lunch. If requested, the subjects will receive one additional light meal. Administration of participant’s regular medicines in the morning before administration of probe drugs will be discussed and agreed during the pre-dose visit at the study centres. Specific instructions will be given to every participant. 5. Follow-up phone call 1 week after the phenotyping probe drugs administration to document possible ADRs. The call will be made a week after the study medication is given as side effects are unlikely to occur later. The subject has the opportunity to contact investigators by telephone throughout the study and to inform the investigator of any adverse drug reaction.  Record all Adverse Events (ADR) that have occurred since Day1 8.2 Schedule of study assessments Contacting Phone contact, Pre-dose Dosing and PK Follow-up pre-screening visit sampling visit phone call interview Invitation letter, e-mail x (phone call) Inclusion criteria x x x Medical history and x x patient characteristics Informed consent x Recheck eligibility x Clinical examination x x Immediately before the Study Dose Haematological x parameters Na, K, Ca, glucose, x transaminases Renal function x (urea, creatinine) 17 Protocol 27.02.2020 Urine pregnancy test for x female participants Study medicines x administration PK Sampling x Concomitant medications x documentation Adverse event reporting x x 8.3 Pharmacokinetic sampling and sample handling Blood samples for pharmacokinetic analysis of probe drugs and metabolites will be collected before dosing and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6 and 8 h after drug administration from an antecubital vein into ethylenediaminetetraacetic acid tubes. A cannula is used for blood sampling. The tubes will be centrifuged (1500g for 10 min at 4 °C) and plasma will be stored at −80 °C until analysis. Sampling schedule is based on the results of a previous phenotyping cocktail study (Donzelli et al, 2014) that included slow metabolizers and showed that a shorter (8h) blood sampling period was sufficient to describe the pharmacokinetic profile of the studied drugs. In addition, the use of a shorter study period is also in the interest of subjects who do not have to spend the night in the hospital. For the plasma concentration measurements of probe drugs and metabolites (omeprazole, metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5- hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be used at the Karolinska institute. The frozen plasma samples of all study participants will be shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2). For issuing of blood samples to Sweden a new application will be submitted to the Estonian Committee on Bioethics and Human Research and thereafter to the Senate of the University of Tartu. Pharmacokinetic endpoints: A noncompartmental model of disposition of probe drugs and its main metabolites (CL, Vd, AUC, Cmax, Tmax). 9. Study medications Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs will be administered: Single dose administration of probe drugs: o 20 mg omeprazole (full 20mg capsule) o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is measured and packed according to the standard procedures (SOP) of the hospital pharmacy of Tartu University Hospital). The reason to use 18 Protocol 27.02.2020 extemporaneous product is caused by the fact that no marketed product of metoprolol is available at such a low dose. 9.1 Contraindications  The following contraindications exist for using phenotyping probe drugs and participants with these conditions shall be excluded: o Known hypersensitivity for the study medicines o Severe hepatic impairment (ChildPugh Class C) o Uncontrolled heart failure (metoprolol) o Bradycardia (metoprolol) o Sick-sinus syndrome (metoprolol) o Prinzmetal's angina (metoprolol) o Untreated phaeochromocytoma (metoprolol) o Metabolic acidosis (metoprolol) o Severe peripheral arterial disease (metoprolol) o History of bronchospasm and asthma (metoprolol) o Hypotension (metoprolol) o Diabetes if associated with frequent episodes of hypoglycaemia (metoprolol) o Chronic obstructive pulmonary disease (metoprolol) o Renal or hepatic failure (metoprolol) o Therapy resistant hypokalaemia and hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia, anuria (metoprolol) 9.2 Description of dosing Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs will be administered with 50 mL of tap water: 20 mg omeprazole (full 20mg capsule) 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is measured and packed according to the standard procedures (SOP) of the hospital pharmacy of Tartu University Hospital). The reason to use extemporaneous product is caused by the fact that no marketed product of metoprolol is available at such a low dose. 19 Protocol 27.02.2020 9.3 Concomitant medication All concomitant medications used will be registered into the CRF stating from recruitment until study dose. 10. Analytical procedures For the plasma concentration measurements of probe drugs and metabolites (omeprazole, metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5- hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be used at the Karolinska institute. The frozen plasma samples of all study participants will be shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2). For issuing of blood samples to Sweden a new application will be submitted to the Estonian Committee on Bioethics and Human Research and thereafter to the Senate of the University of Tartu. 11. Safety reporting All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged to report to State Agency of Medicines and Ethical Committee about any suspected unexpected serious adverse adverse reactions (SUSAR). 11.1 Serious Adverse event evaluating and reporting An adverse event is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities. Pre- or post-treatment complications that occur as a result of protocol mandated procedures (e.g., blood draw) during or after screening will be considered an AE. Clinically significant changes in physical examination findings and abnormal objective test findings (e.g., clinical laboratory, vital signs) should also be recorded as AEs. In the differentiation between medical history and AEs, the following points will be considered: - Conditions that started before signing of the informed consent, and for which no symptoms or treatment are present until signing of either informed consent, are recorded as medical history. - Conditions that started before signing of the informed consent, and for which symptoms or treatment are present after signing of either informed consent, at unchanged intensity, are recorded as medical history. 20 Protocol 27.02.2020 - Conditions that started or deteriorated after signing of the informed consent will be documented as AEs. All AEs will be reported from the time a signed and dated ICF is obtained, until completion of the last study-related procedure. The investigator is responsible for collecting all AEs (both serious and non-serious). All AEs occurring during the clinical investigation will be documented in the source documents and the eCRF. AEs will be discussed in the Clinical study report (CSR). 11.1.1 Serious adverse event Serious adverse event (SAE) is defined as any adverse experience that meets any of the following criteria: - Results in death. Death is not an adverse event but an outcome. It is the cause of death that should be regarded as the adverse event. The only exception to this rule is “sudden death” where no cause has been established; in this latter instance, “sudden death” should be regarded as the adverse event and “fatal” as its reason for being serious. - Is life-threatening. The term “life-threatening” refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. - Requires prolongation of existing hospitalization. - Results in persistent or significant disability/incapacity. Disability means a substantial disruption of a person’s ability to conduct normal life’s functions. - Is another medically important serious event as judges by the Investigator, and is defined as requiring intervention to prevent one of the outcomes listed in the definition above. 11.1.2 Suspected unexpected serious adverse reactions Unexpected adverse reactions are adverse reactions, of which the nature, or severity, is not consistent with the applicable product information (as described in the SmPC, provided in the Investigator’s Brochure). 11.1.3 Follow-up of adverse events All participants will have before the probe drugs administration taken medical history and the following analysis (from clinical charts): Na, K, Ca, glucose, creatinine, transaminases and haematological parameters. AEs will be handled according to common clinical practice. If necessary, in order to obtain additional information to ensure the safety of the subject, additional blood and urine samples may be taken at the Investigator’s discretion. Information relative to other means of investigational diagnostics used in relation to the AE will also be communicated. All AEs occurring at any time during the study (including the follow-up period) will be followed until satisfactory resolution or stabilization or until final database lock. In the case of ongoing AEs at the moment of database closure, the data obtained at the moment of database closure will be used in the statistical analysis. The follow-up of the AE will be documented in the source documents and will be described in the final CSR, only if considered relevant by the Investigator. All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged to report to the State Agency of Medicines and Ethical Committee about any study related adverse effects. 21 Protocol 27.02.2020 12. Study management and monitoring At all stages the study will be performed in accordance with standard operating procedures (SOPs), available for monitoring. The study will be monitored by the representative of Estonian National Centre of Translational and Clinical Research. Data will be collected at the investigational site on source documents, which will be transcribed at the site into eCRFs (provided by Redcap). The eCRFs are to be completed on an ongoing basis during the study. The medical chart and the source documents are the source of verification of data. The PI is responsible for maintaining accurate, complete, and current records for each subject. The PI is also responsible for maintaining any source documentation related to the study, including clinical laboratory data, and electronic records. 13. Statistical considerations 13.1 Pharmacokinetic analysis PK variables for each of the drugs and metabolites were calculated by noncompartmental methods using WinNonlin Version 5.2.1 (Pharsight Corp, Mountain View, California). PK variables evaluated included Cmax, time to reach Cmax (tmax), apparent oral clearance (CL/F), terminal elimination rate (λz), and the AUC from time 0 to the 24‐hour blood draw (AUC0‐24 h) calculated by the linear trapezoidal rule. Concentrations below the LLOQ were removed. Area under the curve was extrapolated to 24 hours when the 24‐hour time point was below the LLOQ by extrapolating concentration at 24 hours (last concentration above LLOQ·exp(−λz·Δt)) and applying the linear trapezoidal rule. PK variables are reported as geometric mean ± standard deviation. Demographic variables are reported as arithmetic mean ± standard deviation. 14. Ethical considerations and confidentiality 14.1 Informed consent The informed consent forms (ICF) are approved by the EC. See representative ICFs for the study attached as Appendix No. 1. Informed consent will be obtained from patient. This will allow the research team to commence: ● Detailed monitoring of the patient ● Collection of samples at specific times ● Access to the patient’s medical notes or clinical data ● The information sheet and researcher will explain the risks of the study (Drug cocktail administration and blood sampling) 22 Protocol 27.02.2020 The information sheet/informed consent will be provided and used to structure a discussion. Patients will be allowed ample time to make their decision. They will be asked how long they would like to consider the information and what time is convenient for them when the researcher may return to answer any questions they may have. At the second discussion they will then be asked if they need more time to make a decision or if they feel that they are sufficiently informed to make the decision. The informed consent process will be delivered by the team member and listed on the delegation log. The study team will adopt a process of “ongoing consent” during which the progress of participants and the study will be discussed, parents/patients will be given repeated opportunities to ask questions, clarify any issues about the study and confirm or withdraw their agreement to participating in the study. The aim of this process is to optimize the comfort of patients with the study when the time comes for blood sampling, OR, to give the opportunity to withdraw consent if they feel that that is appropriate. If a patient withdraws consent, data up until the point of withdrawal will be included in the study unless the patient or parents object. Two copies of the signed consent form (attached to the information sheet) for 1) patient, 2) study chart. 14.2 Ethical considerations The study will be conducted in accordance with the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP) all applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki. The study has been designed and will be conducted in accordance with the ICH Harmonised Tripartite Guideline for clinical investigation of medicinal products (ICH E11) and all other applicable ethical guidelines. 14.3 Confidentiality All information collected will remain strictly confidential and anonymous. Access to medical records is only allowed to people mandated by the sponsor and involved in the progress of the project, as well as a representative of regulatory authorities in order to check collected data accuracy. Regulatory authorities may conduct a regulatory inspection of this study. Such inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the inspector to discuss findings and any relevant issues. 15. Administrative aspects 15.1 Handling and storage of data and documents The consent forms will be stored at the North Estonia Medical Centre in the investigators room in a locked drawer. At Tartu University Hospital the consent forms will be stored in the special locked clinical research room, which is located on the premises of the hospital pharmacy. After completion of the study the consent forms will be transferred to the biobank and stored in 23 Protocol 27.02.2020 similar conditions and during the same time period as it is stated by the law for the consents of the gene donors (HGRA, §12, section (6)). 15.2 Annual progress report Annual progress reports will be presented to the Tartu University Hospital and Ethics Committee. 15.3 End of study report End of study report will be presented to the Tartu University Hospital. 16. Scientific communication The scientific results of the study will be published at the international peer-reviewed journals and presentations will be made at the international conferences. 24 Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Hea geenidoonor! Lisa 1.1 Geenivaramu on alustanud teadusuuringut, kuhu kaasatakse geenidoonoreid. Teie olete üks nendest, kes on valitud sellesse uuringusse. Uurimistöö pealkiri on „Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile“ ja selle viivad läbi Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla ja Rootsi Karolinska Instituudi teadlased ja arstid. Uuringu eesmärk on hinnata, kuidas teatud geenivariandid mõjutavad ravimite lagundamise kiirust inimese organismis. Uuringu tulemused aitavad kaasa sellele, et tulevikus saaks geeniinfot teades annustada inimestele ravimeid täpsemalt ja vältida teatud kõrvaltoimeid. Teie vereproovi alusel Geenivaramus tehtud geenianalüüs viitab sellele, et mõnede ravimite lagundamise kiirus võib Teie organismis olla tavapärasest erinev. Käesoleva uuringu eesmärk on täpsustada, kas leitud geenivariatsioon ka tegelikkuses sellist toimet avaldab. Sarnaseid uuringuid on tehtud ka varasemalt. Vastuvõttude sujuvaks korraldamiseks oleme tänulikud, kui võtate meiega ühendust kahe nädala jooksul. Kui me selleks ajaks ei ole Teilt vastust saanud, saadame Teile uue kirja. Kui me ka korduvale kirjale Teilt vastust ei saa, siis võtame Teiega ühendust telefoni teel, sest eeldame, et Teie kontaktaadress on muutunud. Teie kontaktandmed oleme saanud Teilt geenivaramuga liitumise ajal või andmete täiendamisel rahvastikuregistrist. Oma huvist uuringus osaleda või loobumisest palume teada anda: Geenivaramu telefonil 520 6959 (tööpäevadel kell 9-16), SMS-i teel või meiliaadressil [email protected] Samadelt kontaktidelt on võimalik saada lisainformatsiooni uuringu kohta. Kui olete nõus uuringus osalema, reserveeritakse Teile telefoni teel vastuvõtuaeg esimeseks visiidiks. Kokku toimub kaks visiiti ja Te saate valida, kas soovite tulla Tartu Ülikooli Kliinikumi või Põhja-Eesti Regionaalhaiglasse (Tallinnas). Esimesel visiidil selgitatakse Teile põhjalikult uuringu olemust, toimub arstlik läbivaatus ning võetakse vereproov, et hinnata Teie sobivust uuringusse. Te saate esitada küsimusi, et lõplikult otsustada, kas Te soovite uuringus osaleda. Juhul kui sobite uuringus osalema ja allkirjastate nõusolekuvormi, lepitakse Teiega kokku teise uuringuvisiidi aeg. Teisel visiidil antakse Teile ühekordne annus kahte sageli kasutatavat ravimit, mille abil hinnatakse ravimit lagundavate ensüümide aktiivsust (omeprasooli ja metoprolooli) ning võetakse vereproovid (kuni 50 ml veeniverd). Teisel visiidil tuleb uuringukeskuses (haiglas) viibida kuni 10 tundi ning visiit toimub nädalavahetusel. Visiitidele sõiduga seotud transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel. Uuringu jooksul on tagatud toitlustamine. Soovi korral on kõigil uuringus osalejatel võimalus saada ravimitega seotud geeniandmete kohta personaalset tagasisidet. Soovin Teile kõike head ja tänan koostöö eest Tartu Ülikooli Eesti Geenivaramuga! 1 Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Dr. Lili Milani Tartu Ülikooli Eesti Geenivaramu teaduskeskuse juht 2 Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Hea geenidoonor! Lisa 1.2 See on korduv kutse uuringus osalemiseks. Geenivaramu on alustanud teadusuuringut, kuhu kaasatakse geenidoonoreid. Teie olete üks nendest, kes on valitud sellesse uuringusse. Uurimistöö pealkiri on „Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile“ ja selle viivad läbi Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla ja Rootsi Karolinska Instituudi teadlased ja arstid. Uuringu eesmärk on hinnata, kuidas teatud geenivariandid mõjutavad ravimite lagundamise kiirust inimese organismis. Uuringu tulemused aitavad kaasa sellele, et tulevikus saaks geeniinfot teades annustada inimestele ravimeid täpsemalt ja vältida teatud kõrvaltoimeid. Teie vereproovi alusel Geenivaramus tehtud geenianalüüs viitab sellele, et mõnede ravimite lagundamise kiirus võib Teie organismis olla tavapärasest erinev. Käesoleva uuringu eesmärk on täpsustada, kas leitud geenivariatsioon ka tegelikkuses sellist toimet avaldab. Sarnaseid uuringuid on tehtud ka varasemalt. Vastuvõttude sujuvaks korraldamiseks oleme tänulikud, kui võtate meiega ühendust kahe nädala jooksul. Kui me selleks ajaks ei ole Teilt vastust saanud, saadame Teile uue kirja. Kui me ka korduvale kirjale Teilt vastust ei saa, siis võtame Teiega ühendust telefoni teel, sest eeldame, et Teie kontaktaadress on muutunud. Teie kontaktandmed oleme saanud Teilt geenivaramuga liitumise ajal või andmete täiendamisel rahvastikuregistrist. Oma huvist uuringus osaleda või loobumisest palume teada anda: Geenivaramu telefonil 520 6959 (tööpäevadel kell 9-16), SMS-i teel või meiliaadressil [email protected] Samadelt kontaktidelt on võimalik saada lisainformatsiooni uuringu kohta. Kui olete nõus uuringus osalema, reserveeritakse Teile telefoni teel vastuvõtuaeg esimeseks visiidiks. Kokku toimub kaks visiiti ja Te saate valida, kas soovite tulla Tartu Ülikooli Kliinikumi või Põhja-Eesti Regionaalhaiglasse (Tallinnas). Esimesel visiidil selgitatakse Teile põhjalikult uuringu olemust, toimub arstlik läbivaatus ning võetakse vereproov, et hinnata Teie sobivust uuringusse. Te saate esitada küsimusi, et lõplikult otsustada, kas Te soovite uuringus osaleda. Juhul kui sobite uuringus osalema ja allkirjastate nõusolekuvormi, lepitakse Teiega kokku teise uuringuvisiidi aeg. Teisel visiidil antakse Teile ühekordne annus kahte sageli kasutatavat ravimit, mille abil hinnatakse ravimit lagundavate ensüümide aktiivsust (omeprasooli ja metoprolooli) ning võetakse vereproovid (kuni 50 ml veeniverd). Teisel visiidil tuleb uuringukeskuses (haiglas) viibida kuni 10 tundi ning visiit toimub nädalavahetusel. Visiitidele sõiduga seotud transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel. Uuringu jooksul on tagatud toitlustamine. Soovi korral on kõigil uuringus osalejatel võimalus saada ravimitega seotud geeniandmete kohta personaalset tagasisidet. 3 Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Soovin Teile kõike head ja tänan koostöö eest Tartu Ülikooli Eesti Geenivaramuga! Dr. Lili Milani Tartu Ülikooli Eesti Geenivaramu teaduskeskuse juht 4 Life Science Liability Policy LS 1:6 2017 Introduction This is a Chubb commercial liability insurance policy. This Policy contains four sections: Section 1: Public Liability Section 2: 2A Product and Service Liability; and 2B Clinical Trials Section 3: Product and Service Errors and Omissions Liability Please read the entire policy carefully. Insuring Agreement Chubb European Group Limited (the ‘Company’) agrees to provide the insurance described in each applicable Section of this insurance policy (the ‘Policy’) subject to the following conditions: • the Insured must have paid or agreed to pay the premium set out in the Schedule. • the information provided by the Insured together with any additional information supplied to the Company on behalf of the Insured form the basis of and are part of this Policy. Please Note The term “Schedule” in this wording is equivalent to the Swedish term “Försäkringsbrev”. All parts of this Policy, including the Schedule and any endorsements, shall be read together and considered as one contract. The operative Sections of this Policy are indicated in the Schedule. Unless a particular Section is identified in the Schedule as operative, it is of no effect and no cover is granted under it. Words that appear in bold print are defined in the Definitions. Section 1 Public Liability Bodily Injury, Under this Section of Part 2, the Company will indemnify the Insured for Property Damage damages and related claimants’ costs that the Insured becomes legally liable to pay in respect of: • bodily injury; or • property damage caused by an occurrence in connection with the Insured’s business. This Section will apply only if such bodily injury, property damage happens: • during the Period of Insurance; and • within the Territorial Limits. This Section does not apply to any damages, loss, cost or expense arising out of the Insured’s product or the Insured’s service or any clinical trial. Section 2 Product and Service Liability and Clinical Trials Cover under this Section is divided into two sub-sections: Section 2A (Product Liability) and Section 2B (Clinical Trials). Both Sections 2A and 2B are subject to the overall Limit of Indemnity for Section 2 shown in the Schedule. Section 2A Product and Service Liability Bodily Injury and Under this Section 2A, the Company will indemnify the Insured for damages Property Damage and related claimants’ costs that the Insured becomes legally liable to pay in respect of: • bodily injury; or • property damage; caused by an occurrence in connection with the Insured’s business and resulting from the Insured’s product or the Insured’s service. This Section 2A will apply only if: 1. such bodily injury or property damage happens after the Retroactive Date shown in the Schedule and before the end of the Period of Insurance; 2. such bodily injury or property damage happens within the Territorial Limits; 3. a claim by a person or organisation for damages for such bodily injury or property damage is first made against the Insured: • during the Period of Insurance or within 30 (thirty) days of its termination; • and the claim is reported by the Insured to the Company within 12 (twelve) months from when the Insured first became aware of such claim ; or • in accordance with the condition entitled “Insured’s Duty to Report Circumstances”; and 4. such claim is made within the Territorial Limits. This Section 2A does not apply to any damages, loss, cost or expense arising out of any injury or damage sustained by any research subject in connection with any activities relating to any clinical trial conducted by or on behalf of the Insured. Section 2B Clinical Trials Bodily Injury and Under this Section 2B, the Company will indemnify the Insured for: Property Damage Agreed Compensation Cover • compensation agreed under the applicable Clinical Trial Compensation Guidelines; or Legal Liability Cover • damages and related claimants’ costs that the Insured becomes legally liable to pay, if and to the extent that settlement is not concluded under the Agreed Compensation Cover (above); in respect of bodily injury or property damage: • sustained by a research subject; • caused by an occurrence in connection with the Insured’s business; and • resulting from a clinical trial conducted by or on behalf of the Insured. This Section 2B will apply only if: 1. such bodily injury or property damage happens after the Retroactive Date stated in the Schedule and before the end of the Period of Insurance; 2. such bodily injury or property damage happens within the Territorial Limits; 3. a claim by a person or organisation for such compensation or damages (as applicable) for such bodily injury or property damage is first made against the insured • during the Period of Insurance or within 30 (thirty) days of its termination; • and the claim is reported by the Insured to the Company within 12 (twelwe) months from when the Insured first became aware or should have become aware of such claim; or • in accordance with the condition entitled “Insured’s Duty to Report Circumstances”; and 4. such claim is made within the Territorial Limits. Furthermore, notwithstanding anything to the contrary above, this Section 2B applies only to clinical trials if: • the product being investigated is a life science product; • exposure to such product upon or within research subjects during such trial first happened after the Retroactive Date stated in the Schedule and before the end of the Period of Insurance; and • the Insured has acted in compliance with the Clinical Trials Special Conditions set out in this Policy. Section 3 Product and Service Errors and Omissions Liability Financial Injury Under this Section, the Company will indemnify the Insured for damages and related claimants’ costs that the Insured becomes legally liable to pay in respect of financial injury caused by an act in connection with the Insured’s business and resulting from: 1. a defect, deficiency or inadequacy in: • the Insured’s product; or • the Insured’s service; or 2. the failure: • of the Insured’s product to perform; or • to perform the Insured’s service; in accordance with the terms of a contract or agreement. This Section will only apply if: 1. such act happens after the Retroactive Date shown in the Schedule and before the end of the Period of Insurance; 2. such act happens within the Territorial Limits; 3. a claim by a person or organisation for damages for such financial injury is first made against the Insured: • during the Period of Insurance or within 30 (thirty) days of its termination; • and the claim is reported by the Insured to the Company within 12 (twelwe) months from when the Insured first became aware or should have become aware of such claim; or • in accordance with the condition entitled “Insured’s Duty to Report Circumstances”; and 4. such claim is made within the Territorial Limits. Notwithstanding anything to the contrary above, where cover under this Section applies in respect of injury or damage resulting from a clinical trial, cover will only apply if the Insured has acted in compliance with the Clinical Trials Special Conditions set out in this Policy. Limits of Indemnity Limits of Indemnity If more than one Section of this Policy would otherwise apply to the same occurrence, act or claim or series of occurrences, acts or claims consequent on or attributable to the same or substantially the same source or original cause, then the aggregate maximum Limit of Indemnity under all Sections shall not exceed the highest applicable Limit of Indemnity under any one Section of Part 2. The Limits of Indemnity apply separately to each consecutive annual period and to any remaining period of less than 12 months, starting with the beginning of the Period of Insurance shown in the Schedule, unless the Period of Insurance is extended after issuance for an additional period. In that case, the additional period will be deemed to form part of the last preceding period for purposes of determining the Limits of Indemnity. The Company’s obligations end when the applicable Limit of Indemnity has been exhausted. Part 2, Section 1 Irrespective of the number of claims, the liability of the Company under Section 1 for: (Public Liability) • damages and related claimants’ costs; • other amounts described as reducing the Limits of Indemnity (see below); shall not exceed the applicable aggregate Limit of Indemnity stated in the Schedule. Any such sums the Company pays will reduce the amount of such aggregate limit available for any other payment. The remaining amount of the aggregate limit is the most that will be available for any other payment. Part 2, Section 2 Irrespective of the number of claims or occurrences, the liability of the Company under Section 2 for: (Product and Service Liability and Clinical • compensation or damages (as applicable) and related claimants’ costs; Trials) and • other amounts described as reducing the Limits of Indemnity (see below); shall not exceed the applicable aggregate Limit of Indemnity stated in the Schedule. Any such sums the Company pays will reduce the amount of such aggregate limit available for any other payment. The remaining amount of the aggregate limit is the most that will be available for any other payment. Part 2, Section 3 Irrespective of the number of claims or acts, the liability of the Company under Section 3 for: (Errors and Omissions Liability) • damages and related claimants’ costs; and • other amounts described as reducing the Limits of Indemnity (see below); shall not exceed the applicable aggregate Limit of Indemnity stated in the Schedule. Any such sums the Company pays will reduce the amount of such aggregate limit available for any other payment. The remaining amount of the aggregate limit is the most that will be available for any other payment. Pollution and Subject to all other Limits of Indemnity, irrespective of the number of occurrences or claims, the liability of the Company in connection with Contamination pollution or contamination under all Sections (save for Section 3 – Employers’ Liability) for: • damages and related claimants’ costs; and • other amounts described as reducing the Limits of Indemnity (see below); shall not exceed the applicable aggregate Limit of Indemnity stated in the Schedule. Any such sums the Company pays will reduce the amount of such aggregate limit available for any other payment. The remaining amount of the aggregate limit is the most that will be available for any other payment. Payments that Reduce Payments made: the Limits of Indemnity • for any compensation or damages (as applicable) and related claimants’ costs; • under the Extension entitled ‘Defence Costs’ and • for any amounts under any other Extension; will reduce the applicable Limits of Indemnity. Extensions Extensions are subject to the terms and conditions (including Exclusions and, save where provided to the contrary, Limits of Indemnity) applicable to the Section(s) under which the Extension is provided. The Company’s obligations under any Extension end when the applicable Limit of Indemnity has been exhausted. Compensation for Under Sections 1, 2, and 3 , the Company shall pay the following sums to the Court Attendance Insured in the event that a partner, director, officer or employee of the Insured, at the request of the Company: • attends a court or arbitration hearing as a witness - up to EUR 300 for each day on which that person attends as a witness. • is interviewed by the lawyers conducting the defence against a claim for the purpose of composing a witness statement - up to EUR 60 per hour in respect of the time certified by the lawyers as time being interviewed. • attends a court or arbitration hearing as an observer - up to EUR 60 for each day on which that person attends as an observer, provided that the Company shall only be liable to compensate for the occupation of one observer per day. Personal Data Under Section 1, the Company will indemnify the Insured for damages incurred by a third party natural person relating to that person’s Personal data that the insured in his capacity as Controller may be liable to pay according to Privacy Regulations within the territorial limits stated in the policy schedule. The Company’s obligation to indemnify the Insured under this extension is limited to: • EUR 100,000 each occurrence and in the aggregate for the period of insurance; or • The limit of indemnity (or sublimit) stated in the policy schedule and referring to “Personal data” Whichever is the greater. This extension shall not apply: • in respect of costs and expenses for rectifying or erasing Personal data; • in respect of costs and expenses for notifying third parties; • in respect of administrative fines; • for loss arising out of unauthorised access to Computer Systems where the Personal data is stored; • for loss arising from Insured’s fraud or dishonesty; or • if the Insured has undertaken to store, process or supply Personal data for a fee or by mutual arrangement. DEFINTIONS Controller under this extension means a legal person which alone or jointly with other, determines the purposes and means of the processing of Personal data. Privacy Regulations under this extension means laws and regulations associated with the care, custody, control or use of Personal Data. Personal Data under this extension means • an individual's name, national identity number or national insurance number, medical or healthcare data, other protected health information, driver's licence number, state identification number, credit card number, address, telephone number, email address, account number, or password; and • any other non-public personal information as defined in the Privacy Regulations in any format if such information creates the potential for an individual to be uniquely identified or contacted. Defence Costs Under Sections 1, 2 and 3 the Company will indemnify the Insured for legal defence costs provided they are incurred with the Company's prior written consent. Under Sections 1 and 2 the Company will indemnify the Insured for the following, provided they are incurred with the Company's prior written consent: • legal fees for defence of the Insured against proceedings for manslaughter (including appeal against conviction) resulting from an occurrence which may be the subject of indemnity under this Part of this Policy. Extended Reporting Under Sections 2 and 3, if for a reason other than for non-payment of Period premium, the Company cancels or refuses to renew this Policy, then the Insured may: • by giving written notice to the Company no later than 30 days after the effective date of cancellation or non-renewal; and • upon payment of a non-refundable additional premium (not to exceed 200% of the Policy premium for those Sections to which it applies), paid to the Company within 30 days of the cancellation or non-renewal; secure an Extended Reporting Period (not to exceed 5 years) following the effective date of such cancellation or non-renewal to report claims made against the Insured, notice of which has been received and recorded by the Insured during that period. Provided that the injury or damage or act (as applicable) giving rise to the claim happened prior to the effective date of cancellation or non-renewal, such claims shall be deemed to have been made and reported during the Period of Insurance. An Extended Reporting Period: • does not extend the Period of Insurance or change the scope of cover provided. • does not reinstate or increase any Limit of Indemnity. • may not be cancelled once in effect. Fees and Expenses - Under Section 3, to mitigate potential claims against the Insured by a Mitigation of Potential customer, the Company may at its discretion make payment to the Insured in Claims Against the respect of fees and expenses invoiced to such customer but not collected by the Insured continued Insured provided that: • such fees and expenses are in respect of the Insured’s product having been supplied to, or the Insured’s service having been rendered to, the customer; • during the Period of Insurance, the customer has refused to pay such fees and expenses; and • the basis of the customer’s refusal to pay is expressed by the customer to be a direct consequence of financial injury. This Extension will only apply if: 1. a request for payment under this Extension is first made by the Insured and notified to the Company during the Period of Insurance. 2. the Insured can show to the Company’s satisfaction that: • it has taken reasonable steps to collect such fees and expenses; • taking further steps to collect such fees and expenses would be likely to provoke a claim against the Insured; and the likelihood of a claim being brought is reduced by desisting in efforts to collect such fees and expenses. 3. such claim would be covered under Section 3 of this Policy. 4. the Insured takes all necessary steps to prevent loss and follows all instructions issued by the Company and provides the Company with all relevant documents including contracts, correspondence, records, invoices and any other information. 5. the Insured consents to the interviewing of relevant employees by the Company. Conditions Relating to this Extension 1. If a payment is made by the Company under this Extension and a claim relating to substantially the same supply of the Insured’s product or rendering of the Insured’s service is subsequently made against the Insured, then any amounts paid under this Extension will be deemed to have been paid on account of such claim. 2. Following any payment by the Company under this Extension, the Insured shall take no further steps to collect any sums in respect of substantially the same supply of the Insured’s product or rendering of the Insured’s service. If the Insured, in breach of this condition, takes any such further steps and a claim is brought against the Insured, then there shall be no cover under any part of this Policy in respect of any such claim. 3. The Company shall not be liable to make payment in respect of any element of profit included in fees and expenses invoiced or any Value Added Tax. 4. Payment by the Company under this Extension, in itself, does not constitute an admission or assumption of liability or a conclusion that the Insured’s product or the Insured’s service failed or is defective, deficient or inadequate. Limit and Deductible This Extension is subject to the Limit of Indemnity applicable to Section 3. Any sums paid under this Extension will: • reduce the amount of that limit available for any other payment; and • be deemed to be damages The amount of the Deductible shall in no case be less than: • the amount of the Deductible applicable under Section 3 of this Policy; or • 10% of the fees and expenses invoiced; whichever is the greater. Indemnity to Others Contract Research Under Section 2 only, at the request of the Insured, the Company will Organisations or Life indemnify against liability: Science Product Sales Contractors or Life • contract research organisations; Science Service • life science product sales contractors; or Contractors • life science product service contractors; with respect to their liability for damages for bodily injury or property damage incurred in the regular course of their business, but only: • if and to the minimum extent that the Insured is obliged (pursuant to a written contract or agreement between the Insured and such person or organisation ) to provide them with cover under this Policy; and • with respect to activities happening after the execution of such contract or agreement. In respect of contract research organisations, this Extension will apply only if such injury or damage results from activities in connection with a clinical trial to which this Policy applies. In respect of life science product sales contractors, this Extension will apply only if such injury or damage results from the distribution or sale of the Insured’s life science product to which this Policy applies. In respect of life science product service contractors, this Extension will apply only if such injury or damage results from activities within the scope of the Insured’s life science product service to which this Policy applies. However, this Extension does not apply to any: • assumption of liability or obligations by any such contract research organisation, life science product sales contractor or life science product service contractor in a contract or agreement. • This limitation does not apply to the liability for damages for bodily injury or property damage, to which this Policy applies, that such person or organisation would have in the absence of such contract or agreement. • representation or warranty unauthorized by the Insured. • chemical or physical change in the Insured’s product made intentionally by such person or organisation. • of the Insured’s products which, after distribution or sale by the Insured, have been labeled or relabeled or used as a container, ingredient or part of any other thing or substance by or for such person or organisation. This limitation does not apply to: • the relabeling of the Insured’s product in the regular course of dispensing or furnishing the required amount or dosage of such product. • contract research organisation s. • life science product service contractors. Partners, Directors, 1. Under Sections 1, 2 and 3, at the request of the Insured, the Company Officers, Employees, will indemnify against liability the Insured’s partners, directors, officers Principals Or Various or employees (whilst acting within the scope of their duties as such). Others 2. Under Sections 1, 2 and 3, at the request of the Insured, the Company will indemnify against liability: a. officers or members of the Insured’s social, canteen, welfare or first aid organisations or fire or ambulance services in their respective capacities as such. b. employees in respect of private work undertaken by an employee with the prior consent of the Insured. c. principals for whom the Insured is or has been carrying out work, in respect of an occurrence for which the Insured is responsible, but only: • if and to the minimum extent that the Insured is obliged (pursuant to a written contract or agreement between the Insured and such person or organisation ) to provide them with cover under this Policy; and • with respect to activities happening after the execution of such contract or agreement. Vendors Under Section 2 only, at the request of the Insured, the Company will indemnify against liability vendors of the Insured’s product with respect to their liability for damages for bodily injury or property damage resulting from the distribution or sale of the Insured’s product in the regular course of their business, but only: • if and to the minimum extent that the Insured is obliged (pursuant to a written contract or agreement between the Insured and such vendor) to provide them with cover under this Policy; • with respect to activities happening after the execution of such contract or agreement; and • if and to the extent that this Policy applies to such products. However, this Extension does not apply to any: • assumption of liability by any such vendor in a contract or agreement. This limitation does not apply to the liability for damages for bodily injury or property damage, to which this Policy applies, that such vendor would have in the absence of such contract or agreement. • representation or warranty unauthorized by the Insured. • chemical or physical change in the Insured’s product made intentionally by such vendor. • of the Insured’s products which, after distribution or sale by the Insured, have been labelled or relabelled or used as a container, ingredient or part of any other thing or substance by or for such vendor. • repackaging, unless unpacked solely for the purpose of inspection, demonstration or testing, or the substitution of parts under instruction from the manufacturer and then repacked in the original container. • failure to make such inspections, adjustments, tests or servicing as such vendor has agreed to make or normally undertakes to make in the regular course of their business in connection with the distribution or sale of the Insured’s product. • demonstration, installation, servicing or repair operations, except such operations performed at such vendor’s premises in connection with the distribution or sale of the Insured’s product. Limitations on The provisions of this ‘Indemnity to Others’ Extension apply provided that: Indemnity to Others • the injury or damage results from activities in connection with the Insured’s business; • such person or organisation shall observe, fulfil and be subject to the terms and conditions of this Policy; • such person or organisation is not entitled to indemnity under any other insurance; • such person or organisation has no conflict of interest with the Insured; and • the Company shall be entitled (but not obliged) to take over and conduct the investigation, defence and settlement of any claim at its discretion. However, this Extension does not apply to any rendering of or failure to render any healthcare service whether or not such service is ordinary to the Insured’s profession. This limitation does not apply to contract research organisations. Further, no indemnity will be provided to any person or organisation from whom the Insured has acquired its product, or any container, ingredient or part entering into, accompanying or containing such product. Indemnity to Ethics Under Section 2B (Clinical Trials) only, at the request of the Insured, the Committees Company will indemnify an ethics committee and its individual members (whilst acting within the scope of their duties as members of such ethics committee): • against liability; and • for legal fees for their defence against proceedings for manslaughter (including appeal against conviction) incurred with the Company’s prior written consent; resulting from an occurrence in connection with a clinical trial which may be the subject of indemnity under this Policy, but only: • if and to the minimum extent that the Insured is obliged (pursuant to a written contract or agreement between the Insured and such person or organisation ) to provide them with cover under this Policy; and • with respect to activities happening after the execution of such contract or agreement. provided that: • the injury or damage results from activities in connection with the Insured’s business; • such ethics committee and its individual members shall observe and fulfil the terms and conditions of this Policy; • such ethics committee or its individual members is not entitled to indemnity under any other insurance; • such ethics committee and its individual members have no conflict of interest with the Insured; and • the Company shall be entitled (but not obliged) to take over and conduct the investigation and defence and settlement of any claim at its discretion. This Extension does not apply to any assumption of liability or obligations by any such person or organisation in a contract or agreement. This limitation does not apply to the liability for damages for bodily injury or property damage, to which this Policy applies, that such person or organisation would have in the absence of such contract or agreement. Legal Costs - Criminal Under Section 2B (Clinical Trials), the Company will indemnify the Insured Act 1962:700 and, at the request of the Insured, a partner, director, officer or employee of the Insured for necessary and reasonable legal fees and expenses (including prosecution costs awarded) reasonably incurred with the Company’s prior written consent, in the defence against a prosecution or an appeal against conviction resulting from an actual or alleged breach of the: • Criminal Act 1962:700 or similar legislation in respective country where loss has occurred. Limitations on Legal The provisions of this Legal Costs Extension apply provided that the Costs proceedings relate to an occurrence: • in connection with the Insured's business; and • which may be the subject of indemnity under this Policy. In the event of any dispute arising concerning whether any prosecution should be defended, or an appeal made, such dispute shall be referred to leading counsel (the identity of whom shall be mutually agreed between the Insured and the Company, or in default of agreement nominated by the President of the Law Society) whose decision shall be final and binding on both parties. New Acquisitions Under Sections 1, 2 and 3 at the request of the Insured, the Company will indemnify against liability a subsidiary organisation acquired or formed by the Insured during the Period of Insurance, provided that in respect of any newly acquired or formed organisation: • full underwriting information is provided within 30 days of acquisition or formation, or within such other period as may be agreed by the Company; • the business of the subsidiary organisation is similar to the Insured’s business; and • the Insured accepts any additional terms and conditions determined by the Company and pays any additional premium required. Personal Overseas Under Section 1, at the request of the Insured, the Company will indemnify Liability the Insured’s partners, directors, officers or employees, or members of their families, against liability for damages in respect of bodily injury or property damage incurred in a personal capacity whilst temporarily outside their normal country of residence in connection with the Insured’s business. This Extension does not apply to liability for any damages, loss, cost or expense arising out of any: • ownership or occupation of any land or building; or • possession, ownership or use of any motor vehicle for which insurance or security is required under the provision of any road traffic legislation Exclusions The following exclusions apply to all Sections of this Policy. This Policy does not apply to any: Assumed Liability In respect of Sections 1 and 2: damages, loss, cost or expense arising out of any liability or obligation assumed in a contract or agreement. This exclusion does not apply to liability for damages for bodily injury or property damage, to which this Policy applies, that the Insured would have in the absence of such contract or agreement. Deliberate Acts damages, loss, cost or expense arising out of any act or omission that: • is intended by the Insured; or • would reasonably be expected from, the perspective of a person in the circumstances of the Insured, to cause injury or damage, even if the actual injury or damage caused is of a different degree or type than expected or intended. This exclusion does not apply to bodily injury or property damage: • which is intended to result from reasonable use of a medicinal product or other life science product within or upon research subjects during a clinical trial; • which may be expected, from the perspective of a reasonable professional conducting a clinical trial, to result from reasonable use of a medicinal product or other life science product within or upon research subjects during a clinical trial; or • resulting from the use of reasonable force to protect persons or tangible property. Employment Related damages, loss, cost or expense arising out of any injury or damage sustained by Practices any person, whether or not in the course of employment by the Insured, arising out of any employment-related act, omission, policy, practice or representation, including any: • dismissal, discharge or termination of employment; • breach of any contract of service or apprenticeship; • harassment, whether sexual or otherwise; • discrimination; • deprivation of career opportunity; • negligent evaluation or training; • negligent reference; • misrepresentation, defamation or disparagement, breach of data protection laws, invasion of privacy, breach of confidentiality, malicious falsehood or false imprisonment; or • retaliation on account of whistleblowing or the exercise by any person of their legal rights; or for any award made by an Employment Tribunal (whether or not relating to one of the above actions). Fines, Penalties or • liquidated damages or penalties (contractual or otherwise) or any Restitution criminal or civil fines. • amount that constitutes unjust enrichment, including any restitution or return of any fees or expenses or any consideration owed (whether or not disputed) or paid to the Insured. • loss, cost or expense to perform any obligation assumed by or on behalf of the Insured. • loss, cost or expense incurred, or agreed to, by or on behalf of the Insured, except in a settlement agreed to by the Company. Exclusions – Sections 1, 2 and 3 (Public, Product and Service and Errors and Omissions Liability) The insurance provided by Sections 1, 2 and 3 does not apply to any: Abuse or Molestation damages, loss, cost or expense arising out of any: 1. actual or threatened abuse or molestation, by anyone, of any person; or 2. retention, employment, investigation or supervision, or reporting to or failure to report to the proper authorities, of anyone for whom the Insured is or ever was legally responsible and whose conduct would be excluded in subparagraph 1 above. Adjustment, Recall, In respect of Sections 1 and 2: Repair or Replacement damages, loss, cost or expense arising out of any loss of use of or adjustment, disposal, inspection, recall, removal, repair, replacement or withdrawal of: • the Insured’s product; or • any property containing or incorporating the Insured’s product; if such product or property is recalled or withdrawn from the market or from use by any person or organisation because of a known or suspected defect, deficiency, inadequacy or dangerous condition in it. In respect of Section 3: damages, loss, cost or expense arising out of any adjustment, disposal, inspection, recall, removal, repair, replacement or withdrawal of: • the Insured’s product or the Insured’s service; • any property containing or incorporating the Insured’s product or the Insured’s service; • any property on which the Insured’s service is or was performed; or • any content, information or material. Aircraft, Spacecraft, damages, loss, cost or expense arising out of any aircraft, spacecraft, aerial or Aerial or Aerospatial aerospatial device or missile, or any related product, including any: Device or Missile Products • article, equipment, material, part or spare part installed or otherwise incorporated in, on or under any aircraft, spacecraft, aerial or aerospatial device or missile, or furnished or used in connection therewith; • air or space communication, guidance or navigation system; • ground control, handling or support equipment or tools furnished or used in connection therewith; • equipment or tools furnished or used in connection with manufacturing, repairing or servicing any of the foregoing; • blueprints, designs, drawings, information, instructions, manuals, maps, opinions, reports, representations, software, specifications, surveys, training aids, warnings or warranties or engineering or other data furnished or used in connection with any of the foregoing; or • engineering or other advice, instruction, labour or service relating to any of the foregoing. Anti-trust or Anti- damages, loss, cost or expense arising out of any actual or alleged breach of Competitive Practices any law or regulation designed to prevent any anti-trust or anti-competitive practice, abuse of dominant position, cartel or price-fixing activity or to otherwise protect competition. Asbestos damages, loss, cost or expense arising out of or in any way related to any: • actual, alleged or threatened contaminative, pathogenic, toxic or other hazardous properties of asbestos; • request, demand, order or regulatory or statutory requirement that the Insured or others test for, monitor, clean up, remove, contain, treat, detoxify or neutralize, or in any way respond to, or assess the effects of asbestos; or • claim or proceedings by or on behalf of a government authority or others for any damages, loss, cost or expense arising out of any testing for, monitoring, cleaning up, containing, treating, detoxifying or neutralizing, or in any way responding to, or assessing the effects of asbestos. Benefit Programmes damages, loss, cost or expense arising out of any: • actual or alleged breach of any law; or • duty or obligation (whether contractual or otherwise) of any Insured; in connection with any benefit programme, including any administration, design, disclosure, enrolment, establishment, funding, maintenance, management, marketing or similar activity relating to any such programme. This exclusion applies regardless of whether any Insured is acting: • as a fiduciary or in any other capacity; or • on behalf of any employee or any other person or organisation. Cross Liabilities damages, loss, cost or expense arising out of any injury or damage sustained by: 1. the Insured. 2. any person or organisation that either directly or indirectly controls the Insured through: • controlling or holding a majority of its voting rights; or • the right to appoint or remove a majority of its board of directors. 3. any subsidiary organisation. 4. any manager, member or partner of any limited liability company, partnership or joint venture in which the Insured has an interest. 5. any partner, director, officer or employee of any person or organisation described above. 6. any agent, heir, representative or successor of any person or organisation described above. Damage to the damages, loss, cost or expense for any property damage to the Insured’s Insured’s Product product if arising out of it or any part of it. Damage to Property in damages, loss, cost or expense arising out of any property damage to: the Insured’s Care, 1. any property owned, held in trust or occupied by, leased or rented to or Custody or Control in the care, custody or control of the Insured. (except leased or rented premises or 2. that particular part of any property upon which the Insured or any personal effects) employee of the Insured is or has been carrying out work, if arising out of such work. In respect only of Section 1 (Public Liability), subparagraph 1. of this exclusion does not apply to property damage to: • personal property of partners, directors, officers or employees of the Insured or of visitors to the Insured’s premises. • premises or the fittings or fixtures thereof while leased or rented to the Insured. • premises or the fittings or fixtures thereof, not owned by or leased or rented to the Insured, while temporarily occupied by the Insured for the purpose of carrying out work in or on such premises. Employees damages, loss, cost or expense arising out of any injury or damage sustained by any employee arising out of or in the course of employment by the Insured. Healthcare or Other damages, loss, cost or expense arising out of the rendering of, or failure to Professional Services render any: In respect of Sections 1 and 2: • healthcare service; or • professional service or advice other than a life science product service; In respect of Section 3: • healthcare service; or • accounting, actuarial, architectural, surveying or legal service or advice; whether or not such service or advice is ordinary to the Insured’s profession and regardless of whether or not a claim or proceedings are brought by any client or any other person or organisation . In respect of Sections 1 and 2 only, this exclusion does not apply to bodily injury or property damage to which this Policy applies: • caused by cardiopulmonary resuscitation or other first aid services (other than in connection with a clinical trial); or • resulting from the service provided within the scope of and in accordance with the applicable written protocol of a clinical trial. Information damages, loss, cost or expense arising out of any actual or alleged breach of Distribution Laws any law or regulation relating to any unsolicited communication, distribution, publication, sending or transmitting of content, information or material. Intellectual Property damages, loss, cost or expense arising out of, giving rise to or in any way Laws or Rights related to any actual, alleged or threatened assertion, infringement or violation by any person or organisation of any intellectual property law or right. Nuclear damages, loss, cost or expense arising out of or in any way related to any: • ionising radiation or contamination by radioactivity from any nuclear fuel or from any nuclear waste from the combustion of nuclear fuel; or • radioactive, toxic, explosive or other hazardous properties of any nuclear assembly or nuclear component thereof. With respect to Sections 1 and 2 only, this exclusion does not apply to bodily injury or property damage caused by radioactive isotopes used as a component of or in connection with a medical device or used in medical research. Pollution or damages, loss, cost or expense arising out of or in any way related to any: Contamination 1. actual, alleged or threatened discharge, dispersal, seepage, migration, release or escape of smoke, vapours, soot, fumes, acids, alkalis, chemicals, waste materials or other solid, liquid, gaseous or thermal irritants, contaminants or pollutants; 2. request , demand, order or regulatory or statutory requirement that the Insured or others test for, monitor, clean up, remove, contain, treat, detoxify or neutralize, or in any way respond to, or assess the effects of any irritants, contaminants or pollutants; or 3. claim or proceedings by or on behalf of a government authority or others for any damages, loss, cost or expense arising out of any testing for, monitoring, cleaning up, containing, treating, detoxifying or neutralizing, or in any way responding to, or assessing the effects of any irritants, contaminants or pollutants. In respect of Sections 1 and 2 of this Part 2, subparagraph 1. of this exclusion does not apply to liability for damages for bodily injury or property damage to which this Policy applies, caused by a sudden, identifiable, unintended and unexpected event happening anywhere in the world, other than in the United States of America or its possessions or territories. Prior Claims or Known (with respect to coverage for an individual person or organisation against Circumstances liability to which this Policy applies) damages, loss, cost or expense arising out of any: • injury, damage, claim or other circumstance known or that should have been known by such person or organisation, before the beginning of the Period of Insurance, which could reasonably be expected to result in any payment under this Policy; or • injury or damage known or that should have been known by such person or organisation, before the beginning of the Period of Insurance, to have happened or to have begun, including any change, continuation or resumption thereof at any time. Furthermore, no person or organisation is entitled to any indemnity under this Policy in connection with any damages, loss, cost on expense arising out of any: 1. injury, damage, claim or other circumstance: • reported, in whole or in part at any time, to the Company or any other insurer under any insurance that is prior to this insurance; or • known or that should have been known by any of the Insured´s directors, partners or officers, before the beginning of the Period of Insurance, which could reasonably be expected to result in any payment under this Policy; or 2. injury or damage known or that should have been known by any of the Insured´s directors, partners or officers, before the beginning of the Period of Insurance, to have happened or to have begun, including any change, continuation or resumption thereof at any time. For the purposes of this exclusion, such injury, damage, claim or other circumstance will be considered known by an organisation if such circumstance was known or should have been known by any of such organisation´s directors, partners or officers. Securities Laws damages, loss, cost or expense arising out of any actual or alleged breach of any securities law. Specific Diseases damages, loss, cost or expense arising out of any: 1. specific disease, including any similar or other condition, injury, illness or disease related thereto, by whatever name known; 2. causative agent of any such condition, injury, illness or disease, regardless of whether such agent gives rise to any such condition, injury, illness or disease or any other condition, injury, illness or disease, by whatever name known; or 3. actual or attempted counselling or testing for, or containing, detoxifying, mitigating, monitoring or neutralizing of, or responding to, or assessing the effects of any: • condition, injury, illness or disease; or • causative agent; described in subparagraph 1 or 2 above, including any: • actual or attempted cure, diagnosis, prevention or treatment of any such condition, injury, illness or disease; • actual or attempted cleaning-up, disposing, handling or removing of any such causative agent; or • failure to perform any of the foregoing Specific Products or damages, loss, cost or expense arising out of any defect, deficiency, inadequacy Specific Classes of or dangerous condition in, including the actual, alleged or threatened Products contaminative, pathogenic, toxic or other hazardous properties of any: 1. specific products in any form, including their presence or use in any alloy, by-product, compound or other material or waste; 2. goods, products or materials that have the same or substantially the same chemical formula as any goods, products or materials described in subparagraph 1 above, by whatever name known; or 3. goods, products or materials that are derivatives of any goods, products or materials described in subparagraphs 1 or 2 above, by whatever name known; or 4. specific classes of products, by whatever name known. Successor Liability damages, loss, cost or expense arising out of any: • ownership, maintenance or use of any assets, business or organisation acquired by the Insured; or • conduct of any person or organisation in connection with any assets, business or organisation acquired by the Insured; for any act, occurrence, injury or damage happening, in whole or in part, before such acquisition is executed. Unapproved Clinical damages, loss, cost or expense, in connection with any clinical trial, arising Trials out of any unapproved exposure to material, upon or within research subjects during such a trial, that happens after: • a hold has been placed on the trial; • clinical trial authorization or similar authorization applicable to the trial has been withdrawn; or • the trial has been ordered to be discontinued; by any governmental or regulatory authority having jurisdiction. Unapproved Goods or damages, loss, cost or expense arising out of the actual, alleged or threatened Products hazardous properties of goods or products: 1. declared unsafe by any governmental or regulatory authority on the basis of such hazardous properties, regardless of whether such goods or products were declared unsafe before or after: • the goods or products were sold, supplied, leased or licensed to others, manufactured, repaired, installed, inspected, adjusted, erected, altered, cleaned or treated; or • such damages, loss, cost or expense were incurred; or 2. sold, supplied, leased or licensed to others, manufactured, repaired, installed, inspected, adjusted, erected, altered, cleaned or treated without approval by the applicable governmental or regulatory authority. Subparagraph 1 above does not apply to the Insured’s product, to which this Policy applies, if such goods or products were sold, supplied, leased or licensed to others, manufactured, repaired, installed, inspected, adjusted, erected, altered, cleaned or treated before it was known by the Insured, or would have been known from the perspective of a person in the circumstances of the Insured, that the goods or products had been declared unsafe. Unauthorised Access damages, loss, cost or expense arising out of any actual, alleged or threatened unauthorised access to or use of: • the Insured’s product or the Insured’s service; • any property containing or incorporating the Insured’s product or the Insured’s service; • any property on which the Insured’s service is or was performed; or • any content, information (to include but not being limited to personal data and corporate data) or material; by any person or organisation. Vehicles damages, loss, cost or expense arising out of any ownership, maintenance, possession or use by or on behalf of the Insured of any: 1. mechanically propelled vehicle or trailer attached thereto whilst being used in circumstances which require compulsory insurance or equivalent security to comply with the requirements of any legislation applicable to the use of such vehicle, including road traffic legislation. 2. aircraft, spacecraft, aerial or aerospatial device, hovercraft or waterborne craft. In respect of Section 1 only, subparagraph 2. of this exclusion does not apply to bodily injury or property damage caused by the use of a waterborne craft that is: • a hand or sail propelled craft of less than 15 metres in length: or • not owned by the Insured, provided that such craft is rented to the Insured, with a supplied crew, for business entertainment. This Exclusion does not apply to cover provided under the Extension entitled ‘Motor Liability - Contingent, Incidental Movement, Loading/Unloading or Tool of Trade’. War damages, loss, cost or expense arising out of war. Exclusions – Section 3 (Product and Service Errors and Omissions Liability) The insurance provided by Section 3 does not apply to any: Bodily Injury, damages, loss, cost or expense for any bodily injury, property damage Property Damage or or nuisance. Nuisance Ceasing Support damages, loss, cost or expense arising out of any actual, alleged or threatened decision by the Insured: • not to provide or support; or • to cease to provide or support; the Insured’s product or service. Continuing Acts damages, loss, cost or expense arising out of any continuation or resumption Following Non- of any act, following non-renewal or cancellation of this Policy or Renewal or subsequent renewal or replacement of this Policy that is issued by the Cancellation Company and which would otherwise apply to such act. Crime, Dishonesty Or damages, loss, cost or expense arising out of any criminal, dishonest, Fraud fraudulent or malicious conduct committed by any party with the consent or prior knowledge of any officer, director or partner, or spouse of any officer, director or partner of the Insured. Disappearance or damages, loss, cost or expense arising out of any burglary, inventory Theft shortage, inventory shrinkage, mysterious disappearance, robbery or theft. Delay in Delivery or damages, loss, cost or expense arising out of any actual, alleged or Performance threatened: 1. a. delay in delivery of; or b. failure to deliver; the Insured’s product or any part or phase thereof; or 2. a. delay in performance of; or b. failure to begin; the Insured’s service or any part or phase thereof. Government Claims or damages, loss, cost or expense arising out of any claim made or proceedings Proceedings brought by or on behalf of any central or local governmental authority. This exclusion does not apply to financial injury sustained by such authority resulting from its ownership, maintenance or use of the Insured’s product or the Insured’s service. Maintenance of damages, loss, cost or expense arising out of any actual, alleged or Contracts or Licenses threatened: • failure to effect, maintain, procure or secure; or • cancellation, lapse, modification, non-renewal, revocation, suspension or other impairment of; in whole or in part at any time, any bond, insurance, lease, licence, order, permit or other contract or agreement that the Insured is obliged to effect, maintain, procure or secure. Reputational Injury damages, loss, cost or expense arising out of any actual, alleged or threatened reputational injury by any person or organisation. Conditions The following Conditions apply to all parts of this Policy Adjustment If any part of the Premium is calculated on estimates, then the Insured shall within one month from the expiry of each Period of Insurance furnish such details as the Company may require, and the Premium for such period shall be adjusted subject to any Minimum Premium. Adverse Event Reporting an adverse event to the Company, another insurer or a Reporting governmental or regulatory authority, in itself does not constitute: • a conclusion that the Insured’s product or the Insured’s service caused or contributed to such event; • an admission or assumption of liability; • a notice as described under the claims condition entitled ‘Insured’s Duty to Report Circumstances’; • knowledge of a circumstance that would be expected to result in payment under this Policy; or • that injury or damage was expected or intended. Apportionment of If any award or settlement in respect of any claim exceeds the applicable Limit Defence Costs of Indemnity, then the liability of the Company in respect of related legal defence costs shall be limited to an amount that is in the same proportion as the Company's contribution to such award or settlement. Assignment Assignment of interest under this Policy shall not bind the Company without its prior consent. Audits or Inspections At any time during the Period of Insurance or thereafter, the Insured shall make available to the Company (and the Company shall have the right to audit, inspect and copy) any books, papers and other records of the Insured (including those of its agents and brokers) in connection with this Policy or the subject matter hereof. Cancellation The Company can cancel the insurance with fourteen (14) days written notice from the day the cancellation was sent by the Company, if a) the Policyholder or the Insured has significantly neglected the obligations towards the Company or; b) a circumstance stated in the insurance that is of significant importance for the risk has changed in a way that the Company could not have taken into consideration. The Company shall cancel the insurance without unreasonable delay after the Company received knowledge of the circumstances underlying the cancellation. Should the Company fail to do so, the Company will lose the right to cancel the insurance on these conditions, provided that the Policyholder or the Insured has not acted decisively or in contrary to good faith and honour. The Company may choose to change or amend the terms and conditions of the insurance instead of cancelling the insurance. Changes This Policy may be changed only by a written endorsement issued by a duly authorised representative of the Company. Choice of Law and This policy shall be governed by and construed in accordance with the the Forum provisions of the Swedish Insurance Contracts Act of 2005:104 (FAL). Any dispute or difference arising under or in respect of this Policy shall be subject to and determined within the exclusive jurisdiction of the courts of Sweden. Currency All sums are in the currency expressed in the Schedule, and all payments will be made in that currency. If any calculation or payment is to be made in any other currency, then the rate of exchange to apply shall be that applicable on the date of settlement as published on www.oanda.com. First Named Insured The person or organisation first named as the Insured in the Schedule is primarily responsible for the payment of all premiums. The first named Insured will act on behalf of all other persons or organisations indemnified under this Policy for the giving and receiving of all notices and the receipt of any return premiums that become payable under this Policy. Material Change in The Insured shall advise the Company immediately in writing of any material Risk change, of which it is aware or ought reasonably to be aware, in the risk insured under this Policy. Other Insurance If interests covered by this insurance are also covered by another insurance, and if the latter contains a provision regarding double insurance, the same provision shall apply to both insurances. However each insurer is liable towards the insured as if it had been the solely insurer. The insured does not have the right to a total reimbursement from the insurers that exceeds what corresponds to the loss. The liability will be distributed between the insurances in accordance with Chapter 6, Section 4 of the Insurance Contracts Act (2005:104). Prohibition This Policy does not apply to the extent that trade or economic sanctions or other laws or regulations prohibit the Company from providing such insurance. Reasonable Care The Insured is obliged, at its own expense, to take all reasonable precautions to prevent injury, damage or loss which may give rise to liability, to comply with all statutory or other obligations and to take all reasonable steps to: • ensure that only competent employees are employed; • keep all plant, premises, machinery and ways in good repair; • remedy any defect or danger and to take all necessary precautions as soon as possible after discovery; and • ensure that its products are free from defect and fit for their intended purpose. Third Party Rights A person or organisation who is not party to this Policy has no rights to enforce any term or condition of this policy. Clinical Trials – Special Conditions Clinical Trials – Any cover under this Part of this Policy in respect of any clinical trial is Special Conditions conditional upon the following. The Insured: • shall conduct all clinical trials strictly in accordance with all applicable agreements, laws, regulations and procedures; • shall make all filings that it is required to make under all applicable laws and regulations; • is at all material times in receipt of all necessary authorisations in connection with such clinical trials; and • has not recklessly or wilfully violated or consented to any violation of any agreement, contract, law, procedure, protocol or regulation applicable to the conduct of such clinical trial. With respect to any clinical trial involving exposure to any product upon or within research subjects during such clinical trial that first happens after the beginning of the Period of Insurance, where the Insured is the sponsor of the trial, in connection with: • ‘First-in-Man’ clinical trials; • research subjects who are cognitively impaired; • research subjects who are pregnant; • research subjects who are under eighteen years of age; • planned Emergency Use Research testing; or • prisoners; it is a condition precedent to cover under this Policy that the Company has specifically agreed by endorsement to this Policy to provide cover in respect of such clinical trial. The Company may impose additional terms and conditions in respect of such trial and may require additional premium to be paid. Claims Conditions The following Conditions apply to all parts of this Policy. Company’s Rights: The Company is entitled (but not obliged), at its discretion, to: Investigation, Defence and Settlements • take over and conduct (including in the name of the Insured) the investigation, defence (including appeals) or settlement of any claim; and • prosecute for its own benefit any claim for indemnity, damages or otherwise. The Company, at its discretion, may at any time pay: • the applicable Limit of Indemnity (after deduction of any sums already paid); or • any amount for which any claim can be settled; and may then relinquish any conduct or control of, and shall be under no further liability in respect thereof. Insured’s Duty to If, during the Period of Insurance, the Insured becomes aware of a Report Circumstances circumstance which may result in a claim and, as soon as practicable during the Period of Insurance gives the Company written notice thereof, then subsequent claims notified in accordance with the ‘Insured’s Duties in the Event of a Claim’ will be deemed to be claims made during the Period of Insurance. Written notice of such circumstance shall contain: • particulars sufficient to identify the Insured; • all available information concerning the circumstance, including how, when and where it happened; and • all available names and addresses of any party who has suffered injury, loss or damage and of all available witnesses. Insured’s Duties in the In the event of any circumstance arising that may result in a claim under this Event of a Claim Policy, written notice containing: • particulars sufficient to identify the Insured; • all available information concerning the circumstance, including how, when and where it happened; and • all available names and addresses of any party who has suffered injury, loss or damage and of all available witnesses; shall be given to the Company as soon as practicable after the circumstance becomes known to the Insured. The Insured shall give written notice to the Company of any claim or proceedings as soon as practicable after such claim or proceedings come to the knowledge of the Insured (and in any event within 12 (twelve) months from the time such proceedings or claim first came to the knowledge of the Insured) and shall, as soon as practicable, forward to the Company every pre-action letter, demand, notice, summons, claim form or other process received by the Insured. If the Insured wishes to bring legal proceedings against the Company with regard to a claim, that Insured must commence such proceedings within 10 (ten) years of when the claim was first made. However, if written notice of the claim is given to the Company within the time required by the paragraph immediately above, the insured may always commence such proceedings within 6 (six) months of the time when the Company states that it has made its final decision regarding the Claim. If the Insured does not commence such proceedings within the time required by this paragraph, the Insured shall lose the right to insurance cover in respect of the Claim. When the Company has given its final decision about an Insured´s claim of insurance cover under this Policy, the Company may by written notice to the Insured demand that the Insured commence legal proceedings against that Company regarding that decision within such time (but not less than 12 (twelve) months of that written notice as the Company shall stipulate. If the Insured does not commence legal proceedings within that time, the Insured shall lose the right to do so. The Insured shall not admit liability for or negotiate the settlement of any claim without the written consent of the Company. The Insured shall co-operate with and provide all required assistance to the Company and, at the Company’s request and in accordance with its instructions, shall: • assist in negotiating or concluding settlements; • co-operate in the conduct of any proceedings enforcing any right of contribution or indemnity against any person or organisation who may be liable to the Insured because of injury or damage with respect to which insurance is afforded; and • attend hearings and trials and assist in securing and giving evidence and obtaining the attendance of witnesses. Subrogation The Company shall be subrogated to all the Insured's rights of recovery against any person or organisation, before or after any payment under this Policy. The Insured shall execute and deliver instruments and papers and do whatever else is necessary to secure such rights. The Insured shall do nothing after loss to prejudice such rights. For the purposes of this condition, ‘the Insured’ shall include all persons and organisations indemnified under this Policy. Definitions Words with specific meanings appear in bold print and are defined here. All other words used in this Policy bear their plain English meaning. The following definitions apply to all parts of this Policy. Act • means an act, error or omission. • includes all related acts, errors or omissions and all series of continuous, repeated or related acts, errors or omissions. Adverse Event means any: 1. outcome of the following types, regardless of whether or not such outcome is expected or intended: • congenital anomaly or birth defect; • death; • disability or incapacity; • hospitalization; or • life threatening injury, illness or disease; of any person; 2. intervention to prevent any outcome described above; 3. malfunction of the Insured’s product that may give rise to any outcome described in subparagraphs above; or 4. condition that may give rise to any outcome described above, requiring notification to a governmental or regulatory authority. Asbestos means asbestos in any form, including its presence or use in any alloy, by- product, compound or other material or waste. Waste includes material to be recycled, reconditioned or reclaimed. Benefit Programme means any: • accident, dental, disability, healthcare, homeowners, life, motor vehicle, unemployment or employee compensation; • deferred compensation, financial planning, investment subscription, pension, profit sharing, retirement, severance or share ownership; or • expense reimbursement, holiday, savings, training or travel; account, insurance, payment, plan or programme, or any similar benefit. Bodily Injury means physical: • injury; • illness; or • disease; sustained by a person, including resulting death, mental anguish, mental injury or shock at any time. All such resulting loss shall be deemed to happen at the time of the injury, illness or disease that caused it. Clinical Trial means: 1. an investigation in research subjects intended to: • discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more investigational medicinal product; • identify any adverse reactions to one or more investigational medicinal product; or • study absorption, distribution, metabolism or excretion of one or more investigational medicinal product with the object of ascertaining its safety or efficacy; or 2. other investigation or testing of a life science product upon or within research subjects to establish the effectiveness or safety of such product. includes: • the provision of information necessary to obtain the informed consent of human beings to participate in such investigation or testing; and • other activities in connection with such investigation or testing. Clinical Trial means (as applicable): Compensation Guidlines • the Association of British Pharmaceutical Industries (“ABPI”) Clinical Trial Compensation Guidelines (Issued 1991) or subsequent revisions; • the ABPI Guidelines for Phase 1 Clinical Trials (2007 Edition) or subsequent revisions; • the Association of British Health-Care Industries Medical Devices Clinical Investigation Compensation Guidelines (1995) or subsequent revisions; • guidelines that are imposed on the Insured by a government or regulatory authority of competent jurisdiction; or • written guidelines that are voluntarily accepted by the Insured and specifically agreed to by the Company by endorsement to this Policy; which prescribe the manner and rules by which to determine whether, and to what extent, a research subject in a clinical trial should be paid compensation by the Insured in respect of bodily injury or property damage sustained by such research subject as a result of his or her participation in a clinical trial to which this Policy applies. Cognitively Impaired means suffering from any: • alcohol or drug dependency; • degenerative disease affecting the brain; • dementia or similar disorder; • disabling physical handicap; • mental retardation or similar disorder; • neurosis, psychosis or similar disorder; • terminal physical illness; or • other condition, disease, injury or sickness; that diminishes a human being’s capacity for judgment or reasoning. Contract Research means an organisation engaged to provide service or advice in connection Organisation with: 1. a. clinical; b. laboratory; or c. research; testing activities, within the scope of and in accordance with the applicable written protocol; or 2. the planning, monitoring or review; of a clinical trial. Cosmetic means an article that is intended to be applied to the human body for altering appearance, beautifying, cleansing or promoting attractiveness. Device Family means a medical device or a group of such devices manufactured by or for the same organisation and having the same basic design and performance characteristics and intended function and use. Dietary Supplement means a good or product, other than conventional food, that is or includes: • an amino acid, herb or other botanical, mineral, vitamin or similar substance; or • a combination, concentrate, constituent, extract or metabolite of the substances described above; which is intended to supplement the diet of human beings Employee means any person employed under a contract of service or apprenticeship with the Insured, whether such contract is expressed, implied, oral or in writing, including persons: • supplied by labour only sub-contractors; • providing their services on a labour only basis; • engaged in work experience or similar schemes; • providing their services on a voluntary basis; or • on secondment with the Insured. For the purposes of this Policy, voluntary participation by an employee in a clinical trial is not an activity arising out of or in the course of that employee’s employment by the Insured. Ethics Committee means a board, committee, group or similar organisation designated, directed or requested by an institution or other person or organisation to review a clinical trial, including: • approval; or • periodic review; of such clinical trial. Financial Injury means economic injury, including that resulting from loss of software, data and other information in electronic form, sustained by a person or organisation in connection with the Insured’s product or the Insured’s service, or a part or phase thereof. Healthcare Service means any: • cosmetic service, advice, instruction or treatment; • dental, medical, nursing, physiotherapy, surgical or x-ray service, advice, instruction or treatment; • handling or treatment of dead bodies, including autopsies, organ donations or similar procedures; • health or therapeutic service, advice, instruction or treatment; or • related dispensing or furnishing of any beverages or food, or any life science product or other dental, medical or surgical appliances or supplies. Information and means: Network Technology 1. communication, computer, electronic, information, Internet, network or Product website: • equipment or parts; or • programs or systems; and 2. software, data or other information that is in electronic form. Information and means analysis, design, integration, maintenance, management, processing, Network Technology programming, repair or support services in connection with any information Service and network technology product. Intellectual Property means any: Law or Right 1. right to, or law recognising an interest in, any: • certification mark; • copyright or moral right, database right or mask work or semiconductor topography right; • design right; • patent; • trade dress (including get up); • trade mark; • trade secret, know-how or confidential information; or • other intellectual property; 2. law relating to passing off, piracy, unfair competition or similar practice; or 3. law or right similar to any of the foregoing, anywhere in the world. Legal Defence Costs means the costs, fees and expenses incurred for the defence of the Insured in the investigation, defence and settlement of that part of a specific claim covered by this Policy. Life Science Product means a cosmetic, dietary supplement, medicinal product or medical device. Life Science Product means a person or organisation engaged to provide service or advice in Sales Contractor connection with the dispensing, sale or supply of a life science product, other than in connection with a clinical trial. Life Science Product means: Service • clinical; • design or development review; • laboratory; or • research; service or advice in connection with a life science product. Life Science Product means a person or organisation engaged to provide life science product Service Contractor service, other than in connection with a clinical trial. Medical Device means an instrument, apparatus, appliance, material or other article, whether used alone or in combination, (including software necessary for its proper application) intended by the manufacturer to be used for human beings for the purpose of: • diagnosis, prevention, monitoring, treatment or alleviation of disease; • diagnosis, monitoring, treatment or alleviation of an injury or handicap; • investigation, replacement or modification of the anatomy or of a physiological process; or • control of conception; and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means. Medicinal Product means a substance or combination of substances: • presented as having properties for treating or preventing disease in human beings; or • which may be used in or administered to human beings with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to make a medical diagnosis. Occurrence means an accidental event, including continuous or repeated exposure to substantially the same general harmful conditions. Offshore Activities means any: • embarkation onto a conveyance (until disembarkation from such conveyance onto land) for the purpose of travel to or from; • transit between; or • activities on or from; any offshore structure, platform, installation, accommodation vessel or associated structure. Prisoner means a human being who is: 1. incarcerated: • while awaiting arraignment, trial or sentencing; or • having been sentenced; pursuant to a civil or criminal statute; or 2. detained for drug detoxification, treatment of alcoholism or other purposes, pursuant to a civil or criminal statute which allows or provides for alternatives to incarceration. Product In respect of Sections 1, 2 and 3: means: • goods or products (including life science products) sold, supplied, leased or licensed to others, manufactured, repaired, installed, inspected, adjusted, erected, altered, cleaned or treated by or on behalf of the Insured; • containers, labels, instructions and packaging relating to such goods and products. after such goods or products have ceased to be in the care, custody and control of the Insured. Notwithstanding anything to the contrary above, product includes its use at any time or place whilst loaned or hired to, or located for the use of, another whether or not such product: • has been sold; or • is in the Insured’s possession. In respect of Section 3: means: • goods or products, including life science products, sold supplied, leased or licensed to others, manufactured, repaired, installed, inspected, adjusted, erected, altered, cleaned or treated by or on behalf of the Insured; • containers, labels, instructions and packaging relating to such goods or products; and • the Insured’s service rendered in connection with such goods or products. Property Damage means physical damage to tangible property, including resultant loss of use of such property. Tangible property does not include any software, data or other information in electronic form. All such resultant loss shall be regarded as having happened at the time of the physical damage that caused it. Reputational Injury means injury caused by an act of: 1. false arrest, false detention or other false imprisonment; 2. malicious prosecution; 3. wrongful entry into, wrongful eviction of a person from or other violation of a person's right of private occupancy of a dwelling, premises or room that such person occupies, if committed by or on behalf of its landlord, lessor or owner; 4. electronic, oral, written or other publication of material including on the Internet or in other media that: • libels or slanders a person or organisation (including placing a person in a false light); • disparages a person’s or organisation’s products or services; or • violates a person’s right of privacy; or 5. discrimination, harassment or segregation based on a person’s protected human characteristics as established by law. Research Subject means a person participating in a clinical trial or any pre-trial assessment, including: • such person’s dependants, heirs, executors, administrators and legal representatives; and • children in-utero through the participation of the mother in a clinical trial. Securities Law means any law or regulation designed to: • prevent or prohibit fraudulent, unfair or other similar practices; or • require full or periodic disclosure of information; in connection with any: • offering; • registration; • trading; or • continued listing or registration; of any instrument or other evidence of creditorship or ownership. Service means: • information and network technology services; and • life science product services; performed by the Insured or on its behalf (including related consulting, staffing, training and other support services). Specific Diseases means: • Acquired Immune Deficiency Syndrome (AIDS). • Transmissible Spongiform Encephalopathy (TSE). • Viral Hepatitis. Specific Classes of means: Products • Anticonvulsant products. • Aprotinin • Birth control or fertility products. • Clopidogrel • Cox-2 inhibitor products. • Fibrate products. • HMG CoA reductase inhibitor products. • Hormone replacement products. • Impotence products. • Isotretinoin • Metoclopramide • Orlistat • Selective Serotonin Reuptake Inhibitor products (SSRI). • Serotonin Norepinephrine Reuptake Inhibitors (SNRI). • Thiazolidinediones • Vaccines. • Varenicline Specific Products means: • Bupropion. • Botulinum Toxin • Cisapride. • Dexfenfluramin. • Dopamine Agonist • Di-(2-ethylhexyl) Phthalate (DEHP). • Diazepines, Oxazepines or Thiazepines. • Diethylstilbestrol (DES). • Ephedra or Ephedrine. • Fenfluramine. • Hydroquinone. • Hydroxyquinoline derivative products. • Infusion Pumps • Isotretinoin • L-tryptophan – when used for or as part of any physically ingestible purpose • Latex Gloves. • Mercury. • Phentermine. • Phenylpropanolamine (PPA). • Piper Methysticum (Kava). • Remoxipride. • Risperidone. • Silicone – when used as part of an implantable medical device. • Thalidomide. • Thimerosal. Subsidiary means an organisation that the Insured either directly or indirectly controls Organisation through: • holding a majority of the voting rights; • the right to appoint or remove a majority of its board of directors; or • controlling alone, pursuant to a written agreement with other shareholders, a majority of the voting rights therein. Terrorism means any: • act including the use of force or violence or the threat thereof, taken by any person or group of persons, whether acting alone or on behalf of or in connection with any organisation or government, committed for political, religious, ideological or similar purposes including the intention to influence any government or to put the public, or any section of the public, in fear. • act or failure to act in controlling, preventing or suppressing terrorism. War means any: 1. hostile or warlike action in time of peace or war (including any act or failure to act in controlling, preventing or suppressing any actual, impending or expected attack) by any: • government authority or sovereign power (de jure or de facto) or by any authority maintaining or using military, naval or air forces; • military, naval or air forces; or • agent of any government power, authority or force; 2. insurrection, rebellion, revolution, civil war, usurped power or any activity of any organisation the objects of which are or include the overthrowing or influencing of any government or sovereign power (de jure or de facto) by any violent means, or any act or failure to act by government authority or sovereign power (de jure or de facto) in controlling, preventing or suppressing such activity; or 3. weapon of war employing atomic fission, atomic fusion, radioactive force or radioactive material, whether in time of peace or war. Uuritava informeerimise ja teadliku nõusoleku l eht Varasemalt kirjeldamata geenivaria nti de mõju ravimite metabolismile ehk ravimite lagundamise kiirusele inimese organismis Kutse uuringus osalemiseks Kutsume Teid osalema teadusuuringus. Selleks palume tutvuda järgneva teabega . Uuringumeeskonna esindaja on valmis vastama Teie küsimustele. Teil on aega otsustamiseks, kas osaleda uuringus või mitte. Mis on uuringu eesmärk? Geenidoonorite andmeid analüüsides oleme leidnud umbes 9 00 inimest, kellel esineb varasemalt kirjeldamata geenivariante, mis võivad mõjutada teatud ravimite toimet. Uuringu eesmärk on analüüsida nende geenivariantide mõju ravimite lagundamise kiirusele inimese organismis ehk uurida , kuidas organism ravimeid „ töötleb “. Uuringu tulemused aitavad kaasa sellele, et tulevikus saa ks geeniinfot teades ravimeid inimestele täpsemalt annustada . Selleks et ravimid saaksid organismi le süsteemset toimet avaldada, peavad nad liikuma kehas toime avaldumiseks vajalikku kohta (n äiteks jõudma süsteemsesse vereringesse). Mõned ravimid peavad muunduma ( metaboliseeruma ) kehas toimivateks ühenditeks ja osad ravimid peavad metaboliseeruma sellisteks ühenditeks, mida on võimalik kehast eritada. Ravimite ja ka paljude muude kehavõõraste ainete metabolismis on olulisel kohal ensüümide kogum ehk tsütokroom P450 süsteem (CYP450). Selle t sütokroomide süsteemi liikmed osalevad enamike ravimite metabolismis. Tsütokroom P450 ensüümide aktiivsus võib erinevatel inimestel olla väga suurte kõikuvustega ja selle tõttu on erinev ka ravimite metabolis eerimise võime. Sellest tulenevalt võib mõni ravim olla osadel inimestel tugevama või nõrgema toimega, mõnikord võivad osadel inimestel erinevuste tõttu tsütokroomide süsteemis avalduda teatud ravimi kõrvaltoimed . Tsütokroom P450 ensüümide aktiivsust saab organismis hinnata nii, et inimesele antakse teatud kindla ensüümi vahendusel metaboliseeruva ravimi üks annus ning seejärel määratakse kindlatel ajahetkedel võetud vereproovidest manustatud ravimi ja selle laguproduktide (metaboliitide) sisaldust. Miks on Teid välja valitud? Pöördume Teie poole, kuna olete nõustunud geenidoonorina oma geeniinfo uurimisega . Te olete üks umbes 900st geenidoonorist, kellel on leitud tsütokroom P 450 ensüümides variatsioone ehk erinevusi , mis võivad mõjutada ravimite lammutamise kiirust . Plaanime uuringusse kaasata kuni 250 geenidoonorit. Kas ma pean uuringus osalema? Uuringus osalemine on vabatahtlik. Kui otsustate uuringus osaleda, palutakse Teil allkirjastada nõusoleku vorm. Isegi kui annate nõusoleku uuringus osalemiseks, on Teil võimalus igal ajal uuringus osalemi n e katkestada. Selleks palume Teil esitada vabas vormis avaldus kas paberkandjal või e- kirja teel meiliaadressile [email protected] . Avalduses ei ole vaja välja tuua katkestamise põhjendust . Otsus uuringus mitte osaleda ei mõjuta Teile osutatavat arstiabi. Soovi korral on Teil õigus oma andmetega kohapeal tutvuda ilma et see tooks kaasa mingeid ebameeldivusi. Mida Teiega tehakse, kui otsustate uuringus osaleda? Uuringus osalejatel on vaja käia kahel uuringuvisiidil, mis toimuvad haiglas (Tartu Ülikooli Kliinikum is või Põhja- Eesti Regionaalhaigla s ). Haiglasse sõitmise kulud kompenseeritakse Teile sõidudokumentide alusel, maksimaalselt kuni 50 € ulatuses ühe visiidi kohta . Esimene visiit Sellel visiidil antakse Teile lisaselgitusi ning võetakse Teilt kirjalik nõusolek uuringus osalemise kohta. V isiidi käigus dokumenteeritakse T eie isikuandmed, tehakse mõõt mised (kaal, pikkus), hinnatakse Teie terviseseisundit ja sobivust uuringus osalemiseks ning võetakse vajalikud vereproovid (kokku kuni 10 ml veeniverd). Uurijad võivad vaadata ka Teie varasemaid haiguslugusid, et kindlaks teha, kas Teil on vastunäidustusi mingite ravimite tarvitamisele . Selleks küsitakse Teilt eraldi nõusolek. Info dokumenteeritakse elektroonilises haigusloos haigla info süsteemis sarnaselt sellele, kuidas andmeid dokumenteeritakse tavalise arstivisiidi käigus . Esimese visiidi järgselt selgub, kas Te sobite uuringusse ja soovite selles osaleda ning lepitakse kokku teise visiidi aeg. Kui tarvitate regulaarselt ravimeid, lepitakse Teiega esimesel visiidil kokku, kas võite uuringupäeva hommikul Teile arsti poolt määratud ravimeid võtta. Selle kohta antakse Teile kaasa täpne soovitus. Uuringu esimesel vi siidil kulub haiglas aega umbes 1 tund. Teine visiit Uuringupäeval kontrollitakse veel kord Teie terviseseisundit, küsitletakse Teid ravimite kasutamise kohta ning kinnitatakse sobivus uuringusse . Seejärel antakse Teile suu kaudu korraga kahte sageli kasutatavat ravimit – 20mg omeprasooli ( kõrvetiste ja maohappe tagasivoolusümptomite ravim ) ning 12,5mg metoprolooli ( kõrgvererõhutõve , stenokardia , südame rütmihäirete ja südamepuudulikkuse korral kasutatav ravim ). O meprasool on kapslis valmispreparaat ja metoprolool antakse T eile puhta toimeaine pulbrina, mille uuringuõde lisab 50ml-le kraaniveele ja annab Teile sisse võtmiseks . Ka omeprasooli võtmiseks antakse T eile kraanivett. Ravimite kontsentratsiooni mõõtmiseks veres võetakse Teilt 8 tunni jooksul 10 vereproovi . Ü hekordne võetava vere maht on 5ml. Vereproovi võtmine toimub veenikanüüli kaudu, mis pannakse Teile enne ravimite manustamist. Uuringupäeva hommikul palume Teil mitte süüa, kuna toit võib mõjutada uuringuravimite imendumist. Pärast uuringuravimite manustamist pakutakse Teile uuringukeskuses hommikusööki ning toitlustus tagatakse terve uuringupäeva jooksul. Teine visiit kestab kuni 10 tundi ja seetõttu toimub see nädalavahetusel. Ravimikontsentratsioon id määra takse Teie vereproovist Rootsis, Karolinska Instituudis , kus on selleks olemas kogenud spetsialistid ja vajalik aparatuur. Mida tehakse uuringu tulemustega? Uuringu tulemused avaldatakse teadusajakirjades. Soovi korral saadame Teile uuringu lõppedes kokkuvõtte uuringu tulemustest. Mida ma pean uuringus osalemiseks tegema? Teilt palutakse allkirja nõusoleku lehele, millega kinnitate, et olete nõus uuringus osalemisega. Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning Teile sobival ajal. Uuringu ajal on plaanis katta kuludokumentide alusel Teie transpordikulud. Kui Teil ei ole võimalik uuringukeskusesse tulla uuringuravimi manustamise päeva hommikul või lahkuda uuringupäeva järgsel õhtul, siis tasutakse ka Teie ööbimiskulud . Mis kasu on uuringus osalemisest ja millised on võimalikud riskid? Selles uuringus osalemisest ei ole Teile otsest kasu, kuid Teil on võimalik soovi korral tutvuda uuringu tulemus tega ning Geenivaramus hoitavate geeniandmete põhjal koostatud farmakogeneetika raportiga. Farmakogeneetika raportis on personaalsed soovitused 2 8 erineva ravimi annustamise kohta. Antud uuring aitab paremini selgitada varem kirjeldamata geeni variatsioonide võimalikku mõju ravimite metaboliseerimise ehk lagundamise võimele. Lisaks omeprasoolile ja metoproloolile lagundavad uuritavad ensüümid ka teisi ravimeid, mille puhul on olemas soovitus ed annuste muutmiseks vastavalt inimese ensüümide aktiivsusele . Näiteks ensüüm CYP2C19 lagundab tsitalopraam i , klopidogreel i , sertraliin i , esomeprasool i , amitriptüliin i ; ensüüm CYP2D6 lagundab kodeiin i , nortriptüliin i , paroksetiin i jt ravimite toimeaineid . Uuringu eesmärgil antakse Teile 2 ravimit – 20mg omeprasooli ning 12,5mg metoprolooli . Nende ravimite annused on küll väikesed ning kõrvaltoimete tekkimine on vähetõenäoline, kuid Teie terviseseisundit jälgitakse ikkagi uuringu jooksul pidevalt . Ühekordse annuse manustamise järgselt võivad Teil nende kahe ravimi kõrvaltoimena tekkida peavalu , pearinglus , südame löögisageduse aeglustumine , iiveldus või suukuivus . Lisaks helistatakse T eile nädal pärast uuringu toimumise päeva ning küsitletakse terviseseisundi kohta. Teil on võimalus uurijatega telefoni teel ühendust võtta kogu uuringu ajal ja teavitada uurijat võimalik e st ravimi te kõrvaltoime te st . Veenikanüüli panek võib olla korraks valulik, aga teeme kõik, et seda ära hoida – vereanalüüsid võtab kogenud õde. Võetava vere maht on teise visiidi jooksul kuni 50 ml ja seda ei peeta tervisele ohtlikuks. Kõik uuritavad on uuringu jooksul eraldi kindlustuskaitsega kaetud. Kas uuringus osaledes on minu isiku andmed kaitstud? Jah. Kõik uuringu raames kogutud isiku andmed (andmed, millega saab Teid otse või kaudselt tuvastada – näiteks nimi, isikukood , terviseandmed ) on konfidentsiaalsed ja kaitstud vastavalt rahvusvaheliste ja Eestis kehtestatud reeglitele (kooskõlas Isikuandmete k aitse seadusega). Uuritavad saavad numbrilise koodi, millega tähistatakse kõik meditsiinilised dokumendid ja vere proovid ning andmeid töödeldakse pseudonüümitud kujul ehk kodeeritult. Uuringu andmed edastatakse ka Geenivaramusse, kus toimub andmete kodeerimine ja analüüsimine. Uuringuga seotud infot hoitakse hästi turvatud Geenivaramu, SA Tartu Ülikooli Kliinikumi ja SA Põhja-Eesti Regionaalhaigla serverites. Haigla serverites hoitakse andmeid samadel alustel nagu Teie teisi terviseandmeid. Geenivaramu serveri tes hoitakse andmeid tähtajatult ja kodeeritud kujul . Kes on hinnanud uuringu sobivust ja ohutust? Uuring on heaks kiidetud Eesti bioeetika ja inimuuringute nõukogu poolt . Uuringut võib igal ajahetkel inspekteerida ka Ravimiamet ja rahvusvahelised organisatsioonid. Kes uuringut organiseerib ja finantseerib? Uuringut korraldab Tartu Ülikooli Eesti Geenivaramu koostöös Tartu Ülikooli Kliinikumi ja Põhja-Eesti Regionaalhaigla arstidega ning seda finantseeritakse SA Eesti Teadusagentuuri teadus grandist. Kontakt lisainformatsiooni saamiseks Vastutav uurija Tartu Ülikooli Kliinikumis: Dr. Alar Irs Tel: .......... [email protected] Vastutav uurija Põhja Eesti Regionaalhaiglas: Dr. Kersti Oselin Tel: ....... [email protected] Täname Teid, et kaalusite selles uuringus osalemist! Haigla nimetus: _________________________________ INFORMEERITUD NÕUSOLEKU VORM Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Nõustumisel p alun märkida kasti ees- ja perekonnanime esimesed tähed 1. Ma olen läbi lugenud nimetatud uuringu infolehe kuupäevaga 02/01/20 (versioon 1) ja sellest aru saanud. Mul on olnud võimalus küsida küsimusi. Kinnitan oma nõusolekut uuringus osalemiseks. 2. Ma mõistan, et osalemine on vabatahtlik ja ma võin uuringus osalemise igal ajal ja põhjust nimetamata katkestada. See ei mõjuta mulle antavat arstiabi. 3. Ma annan uuringuga seotud isikutele loa juurdepääsuks oma meditsiinilistele dokumentidele (uuringu ravimitega seotud info saamiseks varasematest elektroonilistest haiguslugudest haigla infosüsteemis) . 4. Olen nõus, et mulle asetatakse ühekordselt veenikanüül. 5. Olen nõus, et mulle manustatakse ühekordselt 20mg omeprasooli ja 12,5mg metoprolooli . 6. Olen nõus, et kogu uuringu jooksul võetakse analüüsideks kuni 6 0 ml veeniverd. Teil on võimalik soovi korral tutvuda uuringu tulemustega ning Geenivaramus hoitavate geeniandmete põhjal koost atud farmakogeneetika raportiga , mis on koostatud Teie kohta Geenivaramus hoitavate geeniandmete põhjal. Farmakogeneetika raport kajastab inimese geneet iliste eripärade mõju ravimite omastamisele, sobivusele või kõrvaltoimete tekkimisele. Raportis on andmed 2 8 erineva toimeaine kohta. Uuringu tulemused ja raport saadetakse Teile soovi korral e-mailile või tavapostiga. Palun tehke valik ja märkige sobivasse kasti ees- ja perekonnanime esitähed . -993775 22860 0 0 2038350 17780 0 0 Soovin teada uuringu tulemusi Soovin saada raportit -984250 99060 0 0 -3228975 95885 0 0 Ei soovi teada uuringu tulemusi Ei soovi saada raportit Kirjutage trükitähtedega e-maili või postiaadress, kuhu saadetakse tulemused ja/või raport. Neid andmeid ei kasutata mingil muul otstarbel ja ei kanta mingisse andmebaasi ja need hävitatakse 5 aastat pärast uurinu lõppu . …………………………………………………………………………………………. Tean, et uuringu käigus tekkivate küsimuste kohta saan mulle vajalikku täiendavat informatsiooni uurijalt. Kontakt lisainformatsiooni saamiseks Vastutav uurija Tartu Ülikooli Kliinikumis: Dr. Alar Irs Tel: .......... [email protected] Vastutav uurija Põhja Eesti Regionaalhaiglas: Dr. Kersti Oselin Tel: ....... [email protected] ____________________ Uuritava ees- ja perenimi _______ Kuupäev ________________ Allkiri ___________________ Isikukood ____________________ Nõusoleku võtnud isiku ees- ja perenimi ________ Kuupäev _________________ Allkiri TÜ Genoomika instituudi vastus Eesti bioeetika ja inimuuringute nõukogu 8-04-2020 esitatud küsimustele ja ettepanekutele seoses uurimistööga „ Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile “ Genoomika instituut on teinud parandused uuritava informeerimise ja teadliku nõusoleku vormi. Kõikidele EBINi poolt esitatud küsimustele ja ettepanekutele on vastatud, v.a. üks küsimus : Esimene visiit lepitakse kokku telefoni teel. Kuidas annab geenidoonor teada, et ta on nõus ja talle sobivad suhtluskanalid? Põhjendus: uuritava esimese visiidi kokkuleppimine toimus juba eelnevalt ja kogu vajaliku informatsiooni esimese visiidi kokkuleppimise kohta saab uuritav eraldi kirjaga ( Kiri geenidoonorile uuringusse kutsumiseks) , mis saad e takse potentsiaalsetele uuritavatele uuringu alguses . I nformeerimise ja teadliku nõusoleku vormi le selle teabe panek oleks eksitav, ku na inimene on juba esimesel visiidil, mille käigus ta sellele vormile alla kirjutab. Kirja koostaja Helene Alavere Alar Irs Sünniaeg 3.07.1973 Telefon 003725118592 ORCID 0000-0002-2244-9699 E-post [email protected] Töökohad ja ametid 01.01.2018–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi radioloogiakliinik, arst-õppejõud kardioloogia erialal (0,50) 2017–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi Südamekliinik, arst-õppejõud kardioloogia erialal (0,50) 01.01.2012–... Ravimiamet, meditsiininõunik 01.02.2009– Tartu Ülikool, Kliinilise farmakoloogia lektor (0,25) 31.12.2017 03.08.2004– Newcastle-i Ülikool, Austraalia, kliinilise farmakoloogia 03.11.2004 külalisteadur (1,00) 2004–31.01.2009 Tartu Ülikool, kliinilise farmakoloogia assistent (0,25) 01.01.2003– Ravimiamet, peadirektori asetäitja (1,00) 31.12.2011 01.01.2001– Ravimiamet, registreerimisosakonna juhataja 31.12.2003 01.01.1998– Ravimiamet, kliiniliste ravimiuuringute spetsialist 31.12.2001 01.09.1997– Tartu Ülikool, lepinguline õppetöö kliinilise farmakoloogia alal 31.12.2003 (0,50) Haridustee 01.09.2012– Kardioloogia residentuur 31.08.2017 1991–1997 MD cum laude, Tartu Ülikooli arstiteaduskond Teadusorganisatsiooniline ja -administratiivne tegevus 2018−... Eesti Kardioloogide Seltsi juhatuse liige 2017−... Eesti Haigekassa ravimikomisjoni esimees 2017−... Riikliku Siirdemeditsiini ja Kliiniliste Teadusuuringute Keskuse kliiniliste uuringute keskuse juhtkomitee liige 2012−... Eesti ravijuhendite nõukoja liige 2010−... Euroopa Ravimiameti kardiovaskulaartöörühma liige (2017 asejuhataja) 2009−... Ravimiameti ravimite müügilubade komisjoni ase-esimees 2004−... Euroopa Ravimiameti inimravimite komitee liige 2013−2016 TÜ arstiteaduse programminõukogu liige 2013−2017 Programmi „Tervishoiuteaduste võimekuse edendamine“ (TerVE) tervisetehnoloogiate hindamise (TTH) nõukogu, liige 2011−2016 Ravimiinfo Assotsiatsiooni Euroopa nõukoja liige 2010−2013 Eesti Farmakoloogia Selts, juhatuse liige (president) 2009−2017 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni hariduse alakomitee, liige 2008−2013 Maailma Terviseorganisatsiooni esmavajalike ravimite komitee liige 2008−2013 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni nõukogu liige 2004−2017 Sotsiaalministeeriumi ravimikomisjoni liige Teadustöö põhisuunad ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B530 Südame-veresoonkonna haigused ; TÄPSUSTUS: Aterosklerootilise kardiovaskulaarhaiguse ennetus ja ravi Lisainfo Olen kuulanud doktorantuuriprogrammis ettenähtud mahus eetikaloenguid, osalenud Euroopa Ravimiameti ja ravimijärelevalvevõrgustiku GCP inpektorite treeningprogrammis, mis hõlmas bioeetikat, ning olles olnud umbes 60 GCP kursuse koordinaator, olen kuulanud neis peetud eetikaloenguid kõigilt lektoreilt, kes neid on Eestis pidanud, sh Andres Soosaar ja Aime Keis. Jooksvad projektid • (RITA1/01-42-01) "Personaalmeditsiini kliinilised juhtprojektid rinnavähi ja südame- veresoonkonna haiguste täppisennetuses (1.01.2018−31.12.2020)", Peeter Padrik, SA Tartu Ülikooli Kliinikum. Publikatsioonid 2019 Alver, Maris; Palover, Marili; Saar, Aet; Läll, Kristi; Zekavat, Seyedeh Maryam; Tõnisson, Neeme; Leitsalu, Liis; Reigo, Anu; Nikopensius, Tiit; Ainla, Tiia; Kals, Mart; Mägi, Reedik; Gabriel, Stacey B; Eha, Jaan; Lander, Eric S; Irs, Alar; Philippakis, Anthony; Marandi, Toomas; Natarajan, Pradeep; Metspalu, Andres ... Esko, Tõnu (2019). Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine, 21 (5), 1−8.10.1038/s41436-018-0311-2. Freemantle, Nick; Irs, Alar; De Paulis, Ruggero; Pagano, Domenico; Falk, Volkmar; Beyersdorf, Friedhelm (2019). Transcatheter versus surgical aortic valve replacement: what does the latest evidence tell us? European Journal of Cardio-thoracic Surgery, 56 (1), 7−9.10.1093/ejcts/ezz163. 2016 Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. (2016). Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open, 2016 (6, 6), e011666.10.1136/bmjopen-2016-011666. Bueno H, de Graeff P, Richard-Lordereau I, Emmerich J, Fox KA, Friedman CP, Gaudin C, El- Gazayerly A, Goldman S, Hemmrich M, Henderson RA, Himmelmann A, Irs A, Jackson N, James SK, Katus HA, Laslop A, Laws I, Mehran R, Ong S, Prasad K, Roffi M, Rosano GM, Rose M, Sinnaeve PR, Stough WG, Thygesen K, Van de Werf F, Varin C, Verheugt FW, de Los Angeles Alonso García M. (2016). Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European Heart Journal, 2016 (Jun 29, Eur Heart J Acute Cardiovasc Care), pii: 2048872616649859.10.1177/2048872616649859 [ilmumas]. Sonn, K.; Irs, A.; Laius, O. (2016). Clinical pharmacology and trends in use of sedative-hypnotic and anxiolytic medications in Estonia. 25. HOBOKEN: Wiley-blackwell, 188−188. (25). 2013 Hoebert, J; Irs, A; Mantel-Teeuwisse, A; Leufkens, H. (2013). Future of the European Union regulatory network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology, 76 (1), 1−6.10.1111/j.1365-2125.2012.04476.x. Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124. Pintson, Madli; Irs, Alar (2013). Involvement of Residents in the National Guideline Development Process in Estonia. 10th EACPT Summer School, Edinburgh, UK, 4-6.07.2013. 2012 Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe; Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit; Habicht, Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe, Erki; Esnar, Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend. Eesti Haigekassa, Tartu Ülikool 2012. 2011 Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20 (5), 474−481.10.1002/pds.2125. Raudsepp, D.; Lass, J.; Saar, M.; Kuld, L.; Irs, A. (2011). Ravimite koos- või kõrvaltoimed erakorralise meditsiini osakonda pöördumise põhjusena - prospektiivne vaatlusuuring. Eesti Arst, 3, 122−128. 2010 Irs, A.; Salupere, R.; Sinisalu, V. (2010). Mittesteroidsete põletikuvastaste ravimite ohutu kasutamine. Eesti Arst, 89 (6), 417−422. Kirss, Anne; Maipuu, Lea; Eelmäe, Imbi; Metsvaht, Tuuli; Sirotkina, Meeli; Irs, Alar (2010). Angiotensiini konverteeriva ensüümi inhibiitori ja angiotensiini II retseptori blokaatori kasutamise ohud raseduse ajal: haigusjuhu kirjeldus ja kirjanduse ülevaade. Eesti Arst, 89, 502−509. Lass, J.; Iljuhhina, J.; Laius, O.; Pisarev, H.; Irs, A. (2010). Retseptiravimite raseduseaegne kasutamine Eestis. Eesti Arst: TÜ Arstiteaduskonna teaduskonverents, 7-8.okt. 2010. 2009 Laius, O.; Irs, A.; Kiivet, R. -A. (2009). FROM USSR TO EU - LONG-TERM TRENDS IN ESTONIAN DRUG UTILIZATION. 105. MALDEN: Wiley-blackwell Publishing, Inc, 96−96. (105). Lass, J.; Laius, O.; Leinemann, T.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Availability of paediatric information in Summaries of Product Characteristics of drugs prescribed to children in Estonia. 12th Congress of European Society for Developmental Perinatal & Paediatric Pharmacology, Chamonix, Prantsusmaa, 17-20.06.2009. Lass, J.; Laius, O.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Substantial proportion of ambulatory prescribing for children is off-label in Estonia. 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, Šotimaa, 12-15.07.2009. 2008 Freemantle, N.; Irs, A. (2008). Observational evidence for determining drug safety. British Medical Journal, 336 (7645), 627−628.10.1136/bmj.39491.493252.80. Zarkovski, Aleksander; Kalda, Anti; Gavronski, Maia; Hartikainen, Sirpa; Irs, Alar (2008). Kliinik 2008 : ravimitest tulenevad ohud [Videosalvestis]. Kliinik 2008, Tartu Ülikooli Kliinikumi õenduskonverents; Tartu; 4.-6. veebruar 2008. Tartu: TÜ IT Multimeedia talitus,. (TÜ filmiarhiiv). 2006 Johnson, K.R.; Ringland, C.; Stokes, B.J.; Anthony, D.M.; Freemantle, N.; Irs, A.; Hill, S.R.; Ward, R.L. (2006). Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology, 7 (9), 741−746. Raal, A.; Fischer, K.; Irs, A. (2006). Determination of drug information needs of health care professionals in Estonia. Medicina (Kaunas), 42 (12), 1030−1034. 2005 Ristimäe, T.; Irs, A.; Teesalu, R. (2005). Arteriaalne hüpertensioon kui südame- veresoonkonnahaiguste oluline riskitegur. Eesti Arst, 4, 277−282. Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2005). Tervisesüsteem muutustes: Eesti. Tallinn: World Health Organization. 2004 Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2004). Health care systems in transition: Estonia. Copenhagen: World Health Organization. 2001 Rootslane, L.; Irs, A.; Kiivet, R. (2001). ATC/DDD methodology: a country perspective. WHO Drug Information, 15 (1), 26−30. Irs, A.; Rootslane, Ly (2001). The use of antihypertensive drugs in in Estonia compared to the Nordic countries. Pharmacology & Toxicology, 89, suppl.. 50. 1999 Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380. Kask, A.; Pahkla, R.; Irs, A.; Rago, L.; Wikberg, JES.; Schioth, HB. (1999). Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport, 10 (4), 707−711. Regionaalhaigla SA Pohja-Eesti Regionaalhaigla koolitustalitus T't IUNNISIUS nr 17lOK-336 Kersti Oselin isikukood 47307262752 Hbis 04.04.2017 koolituse Ravimite kliiniliste uuringute, nende ldbiviimise printsiipide ja heade kliiniliste tavade tdiendkoolitus Koolituse maht: |0 tundi. Ir I11 :fllt^- ll,,tl Katrin Kiisk Ravimiameti peadirektori aset-iitja Tallinn, 04. aprill 2017
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel